

TETRAHYDROISOQUINOLINE DERIVATIVES

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/285,039, filed February 12, 2016, the contents of which are hereby incorporated by reference herein in their entirety.

10

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates to tetrahydroisoquinoline derivatives or salts thereof which are useful as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere.

DISCUSSION OF THE BACKGROUND

The cytoskeleton of skeletal and cardiac muscle cells is unique compared to that of all other cells. It consists of a nearly crystalline array of closely packed cytoskeletal proteins called the sarcomere. The sarcomere is elegantly organized as an interdigitating array of thin and thick filaments. The thick filaments are composed of myosin, the motor protein responsible for transducing the chemical energy of ATP hydrolysis into force and directed movement. The thin filaments are composed of actin monomers arranged in a helical array. There are four regulatory proteins bound to the actin filaments, which allows the contraction to be modulated by calcium ions. An influx of intracellular calcium initiates muscle contraction; thick and thin filaments slide past each other driven by repetitive interactions of the myosin motor domains with the thin actin filaments.

Of the thirteen distinct classes of myosin in human cells, the myosin-II class is responsible for contraction of skeletal, cardiac, and smooth muscle. This class of myosin is significantly different in amino acid composition and in overall structure from myosin in the other twelve distinct classes. Myosin-II forms homo-dimers resulting in two globular head domains linked together by a long alpha-helical coiled-coiled tail to form the core of

the sarcomere's thick filament. The globular heads have a catalytic domain where the actin binding and ATPase functions of myosin take place. Once bound to an actin filament, the release of phosphate (cf. ADP-Pi to ADP) signals a change in structural conformation of the catalytic domain that in turn alters the orientation of the light-chain binding lever arm domain that extends from the globular head; this movement is termed the power stroke. This change in orientation of the myosin head in relationship to actin causes the thick filament of which it is a part to move with respect to the thin actin filament to which it is bound. Un-binding of the globular head from the actin filament (Ca^{2+} regulated) coupled with return of the catalytic domain and light chain to their starting conformation/orientation completes the catalytic cycle, responsible for intracellular movement and muscle contraction.

Tropomyosin and troponin mediate the calcium effect on the interaction on actin and myosin. The troponin complex is comprised of three polypeptide chains: troponin C, which binds calcium ions; troponin I, which binds to actin; and troponin T, which binds to tropomyosin. The skeletal troponin-tropomyosin complex regulates the myosin binding sites extending over several actin units at once.

Troponin, a complex of the three polypeptides described above, is an accessory protein that is closely associated with actin filaments in vertebrate muscle. The troponin complex acts in conjunction with the muscle form of tropomyosin to mediate the Ca^{2+} dependency of myosin ATPase activity and thereby regulate muscle contraction. The troponin polypeptides T, I, and C, are named for their tropomyosin binding, inhibitory, and calcium binding activities, respectively. Troponin T binds to tropomyosin and is believed to be responsible for positioning the troponin complex on the muscle thin filament.

Troponin I binds to actin, and the complex formed by troponins I and T, and tropomyosin inhibits the interaction of actin and myosin. Skeletal troponin C is capable of binding up to four calcium molecules. Studies suggest that when the level of calcium in the muscle is raised, troponin C exposes a binding site for troponin I, recruiting it away from actin. This causes the tropomyosin molecule to shift its position as well, thereby exposing the myosin binding sites on actin and stimulating myosin ATPase activity.

Human skeletal muscle is composed of different types of contractile fibers, classified by their myosin type and termed either slow or fast fibers. Table 1 summarizes the different proteins that make up these types of muscle.

Table 1

	Muscle Fiber Type	
	Fast Skeletal	Slow Skeletal
Myosin Heavy Chain (MHC)	Ila, (IIb*), IIX/d	Cardiac β
Troponin I (TnI)	TnI fast Skeletal	TnI slow Skeletal
Troponin T (TnT)	TnT fast Skeletal	TnT slow Skeletal
Troponin C (TnC)	TnC fast Skeletal	TnC slow/cardiac
Tropomyosin (TM)	TM- β / TM- α /TPM3**	TM- β / TM- α s

*MHC IIb is not expressed in human muscle but is present in rodents and other mammals.

**TPM3 represents tropomyosin 3

5 In healthy humans, most skeletal muscles are composed of both fast and slow fibers, although the proportions of each vary with muscle type. Slow skeletal fibers, often called type I fibers, have more structural similarity with cardiac muscle and tend to be used more for fine and postural control. They usually have a greater oxidative capacity and are more resistant to fatigue with continued use. Fast skeletal muscle fibers, often called type

10 II fibers, are classified into fast oxidative (IIa) and fast glycolytic (type IIX/d) fibers. While these muscle fibers have different myosin types, they share many components including the troponin and tropomyosin regulatory proteins. Fast skeletal muscle fibers tend to exert greater force but fatigue faster than slow skeletal muscle fibers and are functionally useful for acute, large scale movements such as rising from a chair or

15 correcting falls.

Muscle contraction and force generation is controlled through nervous stimulation by innervating motor neurons. Each motor neuron may innervate many (approximately 100 to 380) muscle fibers as a contractile whole, termed a motor unit. When a muscle is required to contract, motor neurons send stimuli as nerve impulses (action potentials) from


20 the brain stem or spinal cord to each fiber within the motor unit. The contact region between nerve and muscle fibers is a specialized synapse called the neuromuscular junction (NMJ). Here, membrane depolarizing action potentials in the nerve are translated into an impulse in the muscle fiber through release of the neurotransmitter acetylcholine (ACh). ACh triggers a second action potential in the muscle that spreads

25 rapidly along the fiber and into invaginations in the membrane, termed t-tubules.

T-tubules are physically connected to Ca^{2+} stores within the sarcoplasmic reticulum (SR) of muscle via the dihydropyridine receptor (DHPR). Stimulation of the DHPR activates a second Ca^{2+} channel in the SR, the ryanodine receptor, to trigger the release of Ca^{2+} from stores in the SR to the muscle cytoplasm where it can interact with the troponin complex to initiate muscle contraction. If muscle stimulation stops, calcium is rapidly taken back up into the SR through the ATP dependent Ca^{2+} pump, sarco/endoplasmic reticulum Ca^{2+} -ATPase (SERCA).

Muscle function can become compromised in disease by many mechanisms. Examples include the frailty associated with old age (termed sarcopenia) and cachexia syndromes associated with diseases such as cancer, heart failure, chronic obstructive pulmonary disease (COPD), and chronic kidney disease/dialysis. Severe muscular dysfunction can arise from neuromuscular diseases (such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and myasthenia gravis) or muscular myopathies (such as muscular dystrophies). Additionally, muscle function may become compromised due to rehabilitation-related deficits, such as those associated with recovery from surgery (e.g., post-surgical muscle weakness), prolonged bed rest, or stroke rehabilitation. Additional examples of diseases or conditions where muscle function becomes compromised include peripheral vascular disease (e.g., claudication), chronic fatigue syndrome, metabolic syndrome, obesity, dysfunctions of pelvic floor and urethral/anal sphincter muscles (e.g., urinary incontinence such as stress urinary incontinence (SUI) and mixed urinary incontinence (MUI), and fecal incontinence), post-spinal cord injury (SCI) muscle dysfunction, and ventilator-induced muscle weakness.


Currently, there is limited treatment or no cure for most neuromuscular diseases. WO2008/016669 discloses a compound represented by the following general formula (A) for treating a patient having a disease responsive to modulation of skeletal troponin C, etc.



formula (A)

For the symbols, refer to this publication.

WO2011/0133888 discloses a compound represented by the following general formula (B) for treating a patient having a disease responsive to modulation of skeletal troponin C, etc.



formula (B)

For the symbols, refer to this publication.

WO2011/0133882, WO2011/133920, and US2013-0060025 disclose another compound for treating a patient having a disease responsive to modulation of skeletal troponin C, etc.

WO2013/151938, WO2013/155262, and WO2015/168064 disclose treatment methods such as improving diaphragm function, improving resistance to skeletal muscle fatigue, reducing decline in vital capacity by using a skeletal muscle troponin activator.

US3947451 and US3301857 along with Journal of Heterocyclic Chemistry, 7 (3) p615-22, (1970) and Synthetic Communications, 32 (12) p1787-90, (2002) disclose compounds having 1,4-dihydroisoquinolin-3(2H) structure, but fail to disclose any pharmacological activities of the compounds described therein.

Tetrahedron Letters, 50 (47) p6476-6479, (2009) discloses 1,1-diallyl-3-oxo-2,4-dihydroisoquinoline-4-carboxylate, but fail to disclose any pharmacological activities of the compounds described therein.

Accordingly, there is a need for the development of new compounds that modulate skeletal muscle contractility. There remains a need for agents that exploit new mechanisms of action and which may have better outcomes in terms of relief of symptoms, safety, and patient mortality, both short-term and long-term and an improved therapeutic index.

SUMMARY OF THE INVENTION

Accordingly, it is one object of the present invention to provide novel tetrahydroisoquinoline compounds and salts thereof which are useful as an active ingredient for pharmaceutical compositions, in particular, pharmaceutical compositions for

treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere.

It is another object of the present invention to provide novel pharmaceutical compositions which contain such a compound.

5 It is another object of the present invention to provide novel methods of preparing such a compound.


It is another object of the present invention to provide novel methods for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere.

10 These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery compounds of formula (I) and (I') described below.

The present invention provides novel compounds which are expected to be used as an active ingredient in a pharmaceutical composition, and in particular, in a pharmaceutical
15 composition for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. Modulation of the skeletal sarcomere may be modulation, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof.

20 Compounds of formula (I), (I'), and embodiments thereof are provided herein, as well as pharmaceutical compositions containing such compounds, methods of preparing such compounds, and methods of using such compounds in therapy. It is intended that any of the pharmaceutical compositions, methods of preparation, and methods of use provided herein encompass any of the compounds of formula (I), (I') and any
25 embodiments thereof provided herein, including, without limitation, Embodiments 1-1 through 8-4 and Embodiments (1)-(57).

The present invention relates to a compound of the formula (I) or a salt thereof, and a pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and an excipient.



wherein,

X^1 : C- R^{11} or N;

X^2 : C- R^{12} or N;

5 R^{11} : i) H, ii) halogen, iii) -CN, or iv) -O- C_{1-6} alkyl;

R^{12} : H or halogen;

R^1 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s), and pyrazolyl(s), iii) C_{2-6} alkenyl, or iv) -OR⁰;

10 R^2 : i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OR⁰(s), halogen(s), -COOR⁰(s), -CONR²¹R²²(s), phenyl(s) which may be substituted with one or more substituent(s) selected from the G¹ group, and heteroaryl(s) which is selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, wherein the heteroaryl
15 may be substituted with one or more substituent(s) selected from the G² group, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) -OR⁰, v) -NR²³R²⁴, vi) -COOR⁰, or vii) phenyl;

R^{21} : H or C_{1-6} alkyl;

R^{22} : i) C_{1-6} alkyl which may be substituted with one or more phenyl(s), or ii) phenyl;

20 R^{23} : i) H, or ii) C_{1-6} alkyl which may be substituted with one or more -OH(s);

R^{24} : i) C_{1-6} alkyl which may be substituted with one or more phenyl(s) which may be substituted with one or more halogen(s), ii) C_{3-8} cycloalkyl which may be substituted with one or more C_{1-6} alkyl(s), iii) phenyl which may be substituted with one or more halogen(s), or iv) tetrahydropyranyl; or

25 R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-piperidine ring or 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom and the 4-piperidine ring may be substituted with one or more substituent(s) selected from the group consisting of -SO₂-(C_{1-6} alkyl) and -COOR⁰;

R^3 , R^4 : the same or different each other, i) C_{1-3} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and -OH(s) or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and heteroaryl(s) which is selected from the group consisting of pyrazolyl and thienyl, wherein the heteroaryl may be substituted with one or more C_{1-6} alkyl(s), or,

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 may interact to form a 3-oxetane ring and the carbon atom bounded by R^3 and R^4 is a spiro atom;

R^5 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more -O-(C_{1-6} alkyl)(s), iii) -O-(C_{1-6} alkyl), iv) halogen, v) -COO-(C_{1-6} alkyl), or vi) C_{3-8} cycloalkyl;


R^6 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -O-(C_{1-6} alkyl(s) which may be substituted with one or more halogen(s)) and halogen(s), iii) -OH, iv) -O-(C_{1-6} alkyl which may be substituted with one or more halogen(s)), v) halogen, vi) -CN, vii) -S-(C_{1-6} alkyl), viii) C_{3-8} cycloalkyl, ix) -NR⁰R⁰, or x) C_{2-6} alkenyl;

G^1 group : i) halogen, ii) -COOR⁰, iii) -CONR⁰R⁰, iv) -OH, v) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen, or vi) -O-(C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s));

G^2 group: i) halogen, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s) or iii) -CONR⁰R⁰;

R^0 : the same or different each other, H or C_{1-6} alkyl.

In one embodiment, the present invention relates to a compound of the formula (I) or a salt thereof, and a pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and an excipient.



wherein,

X^1 : C- R^{11} or N;

X^2 : C- R^{12} or N;

5 R^{11} : i) H, ii) halogen, iii) -CN, or iv) -O- C_{1-6} alkyl;

R^{12} : H or halogen;

R^1 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s), and pyrazolyl(s), iii) C_{2-6} alkenyl, or iv) - OR^0 ;

10 R^2 : i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of - OR^0 (s), halogen(s), - $COOR^0$ (s), - $CONR^{21}R^{22}$ (s), phenyl(s) which may be substituted with one or more substituent(s) selected from the G^1 group, and heteroaryl(s) which is selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, wherein the heteroaryl
15 may be substituted with one or more substituent(s) selected from the G^2 group, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) - OR^0 , v) - $NR^{23}R^{24}$, vi) - $COOR^0$, or vii) phenyl;

R^{21} : H or C_{1-6} alkyl;

R^{22} : i) C_{1-6} alkyl which may be substituted with one or more phenyl(s), or ii) phenyl;

20 R^{23} : i) H, or ii) C_{1-6} alkyl which may be substituted with one or more -OH(s);

R^{24} : i) C_{1-6} alkyl which may be substituted with one or more phenyl(s) which may be substituted with one or more halogen(s), ii) C_{3-8} cycloalkyl which may be substituted with one or more C_{1-6} alkyl(s), iii) phenyl which may be substituted with one or more halogen(s), or iv) tetrahydropyranyl; or

25 R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-piperidine ring or 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom and the 4-piperidine ring may be substituted with one or more substituent(s) selected from the group consisting of - SO_2 -(C_{1-6} alkyl) and - $COOR^0$;

R^3 , R^4 : the same or different each other, i) C_{1-3} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and -OH(s) or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and heteroaryl(s) which is selected from the group consisting of pyrazolyl and thienyl, wherein the heteroaryl may be substituted with one or more C_{1-6} alkyl(s), or,

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 may interact to form a 3-oxetane ring and the carbon atom bounded by R^3 and R^4 is a spiro atom;

R^5 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more -O-(C_{1-6} alkyl)(s), iii) -O-(C_{1-6} alkyl), iv) halogen, v) -COO-(C_{1-6} alkyl), or vi) C_{3-8} cycloalkyl;

R^6 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -O-(C_{1-6} alkyl(s) which may be substituted with one or more halogen(s)) and halogen(s), iii) -OH, iv) -O-(C_{1-6} alkyl which may be substituted with one or more halogen(s)), v) halogen, vi) -CN, vii) -S-(C_{1-6} alkyl), viii) C_{3-8} cycloalkyl, ix) -NR⁰R⁰, or x) C_{2-6} alkenyl;

G^1 group : i) halogen, ii) -COOR⁰, iii) -CONR⁰R⁰, iv) -OH, v) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen, or vi) -O-(C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s));

G^2 group: i) halogen, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s) or iii) -CONR⁰R⁰;

R^0 : the same or different each other, H or C_{1-6} alkyl, provided that said compound is not methyl

1,1-diallyl-3-oxo-2,4-dihydroisoquinoline-4-carboxylate or a salt thereof.

Unless specifically described otherwise, when symbols in one formula in the specification are also used in other formulae, same symbols denote same meanings. When the same symbol is used more than once in a given formula, it is to be understood that each instance of that symbol in the formula represents an independently selected chemical moiety and that all instances of the symbol in the formula need not necessarily represent identical chemical moieties.

Further, the present invention relates to a pharmaceutical composition comprising the compound of the formula (I) or a salt thereof, and a pharmaceutically acceptable excipient. Furthermore, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof, comprising the compound of the formula (I) or a salt thereof. Furthermore, the invention relates to an agent for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof, comprising the compound of the formula (I) or a salt thereof.

Moreover, the present invention relates to use of the compound of the formula (I) or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof; use of the compound of the formula (I) or a salt thereof for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof; the compound of the formula (I) or a salt thereof for use in preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof; and a method for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof, comprising administering to a subject an effective amount of the compound of the formula (I) or a salt

thereof. Further, the “subject” is a human or a non-human animal in need of the prevention or treatment, and in one embodiment, a human in need of the prevention or treatment.

In one aspect, the compound of the formula (I) or a salt thereof modulates the contractility of the skeletal sarcomere. Specifically, the compounds modulate the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. As used in this context, “modulate” means either increasing or decreasing activity. In some instances, the compounds described and/or disclosed herein potentiate (i.e., increase activity) of one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. In other instances, the compounds described and/or disclosed herein inhibit (i.e., decrease activity) of one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. As used in this context, “activation of the fast skeletal muscle fiber such as myofibril” means to amplify the response of fast skeletal muscle fiber (such as myofibril) to stimulation/ Ca^{2+} .

In a further aspect, the compounds and pharmaceutical compositions described and/or disclosed herein are capable of modulating the contractility of the fast skeletal sarcomere in vivo, and can have application in both human and animal disease. Modulation would be desirable in a number of conditions or diseases, including, but not limited to, 1) neuromuscular disorders, such as Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), peripheral neuropathies, and myasthenia gravis; 2) disorders of voluntary muscle, including muscular dystrophies, myopathies and conditions of muscle wasting, such as sarcopenia and cachexia syndromes (e.g., cachexia syndromes caused by diseases such as cancer, heart failure, chronic obstructive pulmonary disease (COPD), and chronic kidney disease/dialysis), rehabilitation-related deficits, such as those associated with recovery from surgery (e.g., post-surgical muscle weakness), prolonged bed rest or stroke rehabilitation, and ventilator-induced muscle weakness; 3) central nervous system (CNS) disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, such as multiple sclerosis, Parkinson’s disease, stroke, and spinal cord injury; 4) muscle symptoms stemming from systemic disorders, including Peripheral Vascular Disease (PVD) or Peripheral Arterial Disease (PAD) (e.g., claudication), metabolic syndrome, chronic fatigue syndrome, obesity, and frailty due to aging; and 5)

dysfunctions of pelvic floor and urethral/anal sphincter muscles such as stress urinary incontinence, mixed urinary incontinence and fecal incontinence.

In a further aspect, the present invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence comprising a compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia comprising a compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising a compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis comprising a compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies comprising a compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction comprising a compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome comprising a compound of the formula (I), or a salt thereof.

In a further aspect, the present invention relates to use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia. In a

further aspect, the present invention relates to use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to a use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and myasthenia gravis, muscular myopathies. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

In a further aspect, the present invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the present invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies. In a further

aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to use of a compound of the formula (I), or a salt thereof for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

In a further aspect, the present invention relates to a method for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence, comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In a further aspect, the present invention relates to a method for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia, comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating chronic obstructive pulmonary disease (COPD), comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies, comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction, comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic

fatigue syndrome, comprising administering to a subject an effective amount of the compound of the formula (I), or a salt thereof. In any variation described herein, the subject is a human or a non-human animal in need of the prevention or treatment, and in one embodiment, a human in need of the prevention or treatment.

5 In a further aspect, the present invention relates to a compound of the formula (I), or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the present invention relates to a compound of the formula (I), or a salt thereof, for use in the prevention or treatment of a
10 disease or condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to a compound of the formula (I), or a salt thereof, for use in the prevention or treatment of chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to a compound of the formula (I), or a salt thereof, for use in the prevention or treatment of cachexia syndrome and/or muscle wasting caused by
15 heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to a compound of the formula (I), or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies. In a further aspect, the invention relates to a compound of the formula (I), or
20 a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to a compound of the formula (I), or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial
25 disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

BRIEF DESCRIPTION OF DRAWINGS

30 A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:

FIG.1 is graphs showing results obtained by an assay of rat treadmill running performance. Significance is defined as $*p < 0.05$ vs. vehicle treatment. In FIG. 1, Example 20 means Example Compound 20, and Example 22b means Example Compound 22b.

5 FIG.2 is a graph showing results obtained by an assay of Electrical Field Stimulation (EFS)-induced concentration of isolated External Anal Sphincter (EAS). In FIG. 2, Example 20 means Example Compound 20.

FIG.3 is a graph showing results obtained by an assay of EFS-induced concentration of isolated EAS. In FIG. 3, Example 22b means Example Compound 22b.

10 FIG.4 is a graph showing results obtained by an assay of anal pressure induced by electrical stimulation of pudendal nerve. In FIG. 4, Example 20 means Example Compound 20, and Example 22b means Example Compound 22b.

FIG.5 is a graph showing results obtained by an assay of urine Leak Point Pressure (LPP) under abdominal pressure. In FIG. 5, Example 20 means Example
15 Compound 20.

FIG.6 is a graph showing results obtained by an assay of urine LPP under abdominal pressure. In FIG. 6, Example 22b means Example Compound 22b.

FIG.7 is a diagram showing study timeline of an assay of Basso, Beattie, and Bresnahan (BBB) score of post-spinal cord injury (SCI). In FIG. 7, Example 52 means
20 Example Compound 52.

FIG.8 is graphs showing results obtained by the assay of BBB score of post-SCI. In FIG. 8, Example 52 means Example Compound 52.

FIG.9 is graphs showing results obtained by an assay of force-calcium relationship in chronic obstructive pulmonary disease (COPD) diaphragm muscle biopsies. In FIG.
25 9, Example 20 means Example Compound 20.

FIG.10 is graphs showing results obtained by an assay of force-calcium relationship in chronic obstructive pulmonary disease (COPD) latissimus dorsi muscle biopsies. In FIG. 10, Example 20 means Example Compound 20.

30 DETAILED DESCRIPTION

Hereinafter, the invention will be described in detail.

The term “alkyl” refers to linear or branched alkyl. Accordingly, the “C₁₋₆ alkyl” is linear or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof

include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, or n-hexyl; in one embodiment, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl; in one embodiment, a group selected from the group consisting of methyl, ethyl, and isopropyl; and in one embodiment, a group selected from the group
5 consisting of methyl and ethyl. It is understood that the linear or branched alkyl refers to a linear or branched saturated hydrocarbon.

The term "alkenyl" refers to an unsaturated linear or branched alkyl group having the indicated number of carbon atoms (e.g., 2 to 8, or 2 to 6 carbon atoms) and at least one carbon-carbon double bond derived by the removal of one molecule of hydrogen from
10 adjacent carbon atoms of the corresponding alkyl. The group may be in either the cis or trans configuration (Z or E configuration) about the double bond(s). Alkenyl groups include, but are not limited to ethenyl, propenyl (e.g., prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl)), and butenyl (e.g., but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl,
15 buta-1,3-dien-2-yl). Alkenyl groups may be prepared by any method known in the art.

The term "alkynyl" refers to an unsaturated linear or branched alkyl group having the indicated number of carbon atoms (e.g., 2 to 8 or 2 to 6 carbon atoms) and at least one carbon-carbon triple bond derived by the removal of two molecules of hydrogen from adjacent carbon atoms of the corresponding alkyl. Alkynyl groups include, but are not
20 limited to, ethynyl, propynyl (e.g., prop-1-yn-1-yl or prop-2-yn-1-yl) and butynyl (e.g., but-1-yn-1-yl, but-1-yn-3-yl or but-3-yn-1-yl). Alkynyl groups may be prepared by any method known in the art.

The term "cycloalkyl" refers to a non-aromatic, fully saturated carbocyclic ring having the indicated number of carbon atoms, for example, 3 to 10, or 3 to 8, or 3 to 6 ring
25 carbon atoms. Cycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic or tricyclic). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, as well as bridged and caged ring groups (e.g., norbornane or bicyclo[2.2.2]octane).

The term "heteroaryl" refers to a monocyclic aromatic hetero ring or a bicyclic aromatic hetero ring. The "monocyclic aromatic hetero ring" includes a monocyclic aromatic hetero ring group having 5 to 7 ring members, which has 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom as a ring-constituting atom, and specific examples thereof include pyrrolyl, pyrazolyl,
30


imidazolyl, triazolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; in one embodiment, pyrazolyl, imidazolyl, triazolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl or pyridyl.

The term “bicyclic aromatic hetero ring” refers to a bicyclic aromatic hetero ring group in which the monocyclic aromatic hetero ring is fused with a benzene ring or monocyclic aromatic hetero ring and includes a partially hydrogenated ring group thereof, and specific examples thereof include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzofuranyl, benzothienyl, benzooxazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, propyridyl, thienopyridyl, indolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, dihydropropyridyl or dihydrothienopyridyl; and in one embodiment, benzothienyl.


The term “saturated hetero ring” includes 3 to 8 membered saturated ring group, which has 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom as a ring-constituting atom, and may be bridged with C₁₋₆ alkylene, in which a sulfur atom as the ring-constituting atom may be oxidized. Specific examples thereof include azepanyl, diazepanyl, oxazepanyl, thiazepanyl, aziridinyl, azetidyl, pyrrolidinyl, imidazolidinyl, piperidinyl, pyrazolidinyl, piperazinyl, azocanyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, morpholinyl, thiomorpholinyl, tetrahydrothiopyranyl, oxathioranyl, oxiranyl, oxetanyl, dioxiranyl, tetrahydrofuranyl, tetrahydropyranyl or 1,4-dioxanyl.

The term “halogen” means fluoro, chloro, bromo or iodo; in one specific embodiment, fluoro, chloro or bromo; in another specific embodiment, fluoro; in a further specific embodiment, chloro, and in another specific embodiment, bromo.

The term “R³, R⁴, and a carbon atom bounded by R³ and R⁴ interact to form a 3-oxetane ring and the carbon atom bounded by R³ and R⁴ is a spiro atom” means, as clear from the description, R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring as described below ;



The term “ R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 interact to form a 4-piperidine ring or 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom” means, as clear from the description, R^1 and R^2 , together with the carbon to which they are attached, form a 4-piperidine ring or 4-tetrahydropyran ring as described below ;



In the specification, the expression "which may be substituted" means “which is not substituted” or “which is substituted with about 1 to about 5 substituents.” Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.

In powder X-ray diffraction pattern described in the present specification, the spacing of the crystal lattice and the overall pattern are important in identifying crystals on the nature of the powder X-ray diffraction data, and the diffraction angle and diffraction intensity should not be strictly interpreted, since they can include some errors according to the crystal growth direction, the particle size and the measurement conditions. The diffraction angles ($2\theta(^{\circ})$) of powder X-ray diffraction pattern in the present specification can include a measurement error of $\pm 0.2^{\circ}$ as an embodiment in consideration of error margin commonly accepted in the measurement method. Moreover, for example, a peak which is nearby a peak derived from pharmaceutical excipients and on a tilted baseline of the peak can visually shift by $\pm 0.3^{\circ}$ in the case that powder X-ray measurement is performed in the state of a mixture with pharmaceutical excipients.

In both preclinical and clinical settings, activators of the fast skeletal troponin complex have been shown to amplify the response of fast skeletal muscle to nerve stimulation, resulting in an increase in muscle force development at sub-maximal muscle activation (see, e.g., Russell et al., “The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force in vitro and in situ”, 2009 Experimental Biology Conference, New Orleans, LA, April 2009). Activators of the fast skeletal troponin complex have been shown to increase the sensitivity of skinned skeletal muscle fibers to

calcium, and in living muscle to the frequency of stimulation, each of which results in an increase in muscle force development at sub-maximal muscle activation. Such activators have also been shown to reduce muscle fatigue and/or to increase the overall time to fatigue in normal and low oxygenated conditions (see, e.g., Russell et al., “The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force and Reduces Muscle Fatigue in vitro and in situ”, 5th Cachexia Conference, Barcelona, Spain, December 2009; Hinken et al., “The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency”, Society for Vascular Medicine’s 2010 Annual Meeting: 21st Annual Scientific Sessions, Cleveland, OH, April 2010). The increase in muscle force in response to nerve input has been demonstrated in healthy human volunteers as well (see, e.g., Hansen et al., “CK-2017357, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects”, Society for Neuroscience 40th Annual Meeting: Neuroscience 2010, November 2010). Work in additional preclinical models of muscle function suggests that activators of the fast skeletal troponin complex also cause an increase in muscle power and/or endurance. These pharmacological properties suggest this mechanism of action could have application in conditions, for example, where neuromuscular function is impaired.

Provided are methods for enhancing fast skeletal muscle efficiency in a patient in need thereof, comprising administering to said patient an effective amount of a compound or composition described and/or disclosed herein that selectively binds the troponin complex of fast skeletal muscle fiber or sarcomere. In some embodiments, the compound disclosed and/or described herein activates fast skeletal muscle fibers or sarcomeres. In some embodiments, administration of a compound disclosed and/or described herein results in an increase in fast skeletal muscle power output. In some embodiments, administration of a compound disclosed and/or described herein results in increased sensitivity of fast skeletal muscle fibers or sarcomeres to calcium ion, as compared to fast skeletal muscle fibers or sarcomeres untreated with the compound. In some embodiments, administration of a compound disclosed and/or described herein results in a lower concentration of calcium ions causing fast skeletal muscle myosin to bind to actin. In some embodiments, administration of a compound disclosed and/or described herein results in the fast skeletal muscle fiber generating force to a greater extent at submaximal levels of muscle activation.

Also provided is a method for sensitizing a fast skeletal muscle fiber to produce force in response to a lower concentration of calcium ion, comprising contacting the fast skeletal muscle fiber with a compound or composition described and/or disclosed herein that selectively binds to troponin complexes in the fast skeletal muscle sarcomere. In

5 some embodiments, contacting the fast skeletal muscle fiber with the compound results in activation of the fast skeletal muscle fiber at a lower calcium ion concentration than in an untreated fast skeletal muscle fiber. In some embodiments, contacting the fast skeletal muscle fiber with the compound results in the production of increased force at a lower calcium ion concentration in comparison with an untreated fast skeletal muscle fiber.

10 Also provided is a method for increasing time to fast skeletal muscle fatigue in a patient in need thereof, comprising contacting fast skeletal muscle fibers with a compound or composition described and/or disclosed herein that selectively binds to the troponin complexes of the fast skeletal muscle fibers. In some embodiments, the compound binds to form ligand-troponin-calcium ion complexes that activate the fast skeletal muscle fibers.

15 In some embodiments, formation of the complexes and/or activation of the fast skeletal muscle fibers results in enhanced force and/or increase time to fatigue as compared to untreated fast skeletal muscle fibers contacted with a similar calcium ion concentration.

Some embodiments of the present invention are described below.

Embodiment 1-1

20 The compound of the formula (I) or a salt thereof, in which

X^1 is $C-R^{11}$ or N;

X^2 is $C-R^{12}$ or N;

R^{11} is i) H, ii) halogen, iii) -CN, or iv) -O- C_{1-6} alkyl; and

R^{12} is H or halogen.

25 Embodiment 1-2

The compound of the formula (I) or a salt thereof, in which

X^1 is $C-R^{11}$ or N;

X^2 is $C-R^{12}$ or N;

R^{11} is i) H, ii) halogen, iii) -CN, or iv) -O- C_{1-6} alkyl; and

30 R^{12} is H.

Embodiment 1-3

The compound of the formula (I) or a salt thereof, in which

X^1 is $C-R^{11}$;

X^2 is $C-R^{12}$;

R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl; and

R^{12} is H.

Embodiment 1-4

5 The compound of the formula (I) or a salt thereof, in which

X^1 is $C-R^{11}$;

X^2 is N; and

R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl.

Embodiment 1-5

10 The compound of the formula (I) or a salt thereof, in which

X^1 is N; and

X^2 is N.

Embodiment 2-1

The compound of the formula (I) or a salt thereof, in which

15 R^1 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and pyrazolyl(s), iii) C_{2-6} alkenyl, or iv) $-OR^0$;

R^2 is i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-OR^0$, halogen, $-COOR^0$, $-CONR^{21}R^{22}$, phenyl which
20 may be substituted with one or more substituent(s) selected from the G^1 group and heteroaryl is selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, wherein the heteroaryl which may be substituted with one or more substituent(s) selected from the G^2 group, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-OR^0$, v) $-NR^{23}R^{24}$, vi) $-COOR^0$, or vii) phenyl;

25 R^{21} is H or C_{1-6} alkyl;

R^{22} is i) C_{1-6} alkyl which may be substituted with one or more phenyl(s), or ii) phenyl;

R^{23} is i) H, or ii) C_{1-6} alkyl which may be substituted with one or more $-OH(s)$; and

30 R^{24} is i) C_{1-6} alkyl which may be substituted with one or more phenyl(s) which may be substituted with one or more halogen(s), ii) C_{3-8} cycloalkyl which may be substituted with one or more C_{1-6} alkyl(s), iii) phenyl which may be substituted with one or more halogen(s), or iv) tetrahydropyranyl; or

R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-piperidine ring or 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom and the 4-piperidine ring may be substituted with one or more substituent(s) selected from the group consisting of $-\text{SO}_2\text{-C}_{1-6}$ alkyl and $-\text{COOR}^0$;

5 G^1 group is selected from group consisting of i) halogen, ii) $-\text{COOR}^0$, iii) $-\text{CONR}^0\text{R}^0$, iv) $-\text{OH}$, v) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-\text{OH}(s)$ and halogen(s), and vi) $-\text{O-C}_{1-6}$ alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-\text{OH}(s)$ and halogen(s);

10 G^2 group is selected from the group consisting of i) halogen, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-\text{OH}(s)$ and halogen(s) and iii) $-\text{CONR}^0\text{R}^0$; and

R^0 is the same or different each other, H or C_{1-6} alkyl.

Embodiment 2-2

15 The compound of the formula (I) or a salt thereof, in which

R^1 is i) H, or ii) C_{1-6} alkyl;

R^2 is i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-\text{OR}^0(s)$, halogen(s), $-\text{CONR}^{21}\text{R}^{22}(s)$, phenyl(s) which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and $-\text{COOR}^0(s)$, and heteroaryl(s) which is selected from the group consisting of pyrazolyl, and triazolyl, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-\text{NR}^{23}\text{R}^{24}$, or v) $-\text{COOR}^0$;

R^{21} is C_{1-6} alkyl;

R^{22} is C_{1-6} alkyl;

R^{23} is C_{1-6} alkyl; and

25 R^{24} is i) C_{3-8} cycloalkyl, or ii) phenyl; or

R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom; and

R^0 is the same or different each other, H or C_{1-6} alkyl.

Embodiment 2-3

30 The compound of the formula (I) or a salt thereof, in which

R^1 is C_{1-6} alkyl;

R^2 is C_{1-6} alkyl which may be substituted with a $-\text{OR}^0$; and

R^0 is the same or different each other, H or C_{1-6} alkyl.

Embodiment 2-4

The compound of the formula (I) or a salt thereof, in which

R^1 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituents selected from the group consisting of halogen and pyrazolyl, iii) C_{2-6} alkenyl, or iv) $-OR^0$;

5 R^2 is i) C_{1-6} alkyl which may be substituted with one or more substituents selected from the group consisting of $-OR^0$, halogen, $-COOR^0$, $-CONR^{21}R^{22}$, phenyl which may be substituted with one or more substituents selected from the G^1 group, and heteroaryl which is selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, wherein the heteroaryl may be substituted with one or more substituents selected from the G^2 group, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-OR^0$, v) $-NR^{23}R^{24}$, or vi) phenyl;

R^{21} is H or C_{1-6} alkyl;

R^{22} is i) C_{1-6} alkyl which may be substituted with one or more phenyl substituents, or ii) phenyl;

15 R^{23} is i) H or ii) C_{1-6} alkyl which may be substituted with one or more $-OH$ substituents;

R^{24} is i) C_{1-6} alkyl which may be substituted with one or more phenyl substituents which may be substituted with one or more halogen substituents, ii) C_{3-8} cycloalkyl which may be substituted with one or more C_{1-6} alkyl substituents, iii) phenyl which may be substituted with one or more halogen substituents, or iv) tetrahydropyranyl;

20 G^1 group is i) halogen, ii) $-COOR^0$, iii) $-CONR^0R^0$, iv) $-OH$, v) C_{1-6} alkyl which may be substituted with one or more substituents selected from the group consisting of $-OH$ and halogen, or vi) $-O-(C_{1-6}$ alkyl which may be substituted with one or more substituents selected from the group consisting of $-OH$ and halogen);

25 G^2 group is i) halogen, ii) C_{1-6} alkyl which may be substituted with one or more substituents selected from the group consisting of $-OH$ and halogen or iii) $-CONR^0R^0$; and each R^0 is independently H or C_{1-6} alkyl.

Embodiment 3-1

The compound of the formula (I) or a salt thereof, in which

30 R^3 and R^4 are the same or different each other, i) C_{1-3} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and $-OH(s)$ or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of $-OH(s)$ and heteroaryl(s) which is

selected from the group consisting of pyrazolyl and thienyl, wherein the heteroaryl(s) may be substituted with one or more C₁₋₆ alkyl(s), or,

R³, R⁴, and a carbon atom bounded by R³ and R⁴ may interact to form a 3-oxetane ring and the carbon atom bounded by R³ and R⁴ is a spiro atom.

5 Embodiment 3-2

The compound of the formula (I) or a salt thereof, in which

R³ and R⁴ are the same or different each other, i) C₁₋₃alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and -OH(s) or ii) C₂₋₆ alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and pyrazolyl(s) which may be substituted with one or more C₁₋₆ alkyl(s), or,

R³, R⁴, and a carbon atom bounded by R³ and R⁴ may interact to form a 3-oxetane ring and the carbon atom bounded by R³ and R⁴ is a spiro atom.

Embodiment 3-3


15 The compound of the formula (I) or a salt thereof, in which

R³ and R⁴ are the same or different each other, C₁₋₃alkyl.

Embodiment 3-4

The compound of the formula (I) or a salt thereof, in which

20 R³, R⁴, and a carbon atom bounded by R³ and R⁴ may interact to form a 3-oxetane ring and the carbon atom bounded by R³ and R⁴ is a spiro atom as represented by formula (II) below;



Embodiment 3-5

25 The compound of the formula (I) or a salt thereof, in which

R³ and R⁴ are independently i) C₁₋₃ alkyl which may be substituted with one or more substituents selected from the group consisting of halogen and -OH, or

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane ring.

Embodiment 4-1

The compound of the formula (I) or a salt thereof, in which

5 R^5 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more -O- C_{1-6} alkyl(s), iii) -O- C_{1-6} alkyl, iv) halogen, v) -COO- C_{1-6} alkyl, or vi) C_{3-8} cycloalkyl;

R^6 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -O-(C_{1-6} alkyl(s) which may be substituted with one or more halogen(s)) and halogen(s), iii) -OH, iv) -O-(C_{1-6} alkyl which may be substituted
10 with one or more halogen(s)), v) halogen, vi) -CN, vii) -S- C_{1-6} alkyl, viii) C_{3-8} cycloalkyl, ix) -NR⁰R⁰, or x) C_{2-6} alkenyl; and

R^0 is the same or different each other, H or C_{1-6} alkyl.

Embodiment 4-2

The compound of the formula (I) or a salt thereof, in which

15 R^5 is i) H, ii) C_{1-6} alkyl, iii) -O- C_{1-6} alkyl, iv) halogen, or v) C_{3-8} cycloalkyl;

R^6 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -O-(C_{1-6} alkyl)(s) and halogen(s), iii) -OH, iv) -O-(C_{1-6} alkyl which may be substituted with one or more halogen(s)), v) halogen, vi) -CN, vii) -S- C_{1-6} alkyl, viii) -NR⁰R⁰, or ix) C_{2-6} alkenyl; and

20 R^0 is the same or different each other, H or C_{1-6} alkyl.

Embodiment 4-3

The compound of the formula (I) or a salt thereof, in which

R^5 is H; and

25 R^6 is i) C_{1-6} alkyl, ii) -O-(C_{1-6} alkyl which is substituted with one to three halogen(s)), iii) halogen, or iv) -CN.

The invention includes the compounds which are a combination of two or more of the embodiments described in 1-1 to 4-3 above, which are not inconsistent with each other. The specific examples include the following embodiments.

Embodiment 5-1

30 The compound of the formula (I) or a salt thereof, in which

X^1 is C-R¹¹ or N;

X^2 is C-R¹² or N;

R^{11} is i) H, ii) halogen, iii) -CN, or iv) -O- C_{1-6} alkyl;

R^{12} is H;

R^1 is i) H, or ii) C_{1-6} alkyl;

R^2 is i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-OR^0(s)$, halogen(s), $-CONR^{21}R^{22}(s)$, phenyl(s) which
 5 may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and $-COOR^0(s)$, and heteroaryl(s) which is selected from the group consisting of pyrazolyl, and triazolyl, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-NR^{23}R^{24}$, or v) $-COOR^0$;

R^{21} is C_{1-6} alkyl;

R^{22} is C_{1-6} alkyl;

10 R^{23} is C_{1-6} alkyl;

R^{24} is i) C_{3-8} cycloalkyl, or ii) phenyl; or

R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom;

R^3 and R^4 are the same or different each other, i) C_{1-3} alkyl which may be
 15 substituted with one or more substituent(s) selected from the group consisting of halogen(s) and $-OH(s)$ or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of $-OH(s)$ and pyrazolyl(s) which may be substituted with one or more C_{1-6} alkyl(s), or,

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 may interact to form a 3-oxetane
 20 ring and the carbon atom bounded by R^3 and R^4 is a spiro atom;

R^5 is i) H, ii) C_{1-6} alkyl, iii) $-O-C_{1-6}$ alkyl, iv) halogen, or v) C_{3-8} cycloalkyl;

R^6 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-O-C_{1-6}$ alkyl and halogen, iii) $-OH$, iv) $-O-C_{1-6}$ alkyl which may be substituted with one or more halogen(s), v) halogen, vi) $-CN$, vii) $-S-C_{1-6}$
 25 alkyl, viii) $-NR^0R^0$, or ix) C_{2-6} alkenyl;

R^0 is the same or different each other, H or C_{1-6} alkyl.


Embodiment 5-2

The compound or a salt thereof as described in embodiment 5-1 above, in which

R^1 is C_{1-6} alkyl;

30 R^2 is C_{1-6} alkyl which may be substituted with a $-OR^0$;

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 interact to form a 3-oxetane ring and the carbon atom bounded by R^3 and R^4 is a spiro atom as represented by formula (II) below ;



R^5 is H; and

- R^6 is i) C_{1-6} alkyl, ii) $-O-C_{1-6}$ alkyl which is substituted with one to three
5 halogen(s), iii) halogen, or iv) $-CN$.

Embodiment 5-3

The compound or a salt thereof as described in embodiment 5-2 above, in which X^1 and X^2
are as described in Embodiment 1-3.

Embodiment 6-1

- 10 The compound of the formula (I) or a salt thereof, in which R^1 and R^2 are as described in
Embodiment 2-1, and

X^1 : $C-R^{11}$ or N;

X^2 : $C-R^{12}$ or N;

R^{11} : i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl;

- 15 R^{12} : H or halogen;

- R^3 , R^4 : the same or different each other, i) C_{1-3} alkyl which may be substituted
with one or more substituent(s) selected from the group consisting of halogen(s) and
 $-OH(s)$ or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s)
selected from the group consisting of $-OH(s)$ and heteroaryl(s) which is selected from the
20 group consisting of pyrazolyl, and thienyl wherein the heteroaryl may be substituted with
one or more C_{1-6} alkyl(s), or,

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 may interact to form a 3-oxetane
ring and the carbon atom bounded by R^3 and R^4 is a spiro atom;

- R^5 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more $-O-(C_{1-6}$
25 alkyl)(s), iii) $-O-(C_{1-6}$ alkyl), iv) halogen, v) $-COO-(C_{1-6}$ alkyl), or vi) C_{3-8} cycloalkyl;

R^6 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s)
selected from the group consisting of $-O-(C_{1-6}$ alkyl)(s) which may be substituted with one
or more halogen(s) and halogen(s), iii) $-OH$, iv) $-O-(C_{1-6}$ alkyl which may be substituted

with one or more halogen(s)), v) halogen, vi) -CN, vii) -S-(C₁₋₆ alkyl), viii) C₃₋₈ cycloalkyl, ix) -NR⁰R⁰, or x) C₂₋₆ alkenyl;

G¹ group : i) halogen, ii) -COOR⁰, iii) -CONR⁰R⁰, iv) -OH, v) C₁₋₆ alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen, or vi) -O-(C₁₋₆ alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s));

G² group: i) halogen, ii) C₁₋₆ alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s) or iii) -CONR⁰R⁰.

Embodiment 6-2

The compound or a salt thereof as described in embodiment 6-1 above, in which R³ and R⁴ are as described in Embodiment 3-1.

Embodiment 6-3

The compound or a salt thereof as described in embodiment 6-2 above, in which R³ and R⁴ are as described in Embodiment 4-1.

Embodiment 7-1

A compound, or a salt thereof, which is selected from the group consisting of

(-)-2-(difluoromethyl)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,

4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile, 8,8-diethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitrile,

(-)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one,

(+)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one,

8,8-diethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbonitrile,

8,8'-diethyl-7'-oxo-7',8'-dihydro-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazine]-2'-carbonitrile,

4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile, 6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
 2-(difluoromethoxy)-8,8-dimethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,
 5 (+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
 (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, and
 (-)-2-(difluoromethoxy)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one.

Embodiment 7-2

A compound, or a salt thereof, which is selected from the group consisting of

(-)-2-(difluoromethyl)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,
 15 4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile,
 8,8-diethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitrile,
 (-)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one,
 20 (+)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one,
 8,8-diethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbonitrile,
 8',8'-diethyl-7'-oxo-7',8'-dihydro-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazine]-2'-carbonitrile,
 25 4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
 6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
 4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
 30 2-(difluoromethoxy)-8,8-dimethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,
 (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, and

(-)-2-(difluoromethoxy)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one.

Embodiment 7-3

A compound, or a salt thereof, which is selected from the group consisting of

5 4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,

10 (+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, and
(-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

Embodiment 7-4

A compound, or a salt thereof, which is

15 4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile.

Embodiment 7-5

A compound, or a salt thereof, which is

6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

Embodiment 7-6

20 A compound, or a salt thereof, which is

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile.

Embodiment 7-7

A compound, or a salt thereof, which is

25 (+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

Embodiment 7-8

A compound, or a salt thereof, which is

30 (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

One embodiment of the present invention includes, but are not limited to, the following Embodiment 8-1 to 8-4:

Embodiment 8-1

A crystalline form of

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile, having an X-ray powder diffraction spectrum, comprising at the following angles $2\theta(^{\circ})$: 12.1, 15.6, 16.6, 21.4 and 23.4, measured with Cu-K α irradiation (1.54184 Å).

5 Embodiment 8-2

A crystalline form of

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile, having an X-ray powder diffraction spectrum, comprising at the following angles $2\theta(^{\circ})$: 8.3, 12.1, 15.6, 16.6, 17.3, 20.5, 21.4, 23.4, 24.0 and 25.7, measured with Cu-K α irradiation (1.54184 Å).

10

 Embodiment 8-3

A crystalline form of

(-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, having an X-ray powder diffraction spectrum, comprising at the following angles $2\theta(^{\circ})$: 12.2, 15.5, 18.3, 21.7 and 22.7, measured with Cu-K α irradiation (1.54184 Å).

15

 Embodiment 8-4

A crystalline form of

(-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, having an X-ray powder diffraction spectrum, comprising at the following angles $2\theta(^{\circ})$: 6.7, 11.1, 12.2, 13.7, 15.5, 16.2, 17.0, 18.3, 21.7 and 22.7, measured with Cu-K α irradiation (1.54184 Å).

20

In a further embodiment of the present invention includes a pharmaceutical composition comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof and a pharmaceutically acceptable excipient. In a further embodiment of the present invention includes a pharmaceutical composition comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, and a pharmaceutically acceptable excipient.

25

In a further aspect, the present invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group

30

consisting of frailty and sarcopenia comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome comprising a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof.

In a further aspect, the present invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a pharmaceutical composition for

preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition
5 selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle
10 dysfunction and post-stroke muscle dysfunction comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced
15 muscle weakness and chronic fatigue syndrome comprising a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above.

In a further aspect, the present invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or
20 condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of frailty and
25 sarcopenia. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to a use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt
30 thereof for the manufacture of a pharmaceutical composition for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for

the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and myasthenia gravis, muscular myopathies. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

In a further aspect, the present invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to a use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and myasthenia gravis, muscular myopathies. In a further aspect, the invention relates to use of a

crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates

5 to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for the manufacture of a pharmaceutical composition for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

10 In a further aspect, the present invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to use of a compound according to any one of

15 Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for preventing or treating chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates

20 to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to

25 Embodiment 7-8 above, or a salt thereof for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to

30 Embodiment 7-8 above, or a salt thereof for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to use of a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits,

metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

In a further aspect, the present invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or
5 treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or treating a disease or
10 condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or treating chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or treating
cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic
15 kidney disease/dialysis. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies. In a further aspect, the invention relates to use of a crystalline form
20 according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to use of a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above for preventing or treating a disease or condition selected from the
25 group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

In a further aspect, the present invention relates to a method for preventing or treating a disease or condition selected from the group consisting of stress urinary
30 incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence, comprising administering to a subject an effective amount of the compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating a disease or condition selected from

the group consisting of frailty and sarcopenia, comprising administering to a subject an effective amount of the compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating chronic obstructive pulmonary disease (COPD),

5 comprising administering to a subject an effective amount of the compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, comprising administering to a subject an effective amount of the compound of the formula
10 (I), or a salt thereof. In a further aspect, the invention relates to a method for preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies, comprising administering to a subject an effective amount of the compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In
15 a further aspect, the invention relates to a method for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction, comprising administering to a subject an effective amount of the compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof. In a further aspect, the invention relates to a
20 method for preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome, comprising administering to a subject an effective amount of the compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof.

25 In a further aspect, the present invention relates to a method for preventing or treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence, comprising administering to a subject an effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates
30 to a method for preventing or treating a disease or condition selected from the group consisting of frailty and sarcopenia, comprising administering to a subject an effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a method for preventing or treating

chronic obstructive pulmonary disease (COPD), comprising administering to a subject an effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a method for preventing or treating cachexia syndrome and/or muscle wasting caused by heart failure,

5 cancer, or chronic kidney disease/dialysis, comprising administering to a subject an effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a method for

preventing or treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis

10 and muscular myopathies, comprising administering to a subject an effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a

further aspect, the invention relates to a method for preventing or treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction, comprising administering to a subject an

15 effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above. In a further aspect, the invention relates to a method for

preventing or treating a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue

20 syndrome, comprising administering to a subject an effective amount of the crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above.

In a further aspect, the present invention relates to a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of

25 stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to a compound according to any

one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to a compound according

30 to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of chronic obstructive pulmonary disease (COPD). In a further

aspect, the invention relates to a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of cachexia


syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies. In a further aspect, the invention relates to a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to a compound according to any one of Embodiment 1-1 to Embodiment 7-8 above, or a salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

In a further aspect, the present invention relates to a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, for use in the prevention or treatment of a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence. In a further aspect, the invention relates to a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, for use in the prevention or treatment of a disease or condition selected from the group consisting of frailty and sarcopenia. In a further aspect, the invention relates to a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, for use in the prevention or treatment of chronic obstructive pulmonary disease (COPD). In a further aspect, the invention relates to a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, for use in the prevention or treatment of cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis. In a further aspect, the invention relates to a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, for use in the prevention or treatment of a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies. In a further aspect, the invention relates to a crystalline form according to any one of Embodiment 8-1 to

Embodiment 8-4 above, for use in the prevention or treatment of a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction. In a further aspect, the invention relates to a crystalline form according to any one of Embodiment 8-1 to Embodiment 8-4 above, for use in the prevention or treatment of a disease or condition selected from the group consisting of peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness and chronic fatigue syndrome.

Moreover, one embodiment of the present invention is described below.

Embodiment (1) A compound of the formula (I') or a salt thereof



wherein,

X^1 is C- R^{11} or N;

X^2 is C- R^{12} or N;

R^{11} is i) H, ii) halogen, iii) -CN, or iv) -O- C_{1-6} alkyl;

R^{12} is H or halogen;

R^1 is i) H, ii) C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen and pyrazolyl, iii) C_{2-6} alkenyl, or iv) -OR⁰;

R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of -OR⁰, halogen, -COOR⁰, -CONR²¹R²², phenyl optionally substituted with one or more substituents independently selected from G¹, and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or more substituents independently selected from G², ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) -OR⁰, v) -NR²³R²⁴, vi) -COOR⁰, or vii) phenyl;

each R²¹ is independently H or C₁₋₆ alkyl;

each R²² is independently i) C₁₋₆ alkyl optionally substituted with one or more phenyl substituents, or ii) phenyl;

R²³ is i) H or ii) C₁₋₆ alkyl optionally substituted with one or more -OH

5 substituents;

R²⁴ is i) C₁₋₆ alkyl optionally substituted with one or more phenyl substituents, wherein the phenyl substituents are independently optionally substituted with one or more halogen substituents, ii) C₃₋₈ cycloalkyl optionally substituted with one or more C₁₋₆ alkyl substituents, iii) phenyl optionally substituted with one or more halogen substituents, or iv) tetrahydropyranyl; or

R¹ and R², together with the carbon to which they are attached, form a 4-piperidine ring or 4-tetrahydropyran ring, wherein the 4-piperidine ring is optionally substituted with one or more substituents selected from the group consisting of -SO₂-(C₁₋₆ alkyl) and -COOR⁰;

15 R³ and R⁴ are independently i) C₁₋₃ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen and -OH, or ii) C₂₋₆ alkenyl optionally substituted with one or more substituents independently selected from the group consisting of -OH and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyrazolyl and thienyl, and wherein each heteroaryl is independently optionally substituted with one or more C₁₋₆ alkyl substituents; or

20 R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring;

R⁵ is i) H, ii) C₁₋₆ alkyl optionally substituted with one or more -O-(C₁₋₆ alkyl) substituents, iii) -O-(C₁₋₆ alkyl), iv) halogen, v) -COO-(C₁₋₆ alkyl), or vi) C₃₋₈ cycloalkyl;

25 R⁶ is i) H, ii) C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents) and halogen, iii) -OH, iv) -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents), v) halogen, vi) -CN, vii) -S-(C₁₋₆ alkyl), viii) C₃₋₈ cycloalkyl, ix) -NR⁰R⁰, or x) C₂₋₆ alkenyl;

30 each G¹ is independently i) halogen, ii) -COOR⁰, iii) -CONR⁰R⁰, iv) -OH, v) C₁₋₆ alkyl optionally substituted with one or more substituents selected from the group consisting of -OH and halogen, or vi) -O-(C₁₋₆ alkyl optionally substituted with one or more substituents selected from the group consisting of -OH and halogen);

each G^2 is independently i) halogen, ii) C_{1-6} alkyl optionally substituted with one or more substituents selected from the group consisting of -OH and halogen or iii) $-\text{CONR}^0\text{R}^0$; and

each R^0 is independently H or C_{1-6} alkyl,

5 provided that said compound is not methyl

1,1-diallyl-3-oxo-2,4-dihydroisoquinoline-4-carboxylate or a salt thereof.

Embodiment (2) The compound of embodiment (1), or a salt thereof, wherein X^1 is $C\text{-}R^{11}$.

Embodiment (3) The compound of embodiment (1) or (2), or a salt thereof,
10 wherein R^{11} is H.

Embodiment (4) The compound of embodiment (1), or a salt thereof, wherein X^1 is N.

Embodiment (5) The compound of any one of embodiments (1)-(4), or a salt thereof, wherein X^2 is $C\text{-}R^{12}$.

Embodiment (6) The compound of embodiment (5), or a salt thereof, wherein R^{12} is H.
15

Embodiment (7) The compound of any one of embodiments (1)-(4), or a salt thereof, wherein X^2 is N.

Embodiment (8) The compound of any one of embodiments (1)-(7), or a salt thereof, wherein R^1 is i) H or ii) C_{1-6} alkyl optionally substituted with one or more halogen substituents.
20

Embodiment (9) The compound of any one of embodiments (1)-(7), or a salt thereof, wherein R^1 is C_{1-6} alkyl.

Embodiment (10) The compound of any one of embodiments (1)-(9), or a salt thereof, wherein R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of $-\text{OR}^0$, halogen, $-\text{COOR}^0$, $-\text{CONR}^{21}\text{R}^{22}$, phenyl optionally substituted with one or more substituents independently selected from G^1 , and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or more substituents independently selected from G^2 , ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-\text{OR}^0$, v) $-\text{NR}^{23}\text{R}^{24}$, or vi) phenyl;
25
30

each R^{21} is independently H or C_{1-6} alkyl;

each R^{22} is independently i) C_{1-6} alkyl optionally substituted with one or more phenyl substituents, or ii) phenyl;

R^{23} is i) H or ii) C_{1-6} alkyl optionally substituted with one or more $-OH$ substituents;

5 R^{24} is i) C_{1-6} alkyl optionally substituted with one or more phenyl substituents, wherein the phenyl substituents are independently optionally substituted with one or more halogen substituents, ii) C_{3-8} cycloalkyl optionally substituted with one or more C_{1-6} alkyl substituents, iii) phenyl optionally substituted with one or more halogen substituents, or iv) tetrahydropyranyl;

10 each G^1 is independently i) halogen, ii) $-COOR^0$, iii) $-CONR^0R^0$, iv) $-OH$, v) C_{1-6} alkyl optionally substituted with one or more substituents selected from the group consisting of $-OH$ and halogen, or vi) $-O-(C_{1-6}$ alkyl optionally substituted with one or more substituents selected from the group consisting of $-OH$ and halogen);

15 each G^2 is independently i) halogen, ii) C_{1-6} alkyl optionally substituted with one or more substituents selected from the group consisting of $-OH$ and halogen or iii) $-CONR^0R^0$; and

each R^0 is independently H or C_{1-6} alkyl.

Embodiment (11) The compound of any one of embodiments (1)-(9), or a salt thereof, wherein R^2 is C_{1-6} alkyl optionally substituted with one or more substituents
20 independently selected from the group consisting of $-OR^0$, halogen, $-COOR^0$, $-CONR^{21}R^{22}$, phenyl optionally substituted with one or more substituents independently selected from G^1 , and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or
25 more substituents independently selected from G^2 ;

each R^{21} is independently C_{1-6} alkyl;

each R^{22} is independently C_{1-6} alkyl optionally substituted with one or more phenyl substituents;

each G^1 is independently i) halogen or ii) $-COOR^0$;

30 each G^2 is independently C_{1-6} alkyl; and

each R^0 is independently H or C_{1-6} alkyl.

Embodiment (12) The compound of any one of embodiments (1)-(9), or a salt thereof, wherein R^2 is C_{1-6} alkyl optionally substituted with one or more substituents

independently selected from the group consisting of $-OR^0$, halogen, and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or more substituents

5 independently selected from G^2 ;

each G^2 is independently C_{1-6} alkyl; and

each R^0 is independently H or C_{1-6} alkyl.

Embodiment (13) The compound of any one of embodiments (10)-(12), or a salt thereof, wherein each heteroaryl is independently selected from the group consisting of
10 pyrazolyl and triazolyl.

Embodiment (14) The compound of any one of embodiments (1)-(9), or a salt thereof, wherein R^2 is C_{1-6} alkyl optionally substituted with one or more $-OR^0$ substituents; and each R^0 is independently H or C_{1-6} alkyl.

Embodiment (15) The compound of any one of embodiments (1)-(9), or a salt
15 thereof, wherein R^2 is C_{1-6} alkyl.

Embodiment (16) The compound of any one of embodiments (1)-(9), or a salt thereof, wherein R^2 is i) C_{2-6} alkenyl, ii) C_{2-6} alkynyl, iii) $-NR^{23}R^{24}$, iv) $-COOR^0$, or v) phenyl;

R^{23} is C_{1-6} alkyl;

20 R^{24} is C_{1-6} alkyl, C_{3-8} cycloalkyl, or phenyl; and

each R^0 is independently H or C_{1-6} alkyl.

Embodiment (17) The compound of any one of embodiments (1)-(7), or a salt thereof, wherein R^1 and R^2 are each methyl.

Embodiment (18) The compound of any one of embodiments (1)-(7), or a salt
25 thereof, wherein R^1 is methyl, R^2 is C_{1-6} alkyl optionally substituted with one or more $-OR^0$ substituents, and each R^0 is independently H or C_{1-6} alkyl.

Embodiment (19) The compound of any one of embodiments (1)-(7), or a salt thereof, wherein R^1 and R^2 , together with the carbon to which they are attached, form a 4-piperidine ring or 4-tetrahydropyran ring, wherein the 4-piperidine ring is optionally
30 substituted with one or more substituents selected from the group consisting of $-SO_2-(C_{1-6}$ alkyl) and $-COOR^0$.

Embodiment (20) The compound of any one of embodiments (1)-(19), or a salt thereof, wherein R^3 and R^4 are independently i) C_{1-3} alkyl optionally substituted with one

or more substituents independently selected from the group consisting of halogen and -OH;
or

R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring.

5 Embodiment (21) The compound of any one of embodiments (1)-(19), or a salt thereof, wherein R³ and R⁴ are independently i) C₁₋₃ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen and -OH, or ii) C₂₋₆ alkenyl optionally substituted with one or more heteroaryl substituents, wherein each heteroaryl is independently selected from the group consisting of pyrazolyl and
10 thienyl, and wherein each heteroaryl is independently optionally substituted with one or more C₁₋₆ alkyl substituents.

Embodiment (22) The compound of any one of embodiments (1)-(19), or a salt thereof, wherein R³ and R⁴ are independently C₁₋₃ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen and -OH.

15 Embodiment (23) The compound of any one of embodiments (1)-(19), or a salt thereof, wherein R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring.

Embodiment (24) The compound of any one of embodiments (1)-(23), or a salt thereof, wherein R⁵ is i) H, ii) C₁₋₆ alkyl, iii) -O-(C₁₋₆ alkyl), iv) halogen, or v) C₃₋₈
20 cycloalkyl.

Embodiment (25) The compound of any one of embodiments (1)-(23), or a salt thereof, wherein R⁵ is H.

Embodiment (26) The compound of any one of embodiments (1)-(25), or a salt thereof, wherein R⁶ is i) H, ii) C₁₋₆ alkyl optionally substituted with one or more
25 substituents independently selected from the group consisting of -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents) and halogen, iii) -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents), iv) halogen, v) -CN, vi) -S-(C₁₋₆ alkyl), or vii) C₃₋₈ cycloalkyl.

Embodiment (27) The compound of any one of embodiments (1)-(25), or a salt thereof, wherein R⁶ is i) H, ii) C₁₋₆ alkyl optionally substituted with one or more halogen
30 substituents, iii) -OH, iv) -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents), v) halogen, vi) -CN, or vii) C₂₋₆ alkenyl.

Embodiment (28) The compound of any one of embodiments (1)-(25), or a salt

thereof, wherein R^6 is i) H, ii) C_{1-6} alkyl, iii) $-O-(C_{1-6}$ alkyl optionally substituted with one or more halogen substituents), iv) halogen, v) $-CN$, vi) $-NR^0R^0$, or vii) C_{2-6} alkenyl.

Embodiment (29) The compound of any one of embodiments (1)-(25), or a salt thereof, wherein R^6 is i) halogen or ii) $-CN$.

5 Embodiment (30) The compound of any one of embodiments (1)-(29), or a salt thereof, wherein each R^0 is H.

Embodiment (31) The compound of any one of embodiments (1)-(29), or a salt thereof, wherein each R^0 is independently C_{1-6} alkyl.

10 Embodiment (32) The compound of any one of embodiments (1)-(7), or a salt thereof, wherein

R^1 is i) H or ii) C_{1-6} alkyl optionally substituted with one or more halogen substituents;

R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of $-OR^0$, halogen, $-COOR^0$, $-CONR^{21}R^{22}$,
15 phenyl optionally substituted with one or more substituents independently selected from G^1 , and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or more substituents independently selected from G^2 , ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv)
20 $-NR^{23}R^{24}$, v) $-COOR^0$, or vi) phenyl;

each R^{21} , R^{22} , and R^{23} is independently C_{1-6} alkyl;

R^{24} is i) C_{1-6} alkyl, ii) C_{3-8} cycloalkyl, or iii) phenyl; or

R^1 and R^2 , together with the carbon to which they are attached, form a 4-piperidine ring or 4-tetrahydropyran ring, wherein the 4-piperidine ring is optionally
25 substituted with one or more substituents selected from the group consisting of $-SO_2-(C_{1-6}$ alkyl) and $-COOR^0$;

R^3 , R^4 are independently i) C_{1-3} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen and $-OH$, or ii) C_{2-6} alkenyl optionally substituted with one or more heteroaryl substituents, wherein each
30 heteroaryl is independently selected from the group consisting of pyrazolyl and thienyl, and wherein each heteroaryl is independently optionally substituted with one or more C_{1-6} alkyl substituents, or

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane

ring

R^5 is i) H, ii) C_{1-6} alkyl, iii) $-O-(C_{1-6}$ alkyl), iv) halogen, or v) C_{3-8} cycloalkyl;

R^6 is i) H, ii) C_{1-6} alkyl optionally substituted with one or more substituents

independently selected from the group consisting of $-O-(C_{1-6}$ alkyl optionally substituted

5 with one or more halogen substituents) and halogen, iii) $-OH$, iv) $-O-(C_{1-6}$ alkyl optionally substituted with one or more halogen substituents), v) halogen, vi) $-CN$, vii) $-S-(C_{1-6}$ alkyl), viii) C_{3-8} cycloalkyl, ix) $-NR^0R^0$, or x) C_{2-6} alkenyl;

each G^1 is independently i) halogen or ii) $-COOR^0$;

each G^2 is independently ii) C_{1-6} alkyl; and

10 each R^0 is independently H or C_{1-6} alkyl.

Embodiment (33) The compound of embodiment (1), or a salt thereof, wherein

X^1 is $C-R^{11}$;

X^2 is $C-R^{12}$;

R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl;

15 R^{12} is H or halogen;

R^1 is i) H or ii) C_{1-6} alkyl optionally substituted with one or more halogen substituents;

R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents

independently selected from the group consisting of $-OR^0$, halogen, $-COOR^0$, $-CONR^{21}R^{22}$,

20 phenyl optionally substituted with one or more substituents independently selected from G^1 , and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, ii) $-NR^{23}R^{24}$, or iii) phenyl;

each R^{21} is independently C_{1-6} alkyl;

25 each R^{22} is independently C_{1-6} alkyl optionally substituted with one or more phenyl substituents;

R^{23} is C_{1-6} alkyl;

R^{24} is i) C_{1-6} alkyl, ii) C_{3-8} cycloalkyl, or iii) phenyl; or

R^1 and R^2 , together with the carbon to which they are attached, form a

30 4-piperidine ring or 4-tetrahydropyran ring, wherein the 4-piperidine ring is optionally substituted with one or more substituents selected from the group consisting of $-SO_2-(C_{1-6}$ alkyl) and $-COOR^0$;

R^3 and R^4 are independently C_{1-3} alkyl optionally substituted with one or more

halogen substituents, or

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane ring;

R^5 is i) H, ii) C_{1-6} alkyl, iii) $-O-(C_{1-6} \text{ alkyl})$, iv) halogen, or v) C_{3-8} cycloalkyl;

5 R^6 is i) H, ii) C_{1-6} alkyl optionally substituted with one or more halogen substituents, iii) $-OH$, iv) $-O-(C_{1-6} \text{ alkyl optionally substituted with one or more halogen substituents})$, v) halogen, v) $-CN$, or v) C_{2-6} alkenyl;

each G^1 is independently i) halogen or ii) $-COOR^0$; and

each R^0 is independently H or C_{1-6} alkyl.

10 Embodiment (34) The compound of embodiment (1), or a salt thereof, wherein

X^1 is $C-R^{11}$ or N;

X^2 is $C-R^{12}$ or N;

R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6} \text{ alkyl}$;

R^{12} is H;

15 R^1 is i) H, or ii) C_{1-6} alkyl;

R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of $-OR^0$, halogen, $-CONR^{21}R^{22}$, phenyl optionally substituted with one or more substituent independently selected from the group consisting of halogen and $-COOR^0$, and heteroaryl, wherein each heteroaryl is
20 independently selected from the group consisting of pyrazolyl and triazolyl, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-NR^{23}R^{24}$, or v) $-COOR^0$;

R^{21} is C_{1-6} alkyl;

R^{22} is C_{1-6} alkyl;

R^{23} is C_{1-6} alkyl;

25 R^{24} is i) C_{3-8} cycloalkyl, or ii) phenyl; or

R^1 , R^2 , together with the carbon to which they are attached, form a 4-tetrahydropyran ring;

R^3 and R^4 are independently i) C_{1-3} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen and $-OH$, or ii)

30 C_{2-6} alkenyl optionally substituted with one or more substituents independently selected from the group consisting of $-OH$ and pyrazolyl, wherein each pyrazolyl is independently optionally substituted with one or more C_{1-6} alkyl substituents; or

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane

ring;

R^5 is i) H, ii) C_{1-6} alkyl, iii) $-O-(C_{1-6} \text{ alkyl})$, iv) halogen, or v) C_{3-8} cycloalkyl;

R^6 is i) H, ii) C_{1-6} alkyl optionally substituted with one or more substituents selected from the group consisting of $-O-(C_{1-6} \text{ alkyl})$ and halogen, iii) $-OH$, iv) $-O-(C_{1-6} \text{ alkyl})$ optionally substituted with one or more halogen substituents), v) halogen, vi) $-CN$,
 5 vii) $-S-(C_{1-6} \text{ alkyl})$, viii) $-NR^0R^0$, or ix) C_{2-6} alkenyl; and

each R^0 is independently H or C_{1-6} alkyl.

Embodiment (35) The compound of embodiment (34), or a salt thereof, wherein

R^1 is C_{1-6} alkyl;

10 R^2 is C_{1-6} alkyl optionally substituted with $-OR^0$;

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane

ring;

R^5 is H; and

R^6 is i) C_{1-6} alkyl, ii) $-O-(C_{1-6} \text{ alkyl})$ optionally substituted with one to three
 15 halogen substituents), iii) halogen, or iv) $-CN$.

Embodiment (36) The compound of embodiment (34) or (35), or a salt thereof,

wherein

X^1 is $C-R^{11}$;

X^2 is $C-R^{12}$;

20 R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl; and

R^{12} is H.

Embodiment (37) The compound of (1), or a salt thereof, wherein

X^1 is $C-R^{11}$;

X^2 is $C-R^{12}$;

25 R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl;

R^{12} is H or halogen;

R^1 is i) H or ii) C_{1-6} alkyl optionally substituted with one or more halogen
 substituents;

R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents
 30 independently selected from the group consisting of $-OR^0$, halogen, $-COOR^0$, $-CONR^{21}R^{22}$,
 phenyl optionally substituted with one or more substituents independently selected from G^1 ,
 and heteroaryl, wherein each heteroaryl is independently selected from the group
 consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl,

isoxazolyl, and triazolyl, ii) $-NR^{23}R^{24}$, or iii) phenyl;

each R^{21} is independently C_{1-6} alkyl;

each R^{22} is independently C_{1-6} alkyl optionally substituted with one or more phenyl substituents;

5 R^{23} is C_{1-6} alkyl;

R^{24} is i) C_{1-6} alkyl, ii) C_{3-8} cycloalkyl, or iii) phenyl; or

R^1 and R^2 , together with the carbon to which they are attached, form a 4-piperidine ring or 4-tetrahydropyran ring, wherein the 4-piperidine ring is optionally substituted with one or more substituents selected from the group consisting of $-SO_2-(C_{1-6}$ alkyl) and $-COOR^0$;

10 R^3 and R^4 are independently C_{1-3} alkyl optionally substituted with one or more halogen substituents, or

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane ring;

15 R^5 is i) H, ii) C_{1-6} alkyl, iii) $-O-(C_{1-6}$ alkyl), iv) halogen, or v) C_{3-8} cycloalkyl;

R^6 is i) H, ii) C_{1-6} alkyl optionally substituted with one or more halogen substituents, iii) $-OH$, iv) $-O-(C_{1-6}$ alkyl optionally substituted with one or more halogen substituents), iv) halogen, v) $-CN$, or v) C_{2-6} alkenyl;

each G^1 is independently i) halogen or ii) $-COOR^0$; and

20 each R^0 is independently H or C_{1-6} alkyl.

Embodiment (38) The compound of embodiment (1), or a salt thereof, wherein X^1 is $C-R^{11}$;

X^2 is N;

R^{11} is H;

25 R^1 is i) H or ii) C_{1-6} alkyl;

R^2 is i) C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of $-OR^0$, halogen and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or more substituents independently selected from G^2 , ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, or vi) $-COOR^0$;

R^3 and R^4 are independently i) C_{1-3} alkyl or ii) C_{2-6} alkenyl optionally substituted with one or more heteroaryl substituents, wherein each heteroaryl is independently selected

from the group consisting of pyrazolyl and thienyl, and wherein each heteroaryl is independently optionally substituted with one or more C₁₋₆ alkyl substituents, or

R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring;

5 R⁵ is H;

R⁶ is i) H, ii) C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents) and halogen, iii) -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents), iv) halogen, v) -CN, or vi) -S-(C₁₋₆ alkyl);

each G² is independently C₁₋₆ alkyl; and

each R⁰ is independently H or C₁₋₆ alkyl.

Embodiment (39) The compound of embodiment (1), or a salt thereof, wherein

X¹ is C-R¹¹;

15 X² is N;

R¹¹ is H;

R¹ is i) H or ii) C₁₋₆ alkyl;

R² is i) C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of -OR⁰, halogen and heteroaryl, wherein each heteroaryl is independently selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, and wherein each heteroaryl is optionally substituted with one or more substituents independently selected from G², ii) C₂₋₆ alkenyl, iii) C₂₋₆ alkynyl, or vi) -COOR⁰;

20 R³ and R⁴ are independently i) C₁₋₃ alkyl or ii) C₂₋₆ alkenyl optionally substituted with one or more heteroaryl substituents, wherein each heteroaryl is independently selected from the group consisting of pyrazolyl and thienyl, and wherein each heteroaryl is independently optionally substituted with one or more C₁₋₆ alkyl substituents, or

R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring;

30 R⁵ is H;

R⁶ is i) H, ii) C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents) and halogen, iii) -O-(C₁₋₆ alkyl optionally

substituted with one or more halogen substituents), iv) halogen, v) -CN, or vi) -S-(C₁₋₆ alkyl);

each G² is independently C₁₋₆ alkyl; and

each R⁰ is independently H or C₁₋₆ alkyl.

5 Embodiment (40) The compound of embodiment (1), or a salt thereof, wherein

X¹ is N;

X² is C-R¹²;

R¹² is H;

R¹ is i) H, ii) C₁₋₆ alkyl;

10 R² is i) C₁₋₆ alkyl optionally substituted with one or more -OR⁰ substituents or ii) -COOR⁰;

R³ and R⁴ are independently C₁₋₃ alkyl, or

R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring;

15 R⁵ is H;

R⁶ is i) halogen or ii) -CN; and

each R⁰ is independently H or C₁₋₆ alkyl.

Embodiment (41) The compound of embodiment (1), or a salt thereof, wherein

X¹ and X² are each N;

20 R¹ is i) H or ii) C₁₋₆ alkyl;

R² is i) C₁₋₆ alkyl or ii) -COOR⁰;

R³ and R⁴ are independently C₁₋₃ alkyl optionally substituted with one or more -OH, or

25 R³ and R⁴, together with the carbon to which they are attached, form a 3-oxetane ring;

R⁵ is H;

R⁶ is i) H, ii) C₁₋₆ alkyl, iii) -O-(C₁₋₆ alkyl optionally substituted with one or more halogen substituents), iv) halogen, v) -CN, iv) -NR⁰R⁰, or vii) C₂₋₆ alkenyl; and

each R⁰ is independently H or C₁₋₆ alkyl.

30 Embodiment (42) The compound of embodiment (1), or a salt thereof, wherein

X¹ is CH;

X² is CH or N;

R¹ is H or C₁₋₆ alkyl;

R^2 is C_{1-6} alkyl optionally substituted with one or more substituents selected from the group consisting of $-OR^0$ and halogen;

R^3 and R^4 are independently C_{1-3} alkyl, or

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane

5 ring;

R^5 is H;

R^6 is H, C_{1-6} alkyl, halogen, or $-CN$; and

each R^0 is independently H or C_{1-6} alkyl.

Embodiment (43) The compound of embodiment (1), or a salt thereof, wherein

10 X^1 and X^2 are each CH;

R^1 is H, methyl, or ethyl;

R^2 is methyl or ethyl, each of which is optionally substituted with one or more substituents selected from the group consisting of $-OH$ and halogen;

R^3 and R^4 , together with the carbon to which they are attached, form a 3-oxetane

15 ring;

R^5 is H; and

R^6 is H, methyl, halogen, or $-CN$.

Embodiment (44) The compound of any one of embodiments (1)-(16), and

(18)-(43), or a salt thereof, wherein the carbon bearing R^1 and R^2 is in the S configuration

20 in case that R^1 is not the same as R^2 .

Embodiment (45) The compound of any one of embodiments (1)-(16), and

(18)-(43), or a salt thereof, wherein the carbon bearing R^1 and R^2 is in the R configuration in case that R^1 is not the same as R^2 .













Embodiment (46) The compound of any one of embodiments (1)-(22) and


25 (24)-(45), or a salt thereof, wherein the carbon bearing R^3 and R^4 is in the S configuration in case that R^3 is not the same as R^4 .













Embodiment (47) The compound of any one of embodiments (1)-(22) and


(24)-(45), or a salt thereof, wherein the carbon bearing R^3 and R^4 is in the R configuration in case that R^3 is not the same as R^4 .


30 Embodiment (48) The compound of embodiment (1), or a salt thereof, wherein X^1 is $C-R^{11}$ and X^2 is $C-R^{12}$, and wherein the compound is selected from the group consisting of:


	
	
	
	
	
	




	
	
	
	
	
	











Embodiment (49) The compound of embodiment (1), or a salt thereof, wherein X^1 is C-R¹¹ and X^2 is N, and wherein the compound is selected from the group consisting of:




























Embodiment (50) The compound of embodiment (1), or a salt thereof, wherein X^1 is N and X^2 is $C-R^{12}$, and wherein the compound is selected from the group consisting of:





Embodiment (51) The compound of embodiment (1), or a salt thereof, wherein X^1 is N and X^2 is N, and wherein the compound is selected from the group consisting of:



Embodiment (52) A compound, or a salt thereof, which is selected from the group consisting of

4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,

5 6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,

(+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, and

10 (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

Embodiment (53) The compound of embodiment (52), or a salt thereof, which is 4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile.

Embodiment (54) The compound of embodiment (52), or a salt thereof, which is 15 6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

Embodiment (55) The compound of embodiment (52), or a salt thereof, which is 4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile.

Embodiment (56) The compound of embodiment (52), or a salt thereof, which is (+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

20 Embodiment (57) The compound of embodiment (52), or a salt thereof, which is (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one.

Embodiment (58) A pharmaceutical composition comprising a compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

25 Embodiment (59) A pharmaceutical composition for treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI), fecal incontinence, frailty, sarcopenia, chronic obstructive pulmonary disease (COPD), cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, amyotrophic lateral sclerosis (ALS),

spinal muscular atrophy (SMA), myasthenia gravis, a muscular myopathy, post-spinal cord injury (SCI) muscle dysfunction, post-stroke muscle dysfunction, peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness, and chronic fatigue syndrome, comprising a
5 compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof.

Embodiment (60) Use of a compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for treating a disease or condition selected from the group consisting of stress
10 urinary incontinence (SUI), mixed urinary incontinence (MUI), fecal incontinence, frailty, sarcopenia, chronic obstructive pulmonary disease (COPD), cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis, a muscular myopathy, post-spinal cord injury (SCI) muscle dysfunction, post-stroke muscle
15 dysfunction, peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness, and chronic fatigue syndrome.

Embodiment (61) Use of a compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof, for treating a disease or condition selected from
20 the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI), fecal incontinence, frailty, sarcopenia, chronic obstructive pulmonary disease (COPD), cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis, a muscular myopathy, post-spinal cord injury (SCI)
25 muscle dysfunction, post-stroke muscle dysfunction, peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness, and chronic fatigue syndrome.

Embodiment (62) A method for treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI),
30 fecal incontinence, frailty, sarcopenia, chronic obstructive pulmonary disease (COPD), cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis, a muscular myopathy, post-spinal cord injury (SCI) muscle

dysfunction, post-stroke muscle dysfunction, peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness, and chronic fatigue syndrome, comprising administering to a subject an effective amount of a compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof.

Embodiment (63) A compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI), fecal incontinence, frailty, sarcopenia, chronic obstructive pulmonary disease (COPD), cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis, a muscular myopathy, post-spinal cord injury (SCI) muscle dysfunction, post-stroke muscle dysfunction, peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness, and chronic fatigue syndrome.

Embodiment (64) A kit comprising a compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof, and instructions for use in the treatment of a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI), fecal incontinence, frailty, sarcopenia, chronic obstructive pulmonary disease (COPD), cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis, a muscular myopathy, post-spinal cord injury (SCI) muscle dysfunction, post-stroke muscle dysfunction, peripheral vascular disease, peripheral arterial disease, rehabilitation-related deficits, metabolic syndrome, obesity, ventilator-induced muscle weakness, and chronic fatigue syndrome.

Embodiment (65) An article of manufacture comprising a compound of any one of embodiments (1)-(57), or a pharmaceutically acceptable salt thereof.

Any variation described herein with reference to formula (I) can also be applied to formula (I') as if each and every such variation had been specifically described for formula (I'). Similarly, any variation described herein with reference to formula (I') can also be applied to formula (I) as if each and every such variation had been specifically described for formula (I). Furthermore, each variation of X^1 , X^2 , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , and R^0

described herein can be combined with one another as if each combination had been specifically and separately described.

With regard to the compound of the formula (I) or the formula (I'), tautomers or geometrical isomers thereof may exist, depending on the kinds of the substituents. In the specification, the compound of the formula (I) or the formula (I') may be described in only one form of isomers in some cases, but the invention includes other isomers, isolated forms of the isomers, or a mixture thereof.

Furthermore, some of the compounds of the formula (I) or the formula (I') may have asymmetric carbon atoms or asymmetries in some cases, and correspondingly, the optical isomers thereof can exist. The invention includes the isolated form of the optical isomer of the compound of the formula (I) or the formula (I'), or a mixture of optical isomers in any ratio.

In addition, a pharmaceutically acceptable prodrug of the compound represented by the formula (I) or the formula (I') is also included in the invention. The pharmaceutically acceptable prodrug refers to a compound having a group which can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like, by solvolysis or under a physiological condition. Examples of the groups forming the prodrug include those as described in Prog. Med., 5, 2157-2161 (1985) or "Pharmaceutical Research and Development" (Hirokawa Publishing Company, 1990), vol. 7, Drug Design, 163-198.

Moreover, the salt of the compound of the formula (I) or the formula (I') is a pharmaceutically acceptable salt of the compound of the formula (I) or the formula (I'), and the compounds of the formula (I) or the formula (I') may form an acid addition salt or a salt with a base, depending on the kinds of the substituents in some cases. Specifically, examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, and with organic acids such as formic acid, acetic acid, propanoic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, ditolyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid, and salts with metal anions such as sodium, potassium, magnesium, calcium, and aluminum, and with organic bases such as methylamine, ethylamine, and

ethanolamine, salts with various amino acids such as acetyl leucine, lysine, and ornithine, or derivatives of amino acids, ammonium salts, and others.


In addition, the present invention also includes various hydrates or solvates, and crystal polymorph substances of the compound of the formula (I) or the formula (I') and a salt thereof. In addition, the invention also includes the compounds labeled with various radioactive or non-radioactive isotopes.

The compound of the formula (I) or the formula (I'), or a salt thereof can be prepared by applying various known synthetic methods, using the characteristics based on their basic structures or the kinds of the substituents. Depending on the types of the functional groups, it is in some cases advantageous to protect the functional group with an appropriate protective group (a group which is capable of being easily converted into the functional group), during the steps from starting materials to intermediates. Examples of the protective group include the protective groups as described in "Greene's Protective Groups in Organic Synthesis (5th edition, John Wiley & Sons, Inc., 2014)", edited by P. G. M. Wuts, and the like, which may be appropriately selected and used depending on the reaction conditions. In these methods, a desired compound can be obtained by introducing the protective group to carry out the reaction, and then, if desired, removing the protective group.

In addition, the prodrug of the compound of the formula (I) or the formula (I') can be prepared by introducing a specific group during the steps from starting materials to intermediates, in the same manner as for the above protective groups, or by further carrying out the reaction using the obtained compound of the formula (I) or the formula (I'). The reaction can be carried out by applying a method known to a person skilled in the art, such as common esterification, amidation, and dehydration.

Herein below, typical preparation methods of the compound of the formula (I) or the formula (I') and the compound of the formula (a) which is the starting compound will be described. Each of the production processes can also be carried out with reference to the documents appended to the description herein. Further, the preparation methods of the invention are not limited to the examples as shown below.

Production Process 1




(in which, R^{3a} , R^{4a} represents the same or different each other, C_{1-3} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and $-OH(s)$ or C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of $-OH(s)$ and heteroaryl(s) which is selected from the group consisting of pyrazolyl and thienyl, wherein the heteroaryl(s) may be substituted with one or more C_{1-6} alkyl(s), which shall apply hereinafter).

This reaction is a method for producing a compound of the formula (1a) which is a compound of the invention, by cyclization reaction known as Pictet-Spengler reaction.

This reaction is carried out using the compound of the formula (a) and (b) in equivalent amounts, or either thereof in an excess amount, by stirring the mixture under the temperature condition ranging from under cooling to heating to reflux in acidic condition, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. Examples of the acid used herein are not particularly limited, but include hydrochloric acid, hydrobromic acid, hydroiodic acid, acetic acid, trifluoroacetic acid, sulfuric acid, nitric acid, phosphoric acid, polyphosphoric acid, methansulfonic acid, and Eaton's reagent. *See also, for example, Synthetic Communications, 32(12), 1787-1790 (2002).*

Production Process 2




(in which, R^{1a} represents C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s), and pyrazolyl(s), ii) C_{2-6} alkenyl, or iii) $-OR^0$, which shall apply hereinafter).

5 This production process is a method for producing the compound of the formula (Ic) which is included in the compound of the formula (I) or the formula (I') from the compound of the formula (Ib) which is also included in the formula (I) or the formula (I') and compound of the formula (c). Examples of L^1 may include chloro and the like.

10 The reaction is carried out using the compound of the formula (Ib) and the compound of the formula (c) in equivalent amounts, or either thereof in an excess amount, by stirring the mixture under the temperature condition ranging from under cooling to under heating, preferably at -20°C to 60°C , usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction, in the presence of a base. Examples of the base used herein are not particularly limited, but include sodium hydride, potassium tert-butoxide,
 15 potassium carbonate, and cesium carbonate. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene and the like, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like, N,N-dimethylformamide,
 20 1,3-dimethylimidazolidin-2-one, 1-methylpyrrolidin-2-one, dimethylsulfoxide, ethyl acetate, acetonitrile, water, and a mixture thereof. *See also, for example, WO2011/159760 A1 and WO2005/26120.*


Production Process 3



This production process is a method for producing the compound of the formula (Id) from the compound of the formula (d) and the compound (e).

The reaction is carried out using the compound of the formula (d) and the compound of the formula (e) in an 2 mole equivalent or more amount of, the compound of the formula (e) by stirring the mixture under the temperature condition ranging from under cooling to under heating, preferably at -40°C to 60°C, more preferably at -20°C to 60°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction, in the presence of 2 mole equivalent or more amount of a base. Examples of the base used herein are not particularly limited, but include sodium hydride, potassium tert-butoxide, potassium carbonate, and cesium carbonate. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene and the like, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like, N,N-dimethylformamide, 1,3-dimethylimidazolidin-2-one, 1-methylpyrrolidin-2-one, dimethylsulfoxide, ethyl acetate, acetonitrile, water, and a mixture thereof. *See* also, for example, WO2011/159760.

Production Process 4




(in which, X^a represents halogen).

This reaction is a method for producing a compound of the formula (Ie) which is a compound of the invention, by cyclization reaction.

This reaction is carried out using the compound of the formula (f), in the presence of equivalent or more amount of a base, by stirring the mixture under the temperature condition ranging from under cooling to room temperature, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. Examples of the base used herein are not particularly limited, but include sodium bis(trimethylsilyl)amide, sodium

hydride, and potassium tert-butoxide. Examples of the solvent used herein are not particularly limited, but include ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like, N,N-dimethylformamide, 1,3-dimethylimidazolidin-2-one, 1-methylpyrrolidin-2-one, and the like. Further, there are some cases where a mixed solvent of the solvent and water is highly suitable for the reaction. *See* also, for example, WO2008/82009.


Production Process 5



This reaction is a method for producing a compound of the formula (If) which is a compound of the invention, by a decarboxylation reaction.

This reaction is carried out using the compound of the formula (Ie), in the presence of equivalent or more amount of an acid, by stirring the mixture under the temperature condition ranging from under cooling to heating to reflux in acidic condition, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. Examples of the acid used herein are not particularly limited, but include hydrochloric acid, hydrobromic acid, hydroiodic acid, formic acid, acetic acid, trifluoroacetic acid, and sulfuric acid. Examples of the solvent used herein are not particularly limited, but include halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform and the like, N,N-dimethylformamide, tetrahydrofuran, and the like. Further, there are some cases where a mixed solvent of the solvent and water is highly suitable for the reaction. *See also, for example, J. Org. Chem.*, 1983, 48 (6), pp 791-796, *Org. Lett.*, 2011, Vol. 13, p 5560-5563.

Production Process 6



This reaction is a method for producing a compound of the formula (Ih) which is a compound of the invention, by cyanation using Pd-catalyst from a compound of the formula (Ig).

This reaction is carried out using the compound of the formula (Ig) and cyanation reagent by stirring the mixture under the temperature condition ranging from under cooling to heating to reflux or using microwave irradiation, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. Examples of the cyanation reagent used herein are not particularly limited, but may include CuCN, Zn(CN)₂, KCN. Further, there are some cases where existence of Palladium catalyst such as palladium(II) diacetate, Pd₂(dba)₃, Pd(TFA)₂ or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) is highly suitable for the reaction. Further, there are some cases where existence of di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (tBuXphos), 2',4',6'-diisopropyl-1,1'-biphenyl-2-ylidicyclohexylphosphine (Xphos), or, 1,1'-bis(diphenylphosphino)ferrocene (dppf) is suitable for the reaction. Further, there are some cases where existence of Zn is suitable for the reaction. Examples of the solvent used herein are not particularly limited, but include halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform and the like, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, and the like. Further, there are some cases where a mixed solvent of the solvent and water is highly suitable for the reaction. See, for example, Org. Lett., 2007, 9 (9), pp. 1711–1714, Med. Chem. Lett., 2013, 4 (2), pp. 211–215, Journal of Medicinal Chemistry, 2005, vol. 48, p. 3953 – 3979.


Some compounds of the formula (I) or the formula (I') can be prepared by known reaction such as Suzuki coupling, ipso substitution, etc., from the compound (If). *See* also, for example, WO2010/131145; WO2008/147547; and US6809097.

Some compounds of the formula (I) or the formula (I') can be prepared by known reaction such as halogenation, reduction, hydroxylation, amido-condensation etc., from the compounds of the formula (I) or the formula (I'). *See* also, for example, Bioorganic and Medicinal Chemistry, 2011, vol. 19, p. 1666 – 1673; Journal of Organic Chemistry, 1980 , vol. 45, p. 4391 – 4398; and WO2010/51373.

The compound of the formula (d) can be prepared by the same method of

Production Process 1. Some synthetic intermediates for preparation of the compound of the formula (I) or the formula (I') can be prepared by known synthetic methods or synthetic methods described in this specification from known compounds. *See* also, for example, WO2008/3690; Org. Lett., 2007, 9 (9), pp. 1711–1714; Med. Chem. Lett., 2013, 4 (2), pp. 211–215; J. Org. Chem. 2013, 78, 2661-2669; Bioorganic and Medicinal Chemistry Letters, 2010 , vol. 20, p. 1890 – 1894; and J. Org. Chem. 2013, 78, 2786–2791.


Production Process of synthetic intermediates 1



This reaction is carried out using the compound of the formula (g) and the compound of the formula (h) under basic condition by stirring the mixture under the temperature condition ranging from under cooling to room temperature, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. Examples of the basic reagent used herein are not particularly limited, but include n-butyllithium, sec-butyllithium, tert-butyllithium. Examples of the solvent used herein are not particularly limited, but include ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like, hydrocarbons such as

n-hexane, n-pentane, and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like.


Production Process of Synthetic Intermediates 2



(where R^{00} represents C_{1-6} alkyl, which shall apply hereinafter).

This reaction is carried out using the compound of the formula (j) and R^{00} -OCO-Lv (Lv represents O-(C_{1-6} alkyl) or halogen) by stirring the mixture under the temperature condition ranging from under cooling to room temperature, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent under basic condition. Examples of the basic reagent used herein are not particularly limited, but include n-butyllithium, sec-butyllithium, tert-butyllithium, lithium diisopropylamide, and lithium 2,2,6,6-tetramethylpiperidide. Examples of the solvent used herein are not particularly limited, but include ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like, hydrocarbons such as n-hexane, n-pentane, and the like.


Production Process of Synthetic Intermediates 3



This reaction is carried out using the compound of the formula (k) under acidic condition in a solvent which is inert to the reaction or without a solvent by stirring the

mixture under the temperature condition ranging from under cooling to room temperature, usually for 0.1 hours to 5 days. Examples of the acid used herein are not particularly limited, but include hydrochloric acid, hydrobromic acid, hydroiodic acid, acetic acid, trifluoroacetic acid, sulfuric acid, nitric acid, and thionyl chloride. Examples of the solvent used herein are not particularly limited, but include ethyl acetate, acetonitrile, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like, hydrocarbons such as n-hexane, n-pentane, and the like, alcohols such as methanol, ethanol, and the like.


10 Production Process of Synthetic Intermediates 4



This reaction is carried out using the compound of the formula (m) in a solvent which is inert to the reaction or without a solvent under basic condition by stirring the mixture under the temperature condition ranging from under cooling to room temperature, usually for 0.1 hours to 5 days. Examples of the basic reagent used herein are not particularly limited, but include sodium hydrogen carbonate, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, potassium hydrogen carbonate, triethylamine, and N,N-diisopropylethylamine. Examples of the solvent used herein are not particularly limited, but include water, alcohols such as methanol, ethanol, and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, cyclopentylmethyl ether and the like.

Production Process of Synthetic Intermediates 5

pentamethylcyclopentadienyliridium(III) dichloride dimer



(in which, R^{1b} represents C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s)).

5 This reaction is carried out using the compound of the formula (da), pentamethylcyclopentadienyliridium(III) dichloride dimer, and R^{1b} -OH by stirring the mixture under the temperature condition ranging from room temperature to heating to reflux or using microwave irradiation, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent under basic condition. Examples of the base
10 used herein are not particularly limited, but may include potassium hydroxide, sodium hydroxide, potassium tert-butoxide, potassium carbonate, and cesium carbonate. Examples of the solvent used herein are not particularly limited, but include alcohol such as R^{1b} -OH, aromatic hydrocarbons such as benzene, toluene, xylene and the like. In case that alcohol is used as solvent, the alcohol needs to be the same as R^{1b} -OH. *See also, for*
15 *example, Tetrahedron, 65 (2009), 4375-4383.*

The compound of the formula (I) or the formula (I') is isolated and purified as its free compound, or a salt, a hydrate, a solvate, or crystal polymorph substance thereof. The salt of the compound of the formula (I) or the formula (I') can also be prepared by a conventional method.

20 Isolation and purification are carried out by employing general chemical operations such as extraction, fractional crystallization, and various types of fractional chromatography.

Various isomers can be prepared by selecting appropriate starting compound, or separated by separation using differences in the physicochemical properties among the
25 isomers. For example, the optical isomers can be obtained by means of general optical resolution methods of racemic compounds (for example, fractional crystallization

introducing the compound into a diastereomer salt with an optically active base or acid; chromatography using a chiral column or the like; and others), or can also be prepared from appropriate optically active starting compound.

5 The pharmacological activity of certain compounds of the formula (I) or the formula (I') was confirmed by the following assay.

Assay Example 1: Preparation and assay of fast skeletal myofibrils

Preparation of fast skeletal myofibrils: Rabbit skeletal myofibrils were prepared based upon the method of Herrmann et al. (Biochem. 32(28):7255-7263(1993).

10 Myofibrils were prepared from rabbit psoas muscle purchased from Pel-Freez Biologicals (Arkansas) within 2 days of ordering, stored on ice. Minced muscle was homogenized in 10 volumes of ice-cold "standard" buffer (50 mM Tris, pH 7.4, 0.1 M KOAc, 5 mM KCl, 2 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μ M leupeptin, 5 μ M pepstatin, and 0.5 mM sodium azide) containing 5 mM
15 ethylenediaminetetraacetic acid (EDTA) and 0.5% Triton X-100 using an Omni-Macro homogenizer. Myofibrils were recovered by low speed centrifugation (3000 rpm for 10 minutes) and washed 2 times in the Triton X-100 containing buffer to ensure removal of cellular membrane. Following the Triton washes, myofibrils were washed 3 times in "standard" buffer containing 2 mM magnesium acetate. A final wash in assay buffer (12
20 mM piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), pH 6.8, 60 mM KCl, 1 mM DTT) was performed and brought to 10% sucrose for flash freezing in liquid nitrogen and storage at -80°C.

Activation of Fast Skeletal Myofibrils: Fast fiber activators were identified by measuring the enzymatic activity of muscle myofibril preparations using the proprietary
25 PUMA (trademark) (see, e.g., U.S. Patent Nos. 6,410,254, 6,743,599, 7,202,051, and 7,378,254) assay system. Myofibril preparations consisted of rabbit skeletal muscle (approximately 90% fast fibers) that had been mechanically homogenized and washed with a detergent (Triton X-100) to remove cellular membranes. This preparation retained all of the sarcomeric components in a native conformation and the enzymatic activity was still
30 regulated by calcium. Compounds were tested using a myofibril suspension and a level of calcium sufficient to increase enzymatic activity of the myofibrils to 25% of their maximal rate (termed pCa25). Enzymatic activity was tracked via a pyruvate kinase and lactate dehydrogenase-coupled enzyme system. This assay regenerates myosin-produced

ADP into ATP by oxidizing NADH, producing an absorbance change at 340 nm. The buffering system was 12 mM PIPES, 2 mM MgCl₂, 1 mM DTT at pH 6.8 (PM12 buffer). Data was reported as AC1.4, which is the concentration at which the compound increased the enzymatic activity by 40%. The results are summarized in Table 2 below. In Table 2, “Ex. Cmpd.” denotes the Example Compound with reference to the structures provided in Table 4 below.

Table 2

Ex. Cmpd.	AC1.4 (μM)
2	1.569
3	1.778
4	0.159
5	1.400
6	0.255
7	0.694
8	>39.200
9a	0.626
9b	0.349
10	0.829
11	0.616
12	12.602
13	0.277
14	11.985
15	1.064
16	0.168
17	1.708
18	0.536
19	3.144
20	1.109
21	1.132
22a	2.317
22b	0.473
23	1.717
24	1.664
25	8.216
26	34.268

Ex. Cmpd.	AC1.4 (μ M)
27	1.581
28	8.625
29	15.846
30	12.465
31a	3.073
31b	>39.200
32	0.384
33	12.478
34	0.229
35	0.565
43	0.051
44	5.982
46	0.106
48	<0.077
49	<0.077
50	0.763
51	0.093
52	0.326
53	0.711
54	0.596
55	0.141
56	2.067
57	0.976
58	5.040
59	0.381
60	0.252
61	0.537
62	>39.200
63	3.707
64	0.390
65	1.052
66	2.502
68	0.830
69	0.485
70	0.522
71	0.367

Ex. Cmpd.	AC1.4 (μ M)
72	0.420
73	1.571
74	0.902
75	1.174
76	0.223
77	7.898
79	<0.077
80	0.112
81	0.098
82	0.084
83	<0.077
84	0.401
88	0.203
90	2.555
91	20.240
92a	1.318
92b	0.400
94	8.994
95	0.720
96	5.393
97	0.332
98	2.085
101	2.228
102	8.474
103	1.247
104	5.017
105	4.313
106	0.494
107	1.080
108	0.450
109	1.919
110	3.478
111	0.321
112	1.437
113	0.271
115	0.474

Ex. Cmpd.	AC1.4 (μ M)
116	0.274
134a	0.626
134b	4.986
137	2.365
138	7.955
139	30.805
140	0.199
141	<0.077
142	2.377
143	2.830
145	0.581
146	0.283
147	2.346
153	1.590
155	8.340
156	5.881
157	2.566
159	11.374
161	1.987
165	1.202
167a	3.293
167b	0.869
169	1.730

Assay Example 2: Preparation and assay of rat isometric ankle plantarflexor muscle force

Female Sprague Dawley rats were placed under a stable anesthetic plane with inhaled isoflurane (1-5%). One incision was made on the mid-thigh region of the right leg to expose the sciatic nerve. To prevent co-contraction of the ankle dorsiflexors, an additional incision was made lateral to the patella to isolate and sever the peroneal nerve. Rats were then placed on a temperature-maintained *in situ* muscle analysis rig (Aurora Scientific, Model 806C). The knee was immobilized in a clamp between two sharpened screws and the foot was taped to a footplate attached to a force transducer (Aurora Scientific, Ontario, Canada). Stainless steel needle electrodes (0.10 mm) were hooked around the exposed sciatic nerve. Isometric ankle plantarflexor muscle contractile force

was assessed with the ankle joint at 90° flexion. A 30 Hz electrical stimulation (under supramaximal voltage conditions) was applied to the nerve and the resulting muscle force was recorded via a servomotor. A pre-dose 30Hz force response was established as the baseline force. A pre-dose 150 Hz force response was established as the maximum isometric force. Compounds were formulated in 50% polyethylene glycol (PEG): 16% Cavitron: 10% dimethylacetamide (DMA) and administered by continuous intravenous infusion over a sixty minute period. The muscle force response to compound was measured every two minutes over the dosing period. Data was reported as an estimated EC₅₀ value, which is the concentration at which muscle force is 50% of the pre-dose maximum tension. The EC₅₀ results are summarized in Table 3 below. In Table 3, “Ex. Cmpd.” denotes the Example Compound with reference to the structures provided in Table 4 below.

Table 3

Ex. Cmpd.	PLANTARFLEXOR EC ₅₀ (μM)
11	17
12	34
13	19.5
15	16.4
16	13
18	16
19	35
20	30
35	23
49	8.2
52	25.6
55	7.6
56	30
57	28
61	10.3
64	10
72	15.4

73	50
74	15.4
101	24
103	23
104	30
106	15
108	23
109	39.7
113	8
22b	9.99

Assay Example 3: Preparation and assay of rat treadmill running performance

Female Sprague Dawley rats were acclimated to a treadmill (Columbus Instruments). Rats were trained to run on a treadmill for 5 days at a speed of 25 meters per minute (m/min) for ten minutes at a 5° incline. An experimenter-blinded cross-over treadmill study was performed to assess the effect of compounds on treadmill running performance. Rats were dosed with vehicle (0.5% hydroxypropyl methylcellulose (HPMC)/0.2% Tween-80) or compound at a pre-treatment time based on each respective compounds' pharmacokinetic properties prior to treadmill testing. Rats then ran until they reached exhaustion at a constant 35 m/min or a graded speed ranging from 25-45 m/min for up to 150 minutes. Treadmill time was recorded. Two days after the first treadmill test, the opposite treatment was administered to rats and the treadmill test protocol was repeated. Terminal blood was collected for plasma compound analysis. Treadmill running distance data is summarized in FIG.1.

Increase of treadmill running distance: As shown in FIG.1, Example Compound 20 and Example Compound 22b increased treadmill running distance.

Assay Example 4: Preparation and assay of Electrical Field Stimulation (EFS)-induced contraction of isolated External Anal Sphincter (EAS)

Preparation of EFS-induced contraction of isolated EAS from the rats. EAS was isolated from the female SD rats (10-11 week old) euthanized using exsanguination under anesthesia. The isolated circular EAS was cut and divided into two strips. One end of each strip was hanged on a tension transducer (TB-611T; Nihon Kohden) attached to an

amplifier (AP-621G; Nihon Kohden) and an interface (Power Lab; Ad Instrument), and the hanged strip was set in a tissue bath filled with Krebs buffer. The Krebs buffer was aerated with 95% O₂ and 5% CO₂, and kept warm at 37°C. Another end of the strip was hanged on an electrode of an EFS system (SEN-7203 and SEN-8203; Nihon Kohden) attached to a drive amplifier (SEG-3104; Nihon Kohden). The hanged strip was washed with Krebs buffer and rested with 0.5 g tension for 30 minutes to stabilize resting tension. This step (washing and 30 minutes resting of the strip) was repeated three times for complete stabilization of resting tension. The stabilized strip was stimulated with a single pulse (20 V and 30 μ sec pulse width) and the strip which showed more than 60 mg contraction was selected and used for the further EFS contraction. After selected strip was washed with Krebs buffer, the strip underwent the EFS whose conditions are 20 V stimulus voltage, 30 μ sec pulse width, 20 Hz frequency, and 1sec duration. The EFS was repeated three times at 30 sec. interval. Contraction power was defined as the difference of the strip tension between pre- and post-EFS contraction. Pre-contraction was defined as the average contraction power of the three times EFS without any compound. After pre-contraction measurement, Example Compound 20, Example Compound 22b, or DMSO was added to the Krebs buffer with the strip. Fifteen minutes after the addition, the strip underwent the EFS three times at 30 sec. interval. Post-contraction was defined as the average contraction power of the three times EFS with each compound and calculated as % of pre-contraction. The effect of Example Compound 20 or Example Compound 22b was analyzed using Dunnett's multiple comparison test (a probability value of less than 0.05 was considered as a significant difference). Data were expressed as the mean $\pm$ standard error of the mean (SEM).

Increase of EFS-induced contraction of isolated EAS: As shown in FIG.2 and 3, Example Compound 20 and Example Compound 22b increased EFS-induced contraction of isolated EAS from the rats.

Assay Example 5: Preparation and assay of anal pressure induced by electrical stimulation of pudendal nerve.

Preparation of the rat anal pressure induced by electrical stimulation of pudendal nerve. Female SD rats (11-12 weeks old) were fasted for 12-16 h and anesthetized with urethane (1.2 g/kg,sc). A cannula (PE 50) for test substance administration was inserted into the jugular vein. A lower back incision was made and electrodes for electrical

stimulation were placed under unilateral pudendal nerves. An UniTip catheter (Unisensor AG) for measurement of anal pressure attached to an amplifier (AP-621G, Nihon Kohden) and an interface (Power Lab, ADInstrument) was inserted into the anus through the anal orifice. Pudendal nerve stimulation (PudNS, frequency: 10 Hz, pulse width: 50 μ sec, duration: 400 msec, voltage: 1 V) was applied by an electric stimulator (SEN-3401, Nihon Kohden) and the position of catheter was fixed at the point where PudNS-induced elevation of anal pressure could be elicited stably. Voltage was adjusted to elicit about 30–90% elevation of maximal anal pressure elicited at 1–10 V. For evaluation of test substance, PudNS (frequency: 10 Hz, pulse width: 50 μ sec, duration: 400 msec, voltage: adjusted above) was repeated at 1 minute intervals. Before the test substance administration, at least 3 times of elevations of anal pressure were elicited and confirmed to be approximately equivalent. Vehicle, Example Compound 20 (3 mg/mL/kg) or Example Compound 22b (3 mg/mL/kg) was administered intravenously. The average pressure calculated from the last three elevations of anal pressure before the administration and the average pressure calculated from the three elevations of anal pressure between 1 to 4 min after the administration were defined as pre- and post-pressure, respectively. Data were expressed as a percentage of pre-pressure and the effect of vehicle, Example Compound 20 or Example Compound 22b was analyzed using Dunnett's multiple comparison test (a probability value of less than 0.05 was considered as a significant difference). Data were expressed as the mean $\pm$ SEM of 4 animals.

PudNS-induced elevation of anal pressure. As shown in FIG. 4, Example Compound 20 and Example Compound 22b significantly potentiated the PudNS-induced elevation of anal pressure.

Assay Example 6: Preparation and assay of urine Leak Point Pressure (LPP) under abdominal pressure

Preparation of the rat model of urine leakage under abdominal pressure. The rat model was prepared based on the method of Conway et. al. (Int Urogynecol J 16:359–363, 2005). Female SD rats (10–14 week old) were anesthetized with pentobarbital. After laparotomy, an incision was made to the bladder dome, and a cannula (PE 100; Becton, Dickinson and Company) was inserted into the bladder and sutured with thread. In addition, another cannula (PE 100; Becton, Dickinson and Company) was inserted into the duodenum and sutured with thread. After abdominal closure, urine within the bladder was

drained and physiological saline was injected via the bladder cannula. The volume of physiological saline in the bladder was kept at 75% of the maximum bladder capacity (the maximum capacity was set as the volume that leakage of physiological saline from urethral orifice starts). Subsequently, physiological saline was infused at 0.6 mL/h via the bladder

5 cannula with infusion pumps (TE-331S and STC-525; Terumo), and the bladder pressure was recorded using the following instruments: a pressure transducer (DX-100; Nihon Kohden), pressure amplifiers (AP-601G, AP-621G, and AP630G; Nihon Kohden), and an interface (Power Lab; ADInstruments). In parallel with physiological saline infusion, abdomen of the rats was manually compressed with the lidside of a plastic 50 mL

10 centrifuge tube, and the bladder pressure at the time when leakage from urethral orifice starts was defined as LPP. Abdominal compression was repeated more than five times at 1 minute interval. Pre-LPP was set as the average of three LPP scores immediately before compound dosing. 5 ml/kg of Example Compound 20, Example Compound 22b, or Vehicle (13.3% DMSO, 13.3% PEG400, 13.3% Tween20, and 60% distilled water) was

15 dosed via the duodenal cannula, and LPP was measured three times at the following each time point: 5, 15, 30, 45, and 60 minutes after the dosing. Delta LPP was calculated based on the difference from Pre-LPP.

Increase of LPP. As shown in FIG.5 and 6, Example Compound 20 and Example Compound 22b increased LPP in the rat model of urine leakage under abdominal pressure.

20 Assay Example 7: Preparation and assay of Basso, Beattie, and Bresnahan (BBB) score of post-spinal cord injury (SCI)

Preparation of the rat model of post-SCI: The rat model was prepared based on the method of Scheff et. al. (J Neurotrauma. 2003 Feb;20(2):179-93.) which uses Infinite

25 Horizon impactor (IH-0400; Precision Systems and Instrumentation). Female SD rats (10 week old) were anesthetized with a mixture of 0.3 mg/kg medetomidine, 4 mg/kg midazolam, and 5 mg/kg butorphanol (s.c.). The dorsal region of the rats was incised and the thoracic spine from T8 to T12 was exposed. Subsequently, laminectomy was performed on T9 and T10. On the stage of IH-0400, the exposed spinal column of the rats was

30 stabilized by clamping with two forceps attached to the joints of IH-0400. Each of the joint and the forceps was tightly locked. Injury of T9 and T10 was induced with a rod impact of 210 kdyn. After dorsal closure, the rats were housed one per cage under the postoperative care which includes the injections of 5 mL saline s.c. and 50 mg/kg Cefamezin s.c twice a

day for a week after the SCI, and includes the manual expression of the bladder of the rats twice a day using Crede maneuver until the function of the bladder recovers. At three time slots (day 6-7, day 13-14, and day 20-21 after the SCI), test substance (Example Compound 52 or vehicle) dosing and BBB scoring were performed as shown in FIG. 7.

- 5 The effect of Example Compound 52 or vehicle was analyzed using unpaired t test (a probability value of less than 0.05 was considered as a significant difference). Data were expressed as the mean $\pm$ SEM .

Increase of BBB score. As shown in FIG. 8, Example Compound 52 increased BBB score in the rat model of post-SCI.

10

Assay Example 8: Preparation and assay of force-calcium relationship in chronic obstructive pulmonary disease (COPD) muscle biopsies.

- Diaphragm and latissimus dorsi biopsy specimens were obtained from control and COPD patients whom underwent a thoracotomy for removal of a primary lung tumor. All
- 15 COPD patients were classified as having moderate or severe disease according to GOLD classification. A part of the fresh biopsy was placed for 24 hours at -20°C in 4 mL relax-glycerol solution (5.89 mM Na₂ATP, 6.48 mM MgCl₂, 40.76 mM Kprop, 100 mM BES, 6.97 mM EGTA, 14.50 mM CrP) containing high concentrations of protease inhibitors (1.0 mM DTT, 0.24 mM PMSF, 0.4 mM leupeptin, 0.1 mM E64). Segments of
- 20 single fibers of approximately 1-1.5 mm were subsequently isolated in a relaxing solution at 5°C. At both ends, two aluminium clips were attached. Myofibers were incubated for 10 minutes in cold (5°C) skinning solution (relax solutions with 1% Triton X-100, 1.0 mM DTT, 0.24 mM PMSF, 0.04 mM leupeptin, 0.01 mM E64) to permeabilize the plasma membrane enabling activation of myofilaments with exogenous calcium. Subsequently, the
- 25 myofibers were mounted horizontally on two stainless-steel hooks in a relax solution filled chamber (200 μ L) with a glass coverslip bottom on the stage of an inverted microscope (Zeiss, The Netherlands). One hook was attached to a force transducer (model 403A Aurora Scientific Inc, Ontario, Canada) with a resonance frequency of 10 kHz, whereas the other end was attached to a servo-motor (model 315C, Aurora Scientific Inc.; Aurora,
- 30 Ontario, Canada) with a step time of 250 μ s. Fiber dimensions were measured by means of a camera device coupled to the objective. Fiber length was determined with 100x magnification, depth and width were measured at the widest part of the cell with 400x magnification (an elliptical cross section of the myofiber was assumed). Fibers were

stretched to optimal length by setting sarcomere length at 2.5 μm with dedicated Aurora software. To ensure stable attachment of the fiber in the clips throughout the mechanical protocol, the myofiber was briefly maximally activated prior to the experiment, and when necessary restretched to a sarcomere length of 2.5 μm . Single myofibers were transferred from relax to pre-, sub- and maximal activating solutions (5.97 mM Na₂ATP, 7.0 mM CaEGTA, 6.28 mM MgCl, 40.64 mM Kprop, 100 mM BES and 14.50 mM CrP with pCa ranging from 4.5 to 9) by means of an automated bath controller device. During the experiment, data were automatically collected by a data acquisition board (sampling rate 10000 Hz). All measurements were performed at 20°C. Fibers were activated with solutions containing incremental calcium concentrations with vehicle (1% DMSO) or 5 μM of Example Compound 20 and the resulting force was recorded. At least five fast-twitch fibers per subject were analysed. The obtained force-pCa data were fit to the Hill equation, providing the pCa₅₀. 5 μM of Example Compound 20 increased the sensitivity of force to calcium in both control and COPD diaphragms (control: 5.74 ± 0.02 vs 6.11 ± 0.03 ; COPD: 5.76 ± 0.02 vs 6.11 ± 0.02 , mean $\pm$ SEM, n=6/ group, p < 0.0001). 5 μM of Example Compound 20 increased the sensitivity of force to calcium in both control and COPD latissimus dorsi (control: 5.76 ± 0.02 vs 6.11 ± 0.03 ; COPD: 5.78 ± 0.02 vs 6.13 ± 0.02 , mean $\pm$ SEM, n=6/ group, p < 0.0001). The force-pCA data are summarized in FIG. 9 and 10. Significance is defined as *p < 0.05 vs. vehicle treatment.

The compounds of the formula (I) or the formula (I'), or a salt thereof modulate the contractility of the skeletal sarcomere, and thus are expected to be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

In an embodiment of the present invention, the compounds and compositions described and/or disclosed herein are expected to be used to treat neuromuscular diseases, i.e., diseases that affect any part of the nerve-muscle unit. Neuromuscular diseases include, for example: 1) diseases of the motor unit, including but not limited to Amyotrophic Lateral Sclerosis (ALS) including bulbar and primary lateral sclerosis (PLS) variants; Spinal Muscular Atrophy (SMA) types 1-4; Kennedy syndrome; post-polio syndrome; motor neuropathies including, for example, critical illness polyneuropathy; multifocal motor neuropathy with conduction block; Charcot-Marie-Tooth disease and

other hereditary motor and sensory neuropathies; and Guillain-Barre syndrome, 2) disorders of the neuromuscular junction, including myasthenia gravis, Lambert-Eaton myasthenic syndrome, and prolonged neuromuscular blockade due to drugs or toxins; and 3) peripheral neuropathies, such as acute inflammatory demyelinating

- 5 polyradiculoneuropathy, diabetic neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, traumatic peripheral nerve lesions, neuropathy of leprosy, vasculitic neuropathy, dermatomyositis/polymyositis, and neuropathy of Friedreich ataxia.

In another embodiment of the present invention, the compounds and compositions described and/or disclosed herein are expected to be used to treat disorders of voluntary
10 muscle. Disorders of voluntary muscle include 1) muscular dystrophies (including, for example, Duchenne, Becker, Limb-Girdle, facioscapulohumeral, Emery-Dreyfus, oculopharyngeal, and congenital muscular dystrophies); and 2) myopathies, such as nemaline myopathy, central core disease, congenital myopathies, mitochondrial myopathies, acute myopathy; inflammatory myopathies (such as
15 dermatomyositis/polymyositis and inclusion body myositis), endocrine myopathies (such as those associated with hyper- or hypothyroidism), Cushing's or Addison's syndrome or disease and pituitary gland disorders, metabolic myopathies (such as glycogen storage diseases, e.g., McArdle's disease, Pompe disease, etc.), drug-induced myopathy (statins, ant-retroviral drugs, and steroid myopathy) restrictive lung disease, sarcoidosis,
20 Schwartz-Jampel Syndrome, focal muscular atrophies, and distal myopathies.

In a specific embodiment, the compounds and compositions described and/or disclosed herein are expected to be used to treat Amyotrophic Lateral Sclerosis (ALS). ALS is a disease that generally arises later in life (Age 50+) and has a rapid progression from initial limb weakness to paralysis and death. Common life expectancy after
25 diagnosis is 3-5 years. The cause of disease for most ALS patients is unknown (termed the spontaneous form) while a small proportion of patients have an inherited form (familial) of disease. The condition causes progressive death of motor neurons through causes that are not clear. Surviving motor units attempt to compensate for dying ones by innervating more fibers (termed sprouting) but this can only partially correct muscle
30 function, as muscles are subsequently more prone to problems of coordination and fatigue. Eventually, surviving motor neurons die, resulting in complete paralysis of the affected muscle. The disease is commonly fatal through the eventual loss of innervation to the diaphragm, resulting in respiratory failure. Current treatment options for ALS are limited.

In another specific embodiment, the compounds and compositions described and/or disclosed herein are expected to be used to treat Spinal Muscular Atrophy (SMA). SMA is a genetic disorder that arises through the mutation of a protein, survival motor neuron 1 (SMN1) that appears to be required for the survival and health of motor neurons.

5 The disease is most common in children as the majority of patients only survive until 11-12 years of age. There is currently no available treatment for SMA.

In another specific embodiment, the compounds and compositions described and/or disclosed herein are expected to be used to treat myasthenia gravis. Myasthenia gravis is a chronic autoimmune neuromuscular disease wherein the body produces
10 antibodies that block, alter, or destroy proteins involved in signaling at the neuromuscular junction, thus preventing muscle contraction from occurring. These proteins include nicotinic acetylcholine receptor (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK) involved in AChR clustering (see, e.g., Drachman, N. Eng. J. of Med., 330:1797-1810, 1994). The disease is characterized by varying degrees of weakness of
15 the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Although myasthenia gravis may affect any voluntary muscle, certain muscles, such as those that control eye and eyelid movement, facial expression, chewing, talking, and swallowing are often, but not always, involved in the disorder. The muscles that control
20 breathing and neck and limb movements may also be affected. In most cases, the first noticeable symptom is weakness of the eye muscles. In others, difficulty in swallowing and slurred speech may be the first signs. The degree of muscle weakness involved in myasthenia gravis varies greatly among patients, ranging from a localized form, limited to eye muscles (ocular myasthenia), to a severe or generalized form in which many muscles -
25 sometimes including those that control breathing - are affected. Symptoms, which vary in type and severity, may include a drooping of one or both eyelids (ptosis), blurred or double vision (diplopia) due to weakness of the muscles that control eye movements, unstable or waddling gait, weakness in arms, hands, fingers, legs, and neck, a change in facial expression, difficulty in swallowing and shortness of breath, and impaired speech
30 (dysarthria). Generalized weakness develops in approximately 85% of patients.

In further embodiments, the compounds and compositions described and/or disclosed herein are expected to be used to treat sarcopenia, e.g., sarcopenia associated with aging or disease (e.g., HIV infection). Sarcopenia is characterized by a loss of

skeletal muscle mass, quality, and strength. Clinically, a decline in skeletal muscle tissue mass (muscle atrophy) contributes to frailty in older individuals. In human males, muscle mass declines by one-third between the ages of 50 and 80. In older adults, extended hospitalization can result in further disuse atrophy leading to a potential loss of the ability for independent living and to a cascade of physical decline. Moreover, the physical aging process profoundly affects body composition, including significant reductions in lean body mass and increases in central adiposity. The changes in overall adiposity and fat distribution appear to be important factors in many common age-related diseases such as hypertension, glucose intolerance and diabetes, dyslipidemia, and atherosclerotic cardiovascular disease. In addition, it is possible that the age-associated decrement in muscle mass, and subsequently in strength and endurance, may be a critical determinant for functional loss, dependence and disability. Muscle weakness is also a major factor predisposing the elderly to falls and the resulting morbidity and mortality.

The compounds and compositions described and/or disclosed herein are expected to be used to treat cachexia. Cachexia is a state often associated with cancer or other serious diseases or conditions, (e.g., chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, and kidney dialysis), that is characterized by progressive weight loss, muscle atrophy and fatigue, due to the loss of adipose tissue and skeletal muscle.

The compounds and compositions described and/or disclosed herein are expected to be used to treat muscular dystrophies. Muscular dystrophy can be characterized by progressive muscle weakness, destruction and regeneration of the muscle fibers and eventual replacement of the muscle fibers by fibrous and fatty connective tissue.

The compounds and compositions described and/or disclosed herein are expected to be used to treat post-surgical muscle weakness, which is a reduction in the strength of one or more muscles following surgical procedure. Weakness may be generalized (i.e., total body weakness) or localized to a specific area, side of the body, limb, or muscle.

The compounds and compositions described and/or disclosed herein are expected to be used to treat post-traumatic muscle weakness, which is a reduction in the strength of one or more muscles following a traumatic episode (e.g., bodily injury). Weakness may be generalized (i.e., total body weakness) or localized to a specific area, side of the body, limb, or muscle.

The compounds and compositions described and/or disclosed herein are expected to be used to treat muscle weakness and fatigue produced by peripheral vascular disease (PVD) or peripheral artery disease (PAD). Peripheral vascular disease is a disease or disorder of the circulatory system outside of the brain and heart. Peripheral artery disease (PAD), also known as peripheral artery occlusive disease (PAOD), is a form of PVD in which there is partial or total blockage of an artery, usually one leading to a leg or arm. PVD and/or PAD can result from, for example, atherosclerosis, inflammatory processes leading to stenosis, embolus/ thrombus formation, or damage to blood vessels due to disease (e.g., diabetes), infection or injury. PVD and/or PAD can cause either acute or chronic ischemia, typically of the legs. The symptoms of PVD and/or PAD include pain, weakness, numbness, or cramping in muscles due to decreased blood flow (claudication), muscle pain, ache, cramp, numbness or fatigue that occurs during exercise and is relieved by a short period of rest (intermittent claudication), pain while resting (rest pain) and biological tissue loss (gangrene). The symptoms of PVD and/or PAD often occur in calf muscles, but symptoms may also be observed in other muscles such as the thigh or hip. Risk factors for PVD and/or PAD include age, obesity, sedentary lifestyle, smoking, diabetes, high blood pressure, and high cholesterol (i.e., high LDL, and/or high triglycerides and/or low HDL). People who have coronary heart disease or a history of heart attack or stroke generally also have an increased frequency of having PVD and/or PAD. Activators of the fast skeletal troponin complex have been shown to reduce muscle fatigue and/or to increase the overall time to fatigue in in vitro and in situ models of vascular insufficiency (see, e.g., Russell et al., "The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force and Reduces Muscle Fatigue in vitro and in situ", 5th Cachexia Conference, Barcelona, Spain, December 2009; Hinken et al., "The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency", Society for Vascular Medicine's 2010 Annual Meeting: 21st Annual Scientific Sessions, Cleveland, OH, April 2010).

The compounds and compositions described and/or disclosed herein are expected to be used to treat symptoms of frailty, e.g., frailty associated with aging which has been shown to affect motor unit depletion and muscle power (McComas, Journal of Electromyography and Kinesiology Vol. 8, 391-402, 1998). Frailty is characterized by one or more of unintentional weight loss, muscle weakness, slow walking speed, exhaustion, and low physical activity.

The compounds and compositions described and/or disclosed herein are expected to be used to treat muscle weakness and/or fatigue due to wasting syndrome, which is a condition characterized by involuntary weight loss associated with chronic fever and diarrhea. In some instances, patients with wasting syndrome lose 10% of baseline body weight within one month.

The compounds and compositions described and/or disclosed herein are expected to be used to treat muscular diseases and conditions caused by structural and/or functional abnormalities of skeletal muscle tissue, including muscular dystrophies, congenital muscular dystrophies, congenital myopathies, distal myopathies, other myopathies (e.g., myofibrillar, inclusion body), myotonic syndromes, ion channel muscle diseases, malignant hyperthermias, metabolic myopathies, congenital myasthenic syndromes, sarcopenia, muscle atrophy, and cachexia.

The compounds and compositions described and/or disclosed herein are also expected to be used to treat diseases and conditions caused by muscle dysfunction originating from neuronal dysfunction or transmission, including amyotrophic lateral sclerosis, spinal muscular atrophies, hereditary ataxias, hereditary motor and sensory neuropathies, hereditary paraplegias, stroke, multiple sclerosis, brain injuries with motor deficits, spinal cord injuries, Alzheimer's disease, Parkinson's disease with motor deficits, myasthenia gravis, and Lambert-Eaton syndrome.

The compounds and compositions described and/or disclosed herein are also expected to be used to treat diseases and conditions caused by CNS, spinal cord or muscle dysfunction originating from endocrine and/or metabolic dysregulation, including claudication secondary to peripheral artery disease, hypothyroidism, hyper- or hypo-parathyroidism, diabetes, adrenal dysfunction, pituitary dysfunction, and acid/base imbalances.

The compounds and compositions described and/or disclosed herein are also expected to be used to treat diseases and conditions caused by dysfunctions of pelvic floor and urethral/anal sphincter muscles including urinary incontinence such as stress urinary incontinence (SUI) and mixed urinary incontinence (MUI), and fecal incontinence (Bharucha et. al., Am. J. Gastroenterol., Vol.110, 127-36 (2015)).

The compounds and compositions described and/or disclosed herein are also expected to be used in combination with one or more electrical muscle stimulation (EMS) devices to treat Stress urinary incontinence, Mixed urinary incontinence, and Fecal

incontinence. Examples of EMS devices include InterStim II® (Sacral nerve stimulator; Medtronic; sacral nerve controls urethral sphincter, anal sphincter, and pelvic floor muscle) and Uromaster® (Interferential low-frequency stimulation to urethral sphincter, anal sphincter, and pelvic floor muscle; Nihon Medix Co.). The combined effect of the compounds of the present invention and EMS to urethral sphincter, anal sphincter, and pelvic floor muscle is relieved by the results of Example 2 of WO2016/039367 or Assay Example 5 of this specification (Preparation and assay of anal pressure induced by electrical stimulation of pudendal nerve).

The compounds and compositions described and/or disclosed herein are also expected to be used in combination with one or more electrical muscle stimulation (EMS) devices to treat post-stroke muscle dysfunction, post-spinal cord injury (SCI) muscle dysfunction, and rehabilitation-related deficits. Examples of EMS devices include NESS L300® (Limb muscle stimulator; Bioness Inc.), NESS L300®Plus (Limb muscle stimulator; Bioness Inc.), NESS H200® (Limb muscle stimulator; Bioness Inc.), IVES® (Limb muscle stimulator; OG Wellness Technologies Co., Ltd), WalkAide® (Limb muscle stimulator; Innovative Neurotronics, Inc.), and NM-F1, (Limb muscle stimulator; ITO PHYSIOTHERAPY&REHABILITATION). The combined effect of the compounds of the present invention and EMS to limb muscle is relieved by the results of Assay Example 2 of this specification (Preparation and assay of rat isometric ankle plantarflexor muscle force) or from the findings of the study described in Muscle Nerve. 2014 Dec;50(6):925-31.

The compounds and compositions described and/or disclosed herein are also expected to be used in combination with one or more electrical muscle stimulation (EMS) devices to treat diaphragm dysfunctions of Amyotrophic lateral sclerosis (ALS) and post-spinal cord injury (SCI). Examples of EMS devices include NeuRx Diaphragm Pacing System (DPS)® (Diaphragm muscle stimulator; SYNAPSE Biomedical Inc.). The combined effect of the compounds of the present invention and EMS to the diaphragm is relieved from the findings of the study described in PLoS One. 2014; 9(5): e96921.

The compounds and compositions described and/or disclosed herein may be administered alone or in combination with other therapies and/or therapeutic agents useful in the treatment of the aforementioned disorders.

A pharmaceutical composition including one or two or more kinds of the compound of the formula (I) or the formula (I') as an active ingredient can be prepared

using an excipient which is usually used in the art, that is, an excipient for a pharmaceutical preparation, a carrier for a pharmaceutical preparation, and the like, according to a method usually used.

A pharmaceutical composition provided herein may comprise one or more of the compounds of the formula (I) or the formula (I') or any embodiment thereof, including, without limitation, any of Embodiments 1-1 through 8-4 and any of Embodiments (1)-(57). A pharmaceutical composition may comprise a single enantiomer of any of the compounds of the formula (I) or the formula (I') contained thereof, or a single diastereomer of any of the compounds of the formula (I) or the formula (I') contained thereof, or a mixture of enantiomers or diastereomers of any of the compounds of the formula (I) or the formula (I') contained thereof in any ratio.

Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration via injections, such as intra-articular, intravenous, and intramuscular injections, suppositories, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalers, and the like.

As a solid composition for oral administration, tablets, powders, granules, and the like are used. In such a solid composition, one kind or two or more kinds of the active ingredients are mixed with at least one inactive excipient. In a conventional method, the composition may contain inactive additives such as a lubricant, a disintegrating agent, a stabilizer, or a solubilization assisting agent. If necessary, tablets or pills may be coated with a sugar or with a film of a gastric or enteric coating substance.

The liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also includes generally used inert diluents, for example, purified water or ethanol. The liquid composition may also include auxiliary agents such as a solubilization assisting agent, a moistening agent, and a suspending agent, sweeteners, flavors, aromatics, and antiseptics, in addition to the inert diluent.

The injections for parenteral administration include sterile aqueous or non-aqueous solution preparations, suspensions, or emulsions. The aqueous solvent includes, for example, distilled water for injection and saline. Examples of the non-aqueous solvent include alcohols such as ethanol. Such a composition may further include a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a

dispersing agent, a stabilizing agent, or a solubilizing assisting agent. These are sterilized, for example, by filtration through a bacteria retaining filter, blending of a bactericide, or irradiation. In addition, these can also be used by preparing a sterile solid composition, and dissolving or suspending it in sterile water or a sterile solvent for
5 injection prior to its use.

Examples of the agent for external use include ointments, hard plasters, creams, jellies, cataplasms, sprays, and lotions. The agent further contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.

10 As the transmucosal agents such as an inhaler and a transnasal agent, those in the form of a solid, liquid, or semi-solid state are used, and can be prepared in accordance with a method known in the related art. For example, a known excipient, and also a pH adjusting agent, an antiseptic, a surfactant, a lubricant, a stabilizing agent, a thickening agent, or the like may be appropriately added thereto. For the administration, an
15 appropriate device for inhalation or blowing can be used. For example, a compound may be administered alone or as a powder of formulated mixture, or as a solution or suspension in combination with a pharmaceutically acceptable carrier, using a known device or sprayer such as a metered administration inhalation device. A dry powder inhaler or the like may be for single or multiple administration use, and a dry powder or a
20 powder-containing capsule may be used. Alternatively, this may be in a form such as a pressurized aerosol spray that uses an appropriate propellant agent, for example, a suitable gas such as chlorofluoroalkanes, and carbon dioxide, or other forms.

Usually, in the case of oral administration, the daily dose is from about 0.001 mg/kg to 100 mg/kg, preferably from 0.1 mg/kg to 30 mg/kg, and more preferably from
25 0.1 mg/kg to 10 mg/kg, per body weight, administered in one portion or in 2 to 4 divided portions. In the case of intravenous administration, the daily dose is suitably administered from about 0.0001 mg/kg to 10 mg/kg per body weight, once a day or two or more times a day. In addition, a transmucosal agent is administered at a dose from about 0.001 mg/kg to 100 mg/kg per body weight, once or plural times a day. The dose is
30 appropriately decided in response to the individual case by taking the symptoms, the age, and the gender, and the like into consideration.

Although there are differences depending on a route of administration, a dosage form, an administration site, and a type of the excipient or additive, a pharmaceutical

composition of the invention comprises 0.01% by weight to 100% by weight of, as an embodiment, 0.01% by weight to 50% by weight of, one or more of the compound of the formula (I) or the formula (I'), or a salt thereof which is the active ingredient.

The compound of the formula (I) or the formula (I') may be used in combination with various agents for treating or preventing diseases on which the compound of the formula (I) or the formula (I') is considered to show the effect. Such combined preparations may be administered simultaneously, or separately and continuously, or at a desired time interval. The preparations to be co-administered may be a blend, or may be prepared individually.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

Herein below, the production process for the compound of the formula (I) or the formula (I') will be described in more detail with reference to Examples. Further, the invention is not limited to the compounds described in the Examples below. Further, the production processes for the starting compounds will be described in Preparation Examples. In addition, the production processes for the compound of the formula (I) or the formula (I') are not limited to the production processes of the specific Examples shown below, but the compound of the formula (I) or the formula (I') can be prepared by a combination of these production processes or a method that is apparent to a person skilled in the art.

Further, in the specification, nomenclature software such as ACD/Name (registered trademark, Advanced Chemistry Development, Inc.) may be used for nomenclature of compounds in some cases.

Moreover, the following abbreviations may be used in Examples, Preparation Examples, and Tables below in some cases. For instance, "Str" means Structural chemical formula ("Me" represents methyl, "Et" represents ethyl, "Ac" represents acetyl, "n-Bu" represents n-butyl, "tBu" or "t-Bu" represents tert-butyl, "cHex" represents cyclohexyl, "Ph" represents phenyl, "Bz" represents benzyl, "SEM" represents [2-(trimethylsilyl)ethoxy]methyl, "TBDMS" represents tert-butyldimethylsilyl, "TMS" represents trimethylsilyl, "Boc" represents tert-butoxy carbonyl, "EtOAc" represents ethyl

acetate, "DMAc" represents N,N-dimethylacetamide, "tBuOH" represents tert-butyl alcohol, "IPE" represents diisopropyl ether, "DMI" represents 1,3-dimethylimidazolidin-2-one, "DMF" represents N,N-dimethylformamide, "THF" represents tetrahydrofuran, "MeCN" represents acetonitrile, "NMP" represents 1-methylpyrrolidin-2-one, "DCE" represents 1,2-dichloroethane, "TFA" represents trifluoroacetic acid, "WSC/HCl" represents N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride, "HOBT" represents 1H-benzotriazol-1-ol, "TBAF" represents tetrabutylammonium fluoride, "Pd₂(dba)₃" represents tris(dibenzylideneacetone)dipalladium, "NaHMDS" represents sodium bis(trimethylsilyl)amide, "n-BuLi" represents n-butyllithium, "KOtBu" represents potassium tert-butoxide, "EtOH" represents ethanol, "Et₂O" represents diethyl ether, "DMSO" represents dimethyl sulfoxide, "KOAc" represents potassium acetate, "MeI" represents methyl iodide and "DIPEA" represents N,N-diisopropylethylamine, "min" represents minutes, "sat." represents saturated, "aq." represents aqueous, "Ar" represents Argon, "HPLC" means high performance liquid chromatography, "DAT" means physicochemical data, "NMR" means nuclear magnetic resonance, "ESI+" means m/z values in mass spectroscopy (electrospray ionization method ESI, representing [M+H]⁺ unless otherwise specified), "APCI/ESI+" means APCI/ESI-MS (atmospheric pressure chemical ionization method APCI, representing [M+H]⁺ unless otherwise specified; in which APCI/ESI means simultaneous measurement of APCI and ESI), "APCI" means m/z values in mass spectroscopy (atmospheric pressure chemical Ionization method APCI, representing [M+H]⁺ unless otherwise specified), ¹H-NMR (CDCl₃) : δ (ppm) of peaks in ¹H-NMR in CDCl₃, ¹H-NMR (DMSO-d₆) : δ (ppm) of peaks in ¹H-NMR in DMSO-d₆, ¹H NMR (CD₃OD) : δ (ppm) of peaks in ¹H-NMR in CD₃OD, s: singlet (spectrum), d: doublet (spectrum), t: triplet (spectrum), q: quartet (spectrum), br: broad line (spectrum) (e.g.: brs), m: multiplet (spectrum). SFC represents supercritical fluid chromatography. Amino-silica represents amino-functionalized silica gel, such as Chromatorex NH(trademark) and Hi-flash amino(trademark).

The symbol "*" in a chemical structural formula indicates that the corresponding compound is a single optical isomer. The symbol "#" indicates that the corresponding compound is a mixture of isomers which have (R) and (S) configurations, respectively, in an asymmetric atom with the steric configuration not indicated (racemate). The symbol "\$" indicates that the corresponding compound is a mixture of 4 stereoisomers. Further,

HCl in the structural formula indicates that the compound is a monohydrochloride; 2HCl indicates that the compound is a dihydrochloride.

In addition, for the sake of convenience, a concentration of mol/L is represented by M. For example, a 1 M aqueous sodium hydroxide solution means a 1 mol/L aqueous sodium hydroxide solution.

In the condition of chiral supercritical fluid chromatography (SFC) in Examples 92a and 92b, CHIRALCEL® OZ-H as a column, CO₂:MeOH = 80:20 as a mobile phase, were used. In the condition of chiral supercritical fluid chromatography (SFC) in Examples 134a and 134b, ChromegaChiral CC4 as a column, CO₂:EtOH with 0.5% isopropylamine = 85:15 as a mobile phase, were used.

The result of powder X-ray diffraction in the present invention was measured by using RINT-TTRII under the conditions of tube: Cu, tube current: 300 mA, tube voltage: 50 kV, sampling width: 0.020°, scanning speed: 4°/min, wavelength: 1.54184 Å, and measurement diffraction angle range (2θ): 2.5° to 40°.

Preparation Example 1 (1a and 1b)

To a solid of P₂O₅ (50.0 g) was added H₃PO₄ (50.6 g), and the mixture was stirred at 140°C for 1.5 hours. To the mixture were added 2-(3-bromophenyl)acetamide (5.00 g) and acetone (3.5 mL) at 80°C, and then stirred at 140°C for 2 hours. To the mixture was added acetone (2.0 mL) at 140°C, and stirred at the same temperature for 1 hour. And then, to the mixture was added acetone (2.0 mL) at 140°C again, and stirred at the same temperature for additional 1 hour. The mixture was poured into iced water, and diluted with EtOAc, and the phases were separated. The organic layer was washed with sat. aq. NaHCO₃ and brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH). The obtained solid was washed with 50% EtOAc/hexanes to give 6-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (2.01 g) as a solid. The mother liquid was concentrated under reduced pressure to give the 1:1 mixture of 6-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one and 8-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (996 mg) as a solid.

Preparation Example 2

A mixture of 6-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (100 mg), N-bromosuccinimide (72 mg), 3-chloroperbenzoic acid (7 mg), and CCl₄ (3 mL) was refluxed for 3 hours. And then, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give 4,6-dibromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (75 mg) as a solid.

Preparation Example 3

To a mixture of 2-(3-bromophenyl)butanoic acid (582 mg) and MeCN (10 mL) were added WSC/HCl (551 mg) and HOBt (389 mg) under Ar atmosphere, and the mixture was stirred at room temperature for 1 hour. To the mixture was added 28% aq. ammonia (0.8 mL) under ice bath cooling dropwise over 5 min. Then the mixture was stirred at room temperature for 13 hours. The mixture was concentrated under reduced pressure, diluted with H₂O and stirred under ice bath cooling for 1 hour. The precipitate was collected to give the crude product as a solid. The obtained solid was purified by silica gel column chromatography (EtOAc/CHCl₃) to give 2-(3-bromophenyl)butanamide (427 mg) as a solid.

Preparation Example 4

A mixture of 1-(2,6-dichloropyridin-3-yl)ethan-1-one (78.8 g), CH₂Cl₂ (300 mL), 2-methylpropane-2-sulfinamide (60.6 g), and titanium tetraethoxide (284.4 g) was stirred at 50°C overnight. Additional titanium tetraethoxide (50.0 g) was added, and the mixture was stirred at 50°C for 4 hours. The mixture was cooled to room temperature and then aq. NaHCO₃ was slowly added. The mixture was then filtered through a pad of Celite, and the Celite pad was washed with CH₂Cl₂. The filtrate was concentrated, suspended in EtOAc, and then washed with sat. aq. NaHCO₃. The organic layer was dried over Na₂SO₄, concentrated, and then purified by silica gel column chromatography (EtOAc/hexanes) to give N-[1-(2,6-dichloropyridin-3-yl)ethylidene]-2-methylpropane-2-sulfinamide (63.9 g) as an oil.

Preparation Example 5

To a mixture of N-[1-(2,6-dichloropyridin-3-yl)ethylidene]-2-methylpropane-2-sulfinamide (130.5 g) and THF (300 mL) was slowly added allyl magnesium bromide (1 M in Et₂O, 447 mL) at -78°C. The mixture was stirred at -78°C for 2 hours, followed by the slow addition of a sat. aq. NaHCO₃ (600 mL). The mixture was warmed to room temperature and filtered through a pad of Celite. The Celite was washed with EtOAc. The filtrate was washed with sat. aq. NaHCO₃ (100 mL) three times. The organic layer was dried over Na₂SO₄ and then concentrated to give N-[2-(2,6-dichloropyridin-3-yl)pent-4-en-2-yl]-2-methylpropane-2-sulfinamide (134.8 g) as an oil.

Preparation Example 6

To a mixture of 5-chloro-2,3-difluoropyridine (9.0 g), isobutyronitrile (4.2 g), and toluene (120 mL) was added NaHMDS (2 M in THF, 30.6 mL) at -78°C. The mixture was then stirred for 1 hour. The mixture was diluted with sat. aq. NH₄Cl (50 mL) and warmed to room temperature. The mixture was then diluted with EtOAc (300 mL), washed with water (100 mL), brine (100 mL), dried over Na₂SO₄, concentrated, and then purified by silica gel column chromatography (EtOAc/hexanes) to give 2-(5-chloro-3-fluoropyridin-2-yl)-2-methylpropanenitrile (10.6 g) as a solid.

Preparation Example 7

A mixture of 2-(2,6-dichloropyridin-3-yl)-2-methylpropanenitrile (10.00 g) and sulfuric acid (100 mL) was stirred at room temperature for 12 hours. The mixture was poured into iced water and the mixture was basified with 28% aq. ammonia. EtOAc and H₂O were added to the mixture, and the phases were separated. Aqueous layer was extracted with EtOAc, and combined organic layers were washed with brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give 2-(2,6-dichloropyridin-3-yl)-2-methylpropanamide (10.76 g) as a solid.

Preparation Example 8

To a mixture of 2-(2,6-dichloropyridin-3-yl)-2-methylpropanamide (10.76 g), MeCN (220 mL), and H₂O (110 ml) was added [bis(trifluoroacetoxy)iodo]benzene (22.00 g) at room temperature. Then the mixture was stirred at room temperature for 24 hours.

5 The mixture was diluted with sat. aq. NaHCO₃. EtOAc and H₂O were added to the mixture, and the phases were separated. Aqueous layer was extracted with EtOAc, and combined organic layers were extracted with 1M aq. HCl. Aqueous layer was basified with aq. NaHCO₃, and extracted with EtOAc, and combined organic layers were washed with brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure to

10 give 2-(2,6-dichloropyridin-3-yl)propan-2-amine (9.40 g) as an oil.

Preparation Example 9

To a mixture of 2-(2,6-dichloropyridin-3-yl)propan-2-amine (4.40 g) and 2,4-dimethoxybenzaldehyde (3.92 g) and CH₂Cl₂ (100 mL) was added sodium

15 triacetoxyborohydride (6.80 g) at room temperature. Then the mixture was stirred at the same temperature for 12 hours. CHCl₃ and sat. aq. NaHCO₃ were added to the mixture, and the phases were separated. Aqueous layer was extracted with CHCl₃, and combined organic layers were washed with brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by amino-silica gel column

20 chromatography (EtOAc/hexanes) to give

2-(2,6-dichloropyridin-3-yl)-N-(2,4-dimethoxybenzyl)propan-2-amine (7.62 g) as an oil.

Preparation Example 10

To a mixture of

25 2-(2,6-dichloropyridin-3-yl)-N-(2,4-dimethoxybenzyl)propan-2-amine (7.62 g), 2,6-dimethylpyridine (7.5 mL), and toluene (100 mL) was added a mixture of ethyl 2-(chlorocarbonyl)butanoate (5.55 g) and toluene (20 mL) with ice bath cooling under Ar atmosphere. Then the mixture was stirred at the same temperature for 30 min, and stirred at room temperature for 6 hours. EtOAc and sat. aq. NaHCO₃ were added to the mixture,

30 and the phases were separated. Aqueous layer extracted with EtOAc, and combined organic layers were washed with brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by amino-silica gel column chromatography (EtOAc/hexanes) to give ethyl

2-{{2-(2,6-dichloropyridin-3-yl)propan-2-yl}(2,4-dimethoxybenzyl)carbamoyl} butanoate (9.65 g) as a solid.

Preparation Example 11

5 To a mixture of tert-butyl
2-{{1-{{tert-butyl(dimethyl)silyl}oxy}-2-(3,5-dichloropyrazin-2-yl)propan-2-yl}carbamoyl
}butanoate (1.17 g, 1:1 mixture of all stereoisomers) and anhydrous toluene (10 mL) was
added NaHMDS (1 M in toluene, 6.95 mL) dropwise under ice bath cooling. The mixture
was stirred at the same temperature for 2 hours. The mixture was diluted with sat. aq.
10 NH₄Cl (30 mL), and extracted with EtOAc (2 x 75 mL). The combined organic extracts
were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel
chromatography (EtOAc/hexanes) to give tert-butyl
5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-8-ethyl-5-methyl-7-oxo-5,6,7,8-tetrahy
15 dropyrido[3,4-b]pyrazine-8-carboxylate (457 mg, 3:2 mixture of all stereoisomers) as an
oil.

Preparation Example 12

 To a mixture of
5,5,8-trimethyl-7-oxo-8-(prop-2-yn-1-yl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitri
20 le (40 mg) and DMSO/H₂O mixture (5:1, 1 mL) were added trimethylsilylmethylazide (100
mg), copper (I) sulfate (1 mg), and sodium ascorbate (3 mg). The mixture was stirred at
room temperature for 18 hours followed by filtration through a syringe filter. The filtrate
was then purified by HPLC (1 to 50% MeCN, 0.1% formic acid) to give
5,5,8-trimethyl-7-oxo-8-({1-[(trimethylsilyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-5,6,7,8
25 -tetrahydro-1,6-naphthyridine-2-carbonitrile (29 mg) as a solid.

Preparation Example 13

 A mixture of 2-(tert-butoxycarbonyl)butanoic acid (14.8 g), thionyl chloride (11.5
mL), CH₂Cl₂ (80 mL), and DMF (4 drops) was stirred at room temperature for 2 hours and
30 then concentrated to give tert-butyl 2-(chlorocarbonyl)butanoate (16.1 g) as an oil.

Preparation Example 14

To a mixture of 2-(5-chloro-3-fluoropyridin-2-yl)-2-methylpropanenitrile (7.5 g), DMSO (75 mL), and K₂CO₃ (7.85 g) was slowly added H₂O₂ (30% aq. solution, 44 mL) under ice bath cooling. The reaction was warmed to room temperature and stirred for 1 hour. The reaction was then diluted with EtOAc (300 mL), washed with H₂O (100 mL), brine (100 mL), dried over Na₂SO₄, and concentrated to give 2-(5-chloro-3-fluoropyridin-2-yl)-2-methylpropanamide (8.2 g) as a solid.

Preparation Example 15

To a mixture of 2,2,6,6-tetramethylpiperidine (45 mL) and THF (350 mL) was added n-BuLi (1.55 M in hexane, 155 mL) with dry ice-acetone bath cooling under Ar atmosphere. Then the mixture was stirred under ice bath cooling for 10 min. To the mixture were added a mixture of 2,6-dichloropyridine (36.96 g) and THF (100 mL) under dry ice-acetone bath cooling over 20 min. Then the mixture was stirred at the same temperature for 1 hour. To the mixture was added a mixture of 2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (35.00 g) and THF (50 mL) at the same temperature over 30 min. Then the mixture was stirred at the same temperature for 1 hour. The mixture was diluted with sat. aq. NH₄Cl (200 mL) at the same temperature. To the mixture was added EtOAc (200 mL), and then organic layer was separated. Aqueous layer was extracted with EtOAc (200 mL), and combined organic layers were washed with brine (200 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography twice (CHCl₃/EtOAc and EtOAc/hexanes) to give N-[3-(2,6-dichloropyridin-3-yl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (31.58 g) as a foam.

Preparation Example 16

To a mixture of N-[3-(2,6-dichloropyridin-3-yl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (79.29 g) and EtOAc (1.2 L) was added HCl (4 M in EtOAc, 184 mL) at room temperature. Then the mixture was stirred at the same temperature for 1 hour. The precipitate was collected, and washed with EtOAc to give 3-(2,6-dichloropyridin-3-yl)oxetan-3-amine monohydrochloride (59.61 g) as a solid.

Preparation Example 17

A mixture of

5 N-[3-(3,5-dichloropyrazin-2-yl)oxetan-3-yl]-2-methylpropane-2-sulfonamide (1.21 g),
2-(tert-butoxycarbonyl)butanoic acid (847 mg), 2-chloro-1-methyl pyridinium iodide (1.44
g), triethylamine (758 mg), and MeCN (20 mL) was refluxed for 4 hours and partially
concentrated (ca 5 mL). The residue was dissolved in EtOAc (30 mL), washed with H₂O,
brine, dried over Na₂SO₄, and concentrated. The residue was purified by silica gel
10 chromatography (EtOAc/hexanes) to give tert-butyl
2-{[3-(3,5-dichloropyrazin-2-yl)oxetan-3-yl]carbamoyl}butanoate (951 mg) as a solid.

Preparation Example 18

To a mixture of

2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.70 g) and DMF
15 (45 mL) was added NaH (55% dispersion in mineral oil, 363 mg) under ice bath cooling.
Then the mixture was stirred at the same temperature for 10 min. To the mixture was
added [2-(chloromethoxy)ethyl](trimethyl)silane (1.20 mL) under ice bath cooling. Then
the mixture was stirred at room temperature for 4 hours. Additional NaH (55%
dispersion in mineral oil, 368 mg) and [2-(chloromethoxy)ethyl](trimethyl)silane (1.20 mL)
20 were added under ice bath cooling, and the mixture was stirred at room temperature for 1
hour. The mixture was diluted with sat. aq. NH₄Cl. H₂O and EtOAc were added to the
mixture, and the phases were separated. Aqueous layer was extracted with EtOAc, and
combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and
concentrated under reduced pressure. The residue was purified by silica gel column
25 chromatography (EtOAc/hexanes) to give
2-chloro-8,8-diethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-
-oxetan]-7(8H)-one (1.73 g) as an oil.

Preparation Example 19

30 To a mixture of

2-chloro-8,8-diethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-
-oxetan]-7(8H)-one (1.73 g), 1,4-dioxane (35 mL), and H₂O (3.5 mL) were added
2,4,6-trivinylcyclotriboroxane pyridine complex (2.08 g),

[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (330 mg), and K₂CO₃ (1.76 g). Then the mixture was stirred at 110°C for 4 hours. The mixture was filtered through a pad of Celite. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give 8,8-diethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-2-vinyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.37 g) as a gum.

Preparation Example 20

To a mixture of 8,8-diethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-2-vinyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.37 g), THF (72 mL), and H₂O (18 mL) was added OsO₄ (2.5 wt% in tBuOH, 3.50 mL) at room temperature. Then the mixture was stirred at room temperature for 10 min. To the mixture was added a mixture of sodium periodate (2.31 g) and H₂O (54 mL). Then the mixture was stirred at room temperature for 3 hours. The mixture was diluted with sat. aq. Na₂S₂O₃ (100 mL), and concentrated under reduced pressure. EtOAc was added to the mixture, and the phases were separated. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give 8,8-diethyl-7-oxo-6-{[2-(trimethylsilyl)ethoxy]methyl}-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbaldehyde (524 mg) as a solid.

Preparation Example 21

To a mixture of 8,8-diethyl-7-oxo-6-{[2-(trimethylsilyl)ethoxy]methyl}-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbaldehyde (524 mg) and THF (15 mL) was added NaBH₄ (66 mg) with ice bath cooling under Ar atmosphere. Then the mixture was stirred at the same temperature for 2 hours. The mixture was diluted with sat. aq. NH₄Cl. EtOAc was added to the mixture, and the phases were separated. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give 8,8-diethyl-2-(hydroxymethyl)-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (567 mg) as a solid.

Preparation Example 22

To a mixture of

8,8-diethyl-2-(hydroxymethyl)-6-([2-(trimethylsilyl)ethoxy]methyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (283 mg) and DMF (6 mL) was added NaH (55% dispersion in mineral oil, 45 mg) under ice bath cooling. Then the mixture was stirred for 10 min.

To the mixture was added MeI (65 μ L). Then the mixture was stirred at room temperature for 1 hour. The mixture was diluted with sat. aq. NH_4Cl . EtOAc was added to the mixture, and the phases were separated. The organic layer was dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give

8,8-diethyl-2-(methoxymethyl)-6-([2-(trimethylsilyl)ethoxy]methyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (299 mg) as an oil.

Preparation Example 23

A mixture of

8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-2-chloro-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (456 mg), $\text{Zn}(\text{CN})_2$ (398 mg), Zn (38 mg), palladium(II) bis(trifluoroacetate) (41 mg), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (tBuXphos, 106 mg) and DMAc (10 mL) (which was bubbled with Ar gas for 15 min prior to use) was heated in the microwave reactor at 130°C for 1 hour. The mixture was diluted with EtOAc and H_2O , and filtered through a pad of Celite. The filtrate was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO_4 , and concentrated under reduced pressure. The residue was purified by silica gel chromatography

(EtOAc/hexanes) to give 8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-8-ethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbonitrile (342 mg) as a solid.

Preparation Example 24

To a mixture of 6-chloro-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (30.00 g) and DMI (150 mL) was added NaH (55% dispersion in mineral oil, 5.78 g) under ice bath cooling. After removal of ice bath, the mixture was stirred for 20 min. To the mixture was added a mixture of tert-butyl(2-iodoethoxy)dimethylsilane (39.74 g) and DMI

(30 mL) dropwise over 5 min under ice bath cooling. After removal of ice bath, the mixture was stirred for 2 hours. The mixture was poured into iced water (500 mL), and then stirred at room temperature overnight. The precipitate was collected to give 4-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-6-chloro-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (49.98 g) as a solid.

Preparation Example 25

To a mixture of tert-butyl

5-([tert-butyl(dimethyl)silyl]oxy)methyl)-2-chloro-8-ethyl-5-methyl-7-oxo-5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-8-carboxylate (457 mg, 3:2 mixture of all stereoisomers) and CH₂Cl₂ (3 mL) was added TFA (3 mL). The mixture was stirred at room temperature for 1.5 hours. The solvents were evaporated under reduced pressure, and the residue was partitioned between EtOAc (50 mL) and sat. aq. NaHCO₃ (20 mL). The layers were separated, and the organic phase was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography (EtOAc/hexanes) to give 5-([tert-butyl(dimethyl)silyl]oxy)methyl)-2-chloro-8-ethyl-5-methyl-5,8-dihydropyrido[3,4-b]pyrazin-7(6H)-one (140 mg, 3:2 mixture of all stereoisomers) as a solid.

Preparation Example 26

To a mixture of 6-bromo-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (1.00 g), KOAc (497 mg), bis(pinacolato)diboron (1.03 g), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (247 mg) was added 1,4-dioxane (15 mL), and the mixture was stirred at 85°C for 18 hours. The mixture was cooled to room temperature and diluted with EtOAc (100 mL) and H₂O (100 mL). The biphasic mixture was filtered through a pad of Celite, and the layers were separated. The aqueous phase was extracted with EtOAc (100 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, and concentrated to a crude solid. The solid was suspended in CH₂Cl₂ (5 mL), triturated, and aged at room temperature for 15 min. The precipitate was collected to give 4,4-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (721 mg) as a solid.

Preparation Example 27

To a mixture of 3-(2,6-dichloropyridin-3-yl)oxetan-3-amine monohydrochloride (31.0 g) and DMF (300 mL) were added 2-(tert-butoxycarbonyl)butanoic acid (27.4 g), WSC/HCl (34.9 g), HOBt (24.6 g), and triethylamine (42 mL) at room temperature. Then the mixture was stirred at the same temperature for 3 hours. To the mixture was added H₂O, and extracted with EtOAc. The organic layer was washed with brine, and dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give tert-butyl 2-{[3-(2,6-dichloropyridin-3-yl)oxetan-3-yl]carbamoyl}butanoate (42.9 g) as a solid.

Preparation Example 28

To a mixture of 2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.18 g), Pd₂(dba)₃ (200 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos, 245 mg), and 1,4-dioxane (24 mL) were added 2-ethylhexyl 3-sulfanylpropanoate (1.35 mL) and DIPEA (2.20 mL). The mixture was stirred at 90°C for 15 hours under Ar atmosphere. After the mixture was cooled to room temperature, the solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc/hexanes) to give 2-ethylhexyl 3-[(8,8-diethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-2-yl)sulfanyl]propanoate (1.78 g) as an oil.

Preparation Example 29

To a mixture of 8-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-chloro-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (20.94 g) and toluene (200 mL) were added Cs₂CO₃ (33.2 g), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos, 1.18 g), palladium(II) diacetate (230 mg), benzyl alcohol (10.55 mL) in this order, and then the mixture was stirred at 110°C for 30 min under Ar atmosphere. The mixture was cooled to room temperature. The mixture was filtered through a pad of Celite, and the filter cake was washed with EtOAc. The filtrate was washed with brine, dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give

2-(benzyloxy)-8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (23.89 g) as a solid.

Preparation Example 30

5 A mixture of
2-(benzyloxy)-8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (23.87g), 10% palladium on carbon (50% wet, 2 g), and EtOH (240 mL) was stirred at room temperature for 2 hours under a hydrogen atmosphere (1 atm). After the mixture was filtered through a pad of Celite, the filter cake was washed
10 with CHCl₃. The filtrate was concentrated under reduced pressure. The residue in 50% IPE/hexane (200 mL) was stirred at reflux, and then cooled to room temperature. The precipitate was collected to give
8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-8-ethyl-2-hydroxy-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (14.15 g) as a solid.

15

Preparation Example 31

 To a mixture of
2-hydroxy-8,8-dimethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.44 g), NMP (15 mL), and H₂O (1.5 mL) were added Cs₂CO₃
20 (2.59 g) and sodium chloro(difluoro)acetate (1.52 g) under Ar atmosphere, then the mixture was stirred at 100°C for 2 hours. The mixture was cooled to room temperature, and Cs₂CO₃ (2.59 g) and sodium chloro(difluoro)acetate (1.52 g) were added to the mixture. The mixture was stirred at 100°C for 1.5 hours. The mixture was cooled to room temperature, and Cs₂CO₃ (2.59 g) and sodium chloro(difluoro)acetate (1.52 g) were
25 added to the mixture. The mixture was stirred at 100°C for 1 hour. The mixture was cooled to room temperature, then diluted with H₂O and extracted with EtOAc. The organic layer was washed with H₂O and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc/hexanes) to give
30 2-(difluoromethoxy)-8,8-dimethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.48 g) as a solid.

Preparation Example 32

A mixture of 2-(5-chloro-3-fluoropyridin-2-yl)-2-methylpropanamide (2.16 g), [bis(trifluoroacetoxy)iodo]benzene (5.16 g), MeCN (48 mL), and H₂O (24 mL) was stirred overnight. The reaction was then diluted with EtOAc (200 mL), washed with H₂O (100 mL), brine (100 mL), dried over Na₂SO₄, and concentrated to give 5-chloro-3-fluoro-2-(2-isocyanatopropan-2-yl)pyridine (1.9 g) as a solid.

Preparation Example 33

To a mixture of 8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-8-ethyl-2-hydroxy-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (14.69 g) and MeCN (75 mL) was added a mixture of KOH (21.0 g) and H₂O (75 mL). To the mixture was added diethyl [bromo(difluoro)methyl]phosphonate (13.0 g) under ice bath cooling, and then the mixture was stirred at the same temperature for 30 min. The mixture was extracted with EtOAc three times, and combined organic layers were washed with sat. aq. NaHCO₃ and brine, and dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue in EtOAc (30 mL) and hexane (100 mL) was stirred at reflux, and then cooled to room temperature. The precipitate was collected to give 8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-2-(difluoromethoxy)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (11.46 g) as a solid.

Preparation Example 34

To a mixture of 8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-2-(difluoromethoxy)-8-methyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.80 g) and THF (36 mL) was added TBAF (1.0 M in THF, 3.5 mL) under ice bath cooling, and then the mixture was stirred for 1 hour at the same temperature, and then stirred at room temperature overnight. The mixture was poured into sat. aq. NaHCO₃, and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc/hexanes) to give 2-(difluoromethoxy)-8-(2-hydroxyethyl)-8-methyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.43 g) as an oil.

Preparation Example 35

A mixture of 5-chloro-3-fluoro-2-(2-isocyanatopropan-2-yl)pyridine (1.7 g), MeOH (8 mL), and trimethylamine (2 mL) was stirred for 1 hour and then partially concentrated. The resultant solid was filtered, and the filtrate was concentrated to give methyl [2-(5-chloro-3-fluoropyridin-2-yl)propan-2-yl]carbamate that was used directly in the next step.

Preparation Example 36

To a mixture of 4-bromo-1-iodo-2-methylbenzene (87.5 g) and THF (400 mL) was added dropwise n-BuLi (1.55 M in hexane, 200 mL) over 50 min with dry ice-acetone bath cooling under Ar atmosphere. Then the mixture was stirred at the same temperature for 10 min. To the mixture was added a mixture of 2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (56.8 g) and THF (40 mL) dropwise over 30 min at the same temperature. Then the mixture was stirred at the same temperature for 1 hour. The mixture was diluted with sat. aq. NH₄Cl (200 mL) at the same temperature, and brine (100 mL) was added, and stirred at room temperature for 30 min. Then organic layer was separated, concentrated, and diluted with EtOAc (300 mL). Aqueous layer was extracted with EtOAc (300 mL), and combined organic layers were washed with brine twice, and dried over MgSO₄, filtered, and concentrated under reduced pressure. To the residue was added IPE (150 mL), and the mixture was stirred at room temperature for 15 min and under ice bath cooling for 30 min. The precipitate was collected, and washed with IPE to give N-[3-(4-bromo-2-methylphenyl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (48.07 g) as a solid.

Preparation Example 37

To a mixture of 2,2,6,6-tetramethylpiperidine (81 mL) and THF (95 mL) was added n-BuLi (1.55 M in hexane, 300 mL) dropwise over 8 min with dry ice-acetone bath cooling under Ar atmosphere. Then the mixture was stirred under ice bath cooling for 30 min. To the mixture was added a mixture of N-[3-(4-bromo-2-methylphenyl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (48.06 g), diethyl carbonate (33.7 mL), and THF (220 mL) dropwise over 30 min under dry

ice-acetone bath cooling. Then the mixture was warmed to -40°C over 30 min, and stirred at the same temperature for 10 min. The mixture was diluted with sat. aq. NH₄Cl (700 mL) at the same temperature, and brine (100 mL) was added. Then organic layer was separated, concentrated, and diluted with EtOAc (500 mL). Aqueous layer was
5 extracted with EtOAc (500 mL), and combined organic layers were washed with brine, and dried over MgSO₄, filtered, and concentrated under reduced pressure to give ethyl (5-bromo-2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}phenyl)acetate (63.78 g) as a solid.

Preparation Example 38

10 To a mixture of HCl (4 M in EtOAc, 115 mL), EtOAc (250 mL), and a piece of seed solid of desired compound (ethyl [2-(3-aminooxetan-3-yl)-5-bromophenyl]acetate monohydrochloride) was added a mixture of ethyl (5-bromo-2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}phenyl)acetate (63.77 g) and EtOAc (250 mL) dropwise at room temperature over 20 min. Then the mixture was stirred at the
15 same temperature for 20 min. The precipitate was collected and washed with EtOAc (100 mL) and 50% EtOAc/hexane (200 mL) to give ethyl [2-(3-aminooxetan-3-yl)-5-bromophenyl]acetate monohydrochloride (48.68 g) as a solid.

The seed solid described above was prepared by the same procedure without seed solid on small scale experiment.

20

Preparation Example 39

To a mixture of NaHCO₃ (15.2 g) and H₂O (700 mL) was added ethyl [2-(3-aminooxetan-3-yl)-5-bromophenyl]acetate monohydrochloride (48.67 g) portionwise at room temperature. Then the mixture was stirred at the same temperature for 40 min.
25 The precipitate was collected and washed with H₂O (100 mL) twice and MeOH (100 mL) twice to give 6-bromo-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (32.35 g) as a solid.

Preparation Example 40

To a mixture of (2,6-dichloropyridin-3-yl)acetonitrile (3.86 g) and THF (120 mL)
30 was added NaH (55% dispersion in mineral oil, 2.00 g) with ice bath cooling under Ar atmosphere. Then the mixture was stirred at the same temperature for 10 min. To the mixture was added MeI (3.25 mL) with ice bath cooling under Ar atmosphere. Then the mixture was stirred at the same temperature for 2 hours. The mixture was diluted with sat.

aq. NH_4Cl at the same temperature. H_2O and EtOAc were added to the mixture, and the phases were separated. Aqueous layer was extracted with EtOAc, and combined organic layers were washed with brine, and dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give 2-(2,6-dichloropyridin-3-yl)-2-methylpropanenitrile (4.39 g) as a solid.

Preparation Example 41

A mixture of methyl 2-(5-chloro-3-fluoropyridin-2-yl)propan-2-ylcarbamate (900 mg), EtOH (12 mL), and NaOH (3 M in H_2O , 4 mL) was heated in a microwave reactor at 150°C for 30 min. The reaction was then concentrated and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over Na_2SO_4 , and concentrated to give 2-(5-chloro-3-fluoropyridin-2-yl)propan-2-amine (520 mg).

15 Preparation Example 42 (42a and 42b)

8-(2-([tert-Butyl(dimethyl)silyl]oxy)ethyl)-2-(difluoromethoxy)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (14.42 g) was resolved with chiral column chromatography (CHIRALFLASH (trademark) IA, eluent; Hexane/EtOAc 80/20 – 0/100, flow rate; 12 – 20 mL/min) to give

8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-2-(difluoromethoxy)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (6.93 g, one enantiomer with shorter retention time) as a solid, and

8-(2-([tert-butyl(dimethyl)silyl]oxy)ethyl)-2-(difluoromethoxy)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (6.78 g: one enantiomer with longer retention time) as a solid.

Preparation Example 83

To a mixture of 1-bromo-4-chloro-2-methylbenzene (73.28 g) and THF (250 mL) was added dropwise n-BuLi (1.55 M in hexane, 220 mL) over 90 min with dry ice-acetone bath cooling under N_2 atmosphere. Then the mixture was stirred at the same temperature for 10 min. To the mixture was added a mixture of

2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (50.00 g) and THF (100 mL) dropwise over 60 min at the same temperature. Then the mixture was stirred at the same

temperature for 20 min. The mixture was diluted with sat. aq. NH_4Cl at the same temperature and warmed up to room temperature. The mixture was partially concentrated under reduced pressure, and then the mixture was diluted with H_2O , and extracted with EtOAc twice. The combined organic layers were washed with brine, and dried over MgSO_4 , filtered, and concentrated under reduced pressure. The combined aqueous layers were filtered through a pad of Celite and the cake was washed with EtOAc three times. The filtrate was extracted with EtOAc, and the organic layer was washed with brine, and dried over MgSO_4 , filtered, and concentrated under reduced pressure. The combined residues were diluted with IPE and then concentrated under reduced pressure. To the residue was added IPE and stood at room temperature overnight. The solid was collected, and washed with 50% IPE/hexanes to give N-[3-(4-chloro-2-methylphenyl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (57.00g) as a solid.

15 Preparation Example 84

To a mixture of 2,2,6,6-tetramethylpiperidine (109 mL) and THF (114 mL) was added n-BuLi (1.55 M in hexane, 400 mL) dropwise over 40 min with dry ice-MeCN bath cooling under N_2 atmosphere. To the mixture was added a mixture of N-[3-(4-chloro-2-methylphenyl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (57.0 g), diethyl carbonate (45.0 mL), and THF (256 mL) dropwise over 90 min under dry ice-MeCN bath cooling. Then the mixture was stirred at the same temperature for 30 min. The mixture was diluted with sat. aq. NH_4Cl at the same temperature. The mixture was partially concentrated under reduced pressure, and the mixture was extracted with EtOAc twice. The combined organic layers were washed with 50% brine/ H_2O twice, and dried over MgSO_4 , filtered, and concentrated under reduced pressure to give ethyl (2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}-5-chlorophenyl)acetate (70.6 g) as an oil.

Preparation Example 85

To a mixture of HCl (4 M in EtOAc, 285 mL) and EtOAc (850 mL) was added a mixture of ethyl (2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}-5-chlorophenyl)acetate (142.46 g) and EtOAc (800 mL) dropwise at room temperature over 25 min. Then the mixture was stirred at the same temperature for 25 min. The precipitate was collected and washed with 50% EtOAc/hexanes three times to give ethyl

[2-(3-aminooxetan-3-yl)-5-chlorophenyl]acetate monohydrochloride (116.70 g) as a solid.

Preparation Example 86

To a mixture of NaHCO₃ (42.0 g) and H₂O (1170 mL) was added ethyl
5 [2-(3-aminooxetan-3-yl)-5-chlorophenyl]acetate monohydrochloride (116.7 g) portionwise at room temperature. Then the mixture was stirred at the same temperature for 1 hour. The precipitate was collected and washed with H₂O twice and EtOAc twice to give 6-chloro-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (62.9 g) as a solid.

10

Preparation Example 95

To a mixture of 2-(3,5-dichloropyrazin-2-yl)-2-methylpropanamide (2.5 g), H₂O (11 mL), MeCN (11 mL), and sulfuric acid (11 mL) was added sodium nitrite (3.7 g) under ice bath cooling. The mixture was stirred at the same temperature for 5 min and then
15 warmed to room temperature and stirred for 2 hours. The resultant solid was collected and washed with H₂O to give 2-(3,5-dichloropyrazin-2-yl)-2-methylpropanoic acid (2.5 g) as a solid.

Preparation Example 96

A mixture of 2-(3,5-dichloropyrazin-2-yl)-2-methylpropanoic acid (2.2 g), toluene (45 mL), triethylamine (1.7 mL) and diphenylphosphorylazide (3.1 g) was stirred at reflux for 2.5 hours. The mixture was then cooled to room temperature, and 4-methoxybenzyl alcohol (5.2 g) and triethylamine (7.8 mL) were added. The mixture was stirred at room temperature for 2 hours and then concentrated. The crude product was dissolved in
25 CH₂Cl₂ (10 mL), followed by the addition of TFA (10 mL). The mixture was stirred at room temperature for 3 hours and then concentrated. To the crude solid was added HCl (4 M in 1,4-dioxane, 10 mL) at room temperature, and then concentrated to give 2-(3,5-dichloropyrazin-2-yl)propan-2-amine monohydrochloride (1.4 g) as a solid.

30 Preparation Example 100

To a mixture of 2-bromo-4-fluoro-1-iodobenzene (3.12 g) and THF (25 mL) was added n-BuLi (1.6 M in hexane, 6.5 mL) dropwise at -100°C under a nitrogen atmosphere. The resulting mixture was stirred at the same temperature for 30 min, and then

2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (2.0 g) in THF (5 mL) was slowly added dropwise while maintaining the internal temperature between -90 and -100°C. The resulting solution was stirred at the same temperature for 30 min. The mixture was diluted with sat. aq. NH₄Cl (50 mL) and H₂O (50 mL), and extracted with EtOAc (2 x 100 mL). Combined organic layers were washed with brine, dried over Na₂SO₄, filtered, concentrated, and then purified by silica gel column chromatography (EtOAc/hexanes) to give N-[3-(2-bromo-4-fluorophenyl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (1.29 g) as a solid.

10 Preparation Example 101

A 200-mL round bottom flask was charged with N-[3-(2-bromo-4-fluorophenyl)oxetan-3-yl]-2-methylpropane-2-sulfinamide (1.05 g), Pd₂(dba)₃ (137 mg), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (Xphos, 143 mg). The flask was evacuated and back-filled with nitrogen 3 times, and anhydrous degassed THF (15 mL) was added via syringe, followed by tert-butoxy-2-oxoethylzinc chloride (0.5 M in Et₂O, 15 mL). The resulting mixture was stirred at 55°C for 1 hour and then cooled to room temperature and diluted with EtOAc (100 mL) and H₂O (50 mL). The mixture was filtered through a pad of Celite. The phases were separated, and the aqueous phase was extracted with EtOAc (50 mL). Combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated to give a brown solid. To a mixture of the crude solid and CH₂Cl₂ (50 mL) was added TFA (10 mL). The resulting mixture was stirred at room temperature for 1.5 hours. The solvents were evaporated, and the remaining residue was partitioned between sat. aq. NaHCO₃ (50 mL) and EtOAc (50 mL). The layers were separated and the aqueous phase was washed with EtOAc (50 mL). The aqueous phase was then acidified to a pH of 5 with formic acid and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over Na₂SO₄, and concentrated to give (2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}-5-fluorophenyl)acetic acid (0.52 g) as a solid.

30 Preparation Example 102

To a mixture of (2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}-5-fluorophenyl)acetic acid (491 mg) and 1,4-dioxane (4 mL) was added HCl (4 M in 1,4-dioxane, 0.45 mL) under ice bath cooling.

The reaction mixture was warmed to room temperature and stirred for 1 hour. The precipitate was filtered to give a crude solid (150 mg), and used directly in the next step. A mixture of the crude solid (150 mg), DMF (2 mL), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU, 326 mg), HOBT (116 mg), and trimethylamine (0.24 mL) was stirred at room temperature for 1 hour. The reaction was then poured into H₂O (25 mL) and EtOAc (25 mL). The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered, and concentrated. The resultant solid was washed by 25% CH₂Cl₂/hexanes to give 6-fluoro-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (85 mg) as a solid.

10

Preparation Example 104

To a mixture of

(2-{3-[(tert-butylsulfinyl)amino]oxetan-3-yl}-5-chloropyridin-3-yl)acetic acid (4.84 g) and MeCN (112 mL) was added thionyl chloride (2.1 mL) under ice bath cooling. The reaction mixture was stirred at the same temperature for 90 min. To the mixture was added sat. aq. NaHCO₃ (40 mL), and then the mixture was concentrated to a volume of about 80 mL, and the resultant solid was filtered and washed with H₂O (15 mL), Et₂O (30 mL), and EtOAc (10 mL). The resultant solid was then triturated with a 10% MeOH/hexane to give 3-chloro-5H-spiro[1,7-naphthyridine-8,3'-oxetan]-6(7H)-one (1.12g) as a solid.

20

Example 1

A 1000 mL 3-necked flask was charged with

6-bromo-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (17.35 g) and DMF (160 mL). The flask was evacuated and back-filled with Ar twice, and NaH (55% dispersion in mineral oil, 6.50 g) was added portionwise under ice bath cooling, and then the mixture was stirred at room temperature for 30 min. To the mixture was added a mixture of MeI (8.1 mL) and DMF (35 mL) dropwise under ice bath cooling over 1 hour. Additional MeI (0.5 mL) was added under ice bath cooling, and the mixture was stirred at the same temperature for 10 min. The mixture was diluted with H₂O (250 mL) and sat. aq. NH₄Cl (150 mL), and stirred at room temperature for 1 hour. The precipitate was collected, and a mixture of the solid and 40% toluene/hexane (200 mL) was stirred at reflux for 1 hour,

30

and then cooled to room temperature. The mixture was stirred at room temperature for 30 min, and the precipitate was collected to give

6-bromo-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (14.47 g) as a solid.

5 Example 2

To a solid of P₂O₅ (20.00 g) was added H₃PO₄ (12 mL), and the mixture was stirred at 140°C for 1 hour. To the mixture were added 2-(3-methylphenyl)butanamide (3.00 g) and acetone (2.70 mL) at 100°C, and stirred at the same temperature for 2 hours. To the mixture was added acetone (2.70 mL) at 120°C, and stirred at the same temperature
10 for 2 hours. The mixture was poured into iced water, and diluted with EtOAc, and separated. The organic layer was washed with brine and dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was washed with EtOAc/hexanes to give 4-ethyl-1,1,6-trimethyl-1,4-dihydroisoquinolin-3(2H)-one (2.83 g) as a solid.

15 Example 3

A mixture of 4-ethyl-1,1,6-trimethyl-1,4-dihydroisoquinolin-3(2H)-one (600 mg), NaH (60% dispersion in mineral oil, 167 mg) and DMF (6.0 mL) was stirred under ice bath cooling for 30 min. To the mixture was added 2-(3-bromopropoxy)tetrahydro-2H-pyran (924 mg) at the same temperature and stirred at room temperature overnight. To the
20 mixture were added EtOAc and brine, and the phases were separated. The organic layer was washed with H₂O, and brine, and dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes). To the residue were added HCl (1 M aq., 5.0 mL) and THF (5.0 mL), and stirred at 70°C for 2 hours. To the mixture were added EtOAc and brine, and the
25 phases were separated. The organic layer was washed with H₂O, and brine, and dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes to CHCl₃/MeOH). The residue was washed with hexane to give
30 4-ethyl-4-(3-hydroxypropyl)-1,1,6-trimethyl-1,4-dihydroisoquinolin-3(2H)-one (84 mg) as a solid.

Example 4

A 500 mL flask was charged with 6-bromo-4,4-diethyl-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (15.0 g), palladium(II) bis(trifluoroacetate) (1.62 g), Zn (1.27 g),
5 di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (tBuXPhos, 4.11 g), and degassed DMAc (prepared by Ar bubbling for 5 min, 150 mL). The flask was evacuated and back-filled with Ar three times, and Zn(CN)₂ (7.39 g) was added at room temperature. The mixture was stirred at 80°C for 6 hours. After cooling to room temperature, to the mixture was added EtOAc (300 mL). Then insoluble matter was filtered through a pad of
10 Celite, and washed with EtOAc (300 mL). The filtrate was washed with H₂O (150 mL) twice and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. To the residue was added 50% hexane/EtOAc (240 mL), and stirred at 80°C for 30 min and room temperature for 30 min. The precipitate was collected, and washed with 50% hexane/EtOAc (80 mL) to give
15 4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (6.18 g) as a solid.

Example 5

To a mixture of 4,6-dibromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (150
20 mg) and THF (3.0 mL) was added N-methylcyclohexylamine (153 mg). Then the mixture was stirred at room temperature for 15 hours. The mixture was poured into the sat. aq. NaHCO₃, and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give
25 6-bromo-4-[cyclohexyl(methyl)amino]-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (118 mg) as a solid.

Example 6

To a mixture of
30 2-chloro-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (6.0 g) and DMF (150 mL) was added NaH (55% dispersion in mineral oil, 1.13 g) with ice bath cooling under Ar atmosphere. After 10 min, EtI (2.0 mL) was added and the mixture was stirred at room temperature for 1 hour. Sat. aq. NH₄Cl and EtOAc were added and the organic

layer was separated, washed with H₂O twice and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give

2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (6.19 g) as a solid.

Example 7

To a mixture of methyl

4-[(6-bromo-4-ethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)methyl]benzoate (300 mg), THF (6.0 mL), and MeOH (6.0 mL) was added NaOH (1 M aq., 1.4 mL) at room temperature, and stirred at the same temperature for 72 hours. The mixture was neutralized to pH7-8 with 1 M aq. HCl and H₂O under ice bath cooling. To the mixture was added EtOAc, and the phases were separated. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH) to give a solid. The obtained solid was washed with EtOAc to give

4-[(6-bromo-4-ethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)methyl]benzoic acid (212 mg) as a solid.

Example 8

To a mixture of

(6-bromo-4-ethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)acetic acid (170 mg) and DMF (2 mL) were added HOBt (101 mg), WSC/HCl (144 mg), dimethylamine monohydrochloride (122 mg), and DIPEA (260 μ L), and the mixture was stirred at room temperature for 15 hours. The mixture was diluted with H₂O and extracted with EtOAc. The organic layer was washed with H₂O and brine, dried over MgSO₄, filtered, and concentrated under reduced pressure to give

2-(6-bromo-4-ethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N-dimethylacetamide (128 mg) as a solid.

Example 9

6-Bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-

one (210 mg) was resolved by chiral supercritical fluid chromatography (SFC) (CHIRALPAK[®] IC, elute CO₂:MeOH = 65:35, flow rate; 15 mL/min, back pressure; 100 bar, column temperature; 40°C). One enantiomer with shorter retention time was washed with hexane to give

- 5 (+)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (82 mg) as a solid. The other enantiomer with longer retention time was washed with hexane to give
- (-)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (82 mg) as a solid.

10

Example 10

To a mixture of

- 2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.65 g), 1,4-dioxane (40 mL), and H₂O (4 mL) (which were bubbled with Ar gas prior to use) were
- 15 added trimethylboroxine (1.64 mL), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (430 mg), and K₂CO₃ (3.0 g). Then the mixture was stirred at 110°C for 4 hours. The mixture was diluted with EtOAc and H₂O, and filtered through a pad of Celite. The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The
- 20 residue was purified sequentially by silica gel column chromatography (EtOAc/hexanes), by amino-silica gel column chromatography (EtOAc/hexanes), and then by silica gel column chromatography (CHCl₃/MeOH). The residue was solidified with 9% IPE/hexane (10 mL) to give
- 8,8-diethyl-2-methyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.3 g) as a solid.

25

Example 11

A mixture of

- 2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (0.75 g), 2,2,2-trifluoroethanol (1.90 mL), Cs₂CO₃ (1.75 g), palladium(II) diacetate (60 mg),
- 30 di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (tBuXphos, 225 mg), and degassed toluene (15 mL) was heated in the microwave reactor at 150°C for 90 min. An additional batch (total two batches) was performed with the same procedure as above. The mixture in 2 vials were diluted with H₂O and EtOAc, and filtered through a pad of

Celite. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes). The residue was solidified with 6% IPE/hexane (10 mL), and collected to give

- 5 8,8-diethyl-2-(2,2,2-trifluoroethoxy)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (1.56 g) as a solid.

Example 12

To a mixture of

- 10 2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (500 mg) and EtOH (17 mL) were added triethylamine (500 μ L) and 10% palladium on carbon (50% wet, 100 mg) under a positive flow of Ar. The mixture was stirred at room temperature under a hydrogen atmosphere overnight. The mixture was filtered, and the filtrate was concentrated under reduced pressure. To the residue was added H₂O, and the mixture was
15 extracted with CHCl₃. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give 8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (385 mg) as a solid.

Example 13

- 20 To a mixture of 8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (100 mg), zinc bis(difluoromethanesulfinate) (253 mg), TFA (31 μ L), CH₂Cl₂ (2.1 mL), and H₂O (0.6 mL) was added t-butyl hydroperoxide (70% aq., 177 μ L) under ice bath cooling. Then the mixture was stirred at room temperature for 22 hours. The mixture was diluted with 50% sat. aq. Na₂S₂O₃/sat. aq. NaHCO₃. The mixture was extracted with
25 CHCl₃. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give 2-(difluoromethyl)-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (62 mg).

30

Example 14

To a mixture of

8,8-diethyl-2-(methoxymethyl)-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphth

pyridine-5,3'-oxetan]-7(8H)-one (299 mg) and DMF (9 mL) was added TBAF (550 mg). Then the mixture was stirred at 100°C for 8 hours. H₂O and EtOAc were added to the mixture, and the phases were separated. The organic layer was washed with H₂O twice and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes). The residue was washed with 5% IPE/hexane (2 mL) to give 8,8-diethyl-2-(methoxymethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (100 mg) as a solid.

10 Example 15

To a mixture of

8-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-(difluoromethoxy)-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (8260 mg, one enantiomer with shorter retention time) and THF (80 mL) was added HCl (1M aq., 25 mL) under water bath, and then the mixture was stirred for 10 min at room temperature. The mixture was diluted with sat. aq. NaHCO₃, and concentrated under reduced pressure, and the mixture was extracted with CHCl₃ three times. The combined organic layers were dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH). The residue in IPE (20 mL) was heated. After the mixture was cooled to room temperature, the precipitate was collected to give (-)-2-(difluoromethoxy)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (5.73 g) as a solid.

Example 16

25 A mixture of

2-chloro-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (118 mg), Zn(CN)₂ (150 mg), Zn (12 mg), palladium(II) bis(trifluoroacetate) (15 mg), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (tBuXphos, 38 mg), and DMAc (4 mL) was heated in the microwave reactor at 130°C for 1 hour. After cooling, the mixture was diluted with EtOAc and H₂O, and then filtered through a pad of Celite. The organic layer was separated, washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give

8,8-diethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbonitrile (78 mg) as a solid.

Example 17

5 To a mixture of 2-ethylhexyl
3-[(8,8-diethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-2-yl)sulfanyl]p
ropanoate (625 mg), THF (6.3 mL), and MeOH (6.3 mL) was added KOtBu (168 mg)
under ice bath cooling, and the mixture was stirred at room temperature for 1 hour and at
60°C for 20 hours under Ar atmosphere. After cooled to room temperature, to the
10 mixture was added MeI (110 µL) and the mixture was stirred at room temperature for 1
hour. Solvents were evaporated under reduced pressure. The residue was purified by
silica gel chromatography (EtOAc/hexanes) and amino-silica gel chromatography
(EtOAc/hexanes). To the residue was added IPE (2 mL), and the mixture was sonicated.
After hexane (10 mL) was added, the mixture was stirred at room temperature for 10 min.
15 The precipitate was collected to give
8,8-diethyl-2-(methylsulfanyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (225
mg) as a solid.

Example 18

20 To a mixture of
2-(difluoromethoxy)-8,8-dimethyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-nap
hthyridine-5,3'-oxetan]-7(8H)-one (1.40 g) and NMP (25 mL) was added TBAF hydrate
(2.90 g), and the mixture was stirred at 100°C for 3 hours. The mixture was cooled to
room temperature, then diluted with H₂O and extracted with EtOAc. The organic layer
25 was washed with brine, dried over MgSO₄, filtered and concentrated under reduced
pressure. The residue was purified by silica gel column chromatography
(EtOAc/hexanes) to give a solid. The obtained solid was diluted with IPE (3 mL) and
hexane (15 mL), and the mixture was stirred at room temperature for 10 min. The solid
was collected to give a crude solid. The solid obtained above (crude, 483 mg) was
30 dissolved with MeCN (6 mL) and MeOH (4 mL). Then the solution was purified by
HPLC [column: YMC-Pack ODS-A, S-15 µm, 12 nm, 250 x 50, flow rate: 80 mL/min,
detection: ELSD (evaporative light scattering detector) (and UV = 210 nm), eluent:
MeCN/0.1% HCO₂H aq.] to give

2-(difluoromethoxy)-8,8-dimethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (406 mg) as a solid.

Example 19

5 To a mixture of
2-(difluoromethoxy)-8-(2-hydroxyethyl)-8-methyl-6-{[2-(trimethylsilyl)ethoxy]methyl}-6
H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (343 mg) and CH₂Cl₂ (7 mL) was added
TFA (0.3 mL) under ice bath cooling, and then the mixture was stirred for 3 hours at the
same temperature. To the mixture was added TFA (0.3 mL) under ice bath cooling and
10 then the mixture was stirred for additional 1 hour. The mixture was concentrated, and the
residue was diluted with CHCl₃ (4 mL) and MeCN (4 mL). To the mixture was added
ethylenediamine (1 mL), and then the mixture was stirred at room temperature overnight.
The mixture was concentrated, and the residue was purified by silica gel chromatography
(CHCl₃/MeOH) to give a solid (132mg). The residue was solidified with MeOH and IPE
15 to give
2-(difluoromethoxy)-8-(2-hydroxyethyl)-8-methyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan
]-7(8H)-one (93 mg) as a solid.

Example 20

20 To a mixture of
6-bromo-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (24.9 g) and
degassed DMF (prepared by Ar bubbling for 10 min) were added Zn(CN)₂ (9.9 g), Zn
(2.75 g), Pd₂(dba)₃ (770 mg), and 1,1'-bis(diphenylphosphino)ferrocene (932 mg). Then
the mixture was stirred at 80°C for 14 hours. To the mixture was added EtOAc (500 mL)
25 and stirred for 10 min. Then insoluble matter was filtered through a pad of Celite, and
washed with EtOAc (500 mL). The filtrate was washed with H₂O (50 mL), 28% aq.
ammonia (100 mL), and brine (50 mL) twice, and combined aqueous layers were extracted
with EtOAc (250 mL) twice. Combined organic layers were washed with brine, dried
over MgSO₄, filtered, and concentrated under reduced pressure. The residue was
30 dissolved in THF (750 mL) under heating condition, and after cooling to room temperature,
ammonium pyrrolidine-1-carbodithioate (1.22 g) was added. Then the mixture was
stirred at room temperature for 1 hour. The mixture was filtered through a pad of Celite,
and filtrate was concentrated under reduced pressure. The residue was solidified with

EtOAc (200 mL), and collected. The solid was purified by amino-silica gel column chromatography (CHCl₃/hexane) to give 4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile (18.87 g) as a solid.

5

Example 21

To a mixture of

7-chloro-4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (80 mg) and 1,4-dioxane (800 µL) were added MeOH (56 µL) and KOtBu (38 mg) at room temperature. The mixture was heated in the microwave reactor at 120°C for 30 min. To the mixture was added sat. aq. NH₄Cl, and extracted with CHCl₃. The organic layer was concentrated under reduced pressure. The residue was purified by amino-silica gel column chromatography (EtOAc/hexanes). To the obtained solid was added 50% hexane/EtOAc (2 mL), and then the mixture was stirred at room temperature for 10 min. The precipitate was collected, washed with 50% hexane/EtOAc (1 mL) to give 4,4-diethyl-7-methoxy-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (14 mg) as a solid.

10

15

Example 22

6-Chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (130.00 g) was resolved with chiral column chromatography (CHIRALPAK(trademark) IC, eluent; 100% MeOH) to give (+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (58.4 g: >99%ee, shorter retention time) as a solid, and (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (58.3 g: 99%ee, longer retention time) as a solid.

20

25

Example 23

To a mixture of

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbaldehyde (150 mg) and CH₂Cl₂ (4 mL) was added bis(2-methoxyethyl)aminosulfur trifluoride (2.70 g). The mixture was stirred at room temperature for 48 hours. To the mixture were added CH₂Cl₂ (25 mL) and sat. aq. NaHCO₃ (25 mL). The layers were separated, and the

30

aqueous phase was extracted with additional CH₂Cl₂ (20 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by reverse phase HPLC with a gradient from 10% to 100% MeCN/H₂O with 0.1% formic acid over 40 min (Phenomenex Gemini, 5 micron C18) to give

- 5 6-(difluoromethyl)-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (38 mg) as a solid.

Example 24

To a mixture of

- 10 6-hydroxy-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (475 mg) and DMF (4 mL) were added Cs₂CO₃ (1.20 g) and sodium chlorodifluoroacetate (700 mg), and the mixture was stirred at 90°C for 18 hours. The mixture was cooled to room temperature, and EtOAc (100 mL) and H₂O (100 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (50 mL). The combined organic phases were
- 15 dried over Na₂SO₄ and concentrated. The residue was purified by reverse phase HPLC with a gradient from 10% to 100% MeCN/H₂O with 0.1% formic acid over 40 min (Phenomenex Gemini, 5 micron C18) to give
- 6-(difluoromethoxy)-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (107 mg) as a solid.

20

Example 25

To a mixture of DMF (0.5 mL), 2,2,2-trifluoroethanol (0.5 mL), and NaH (60% dispersion in mineral oil, 28 mg) was added

2'-chloro-8',8'-diethyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (20 mg).

- 25 The mixture was stirred at 100°C for 1 hour. The mixture was cooled to room temperature and diluted with sat. aq. NH₄Cl (10 mL). EtOAc (30 mL) and H₂O (20 mL) were then added, and the resultant organic layer was separated, washed with brine, dried over Na₂SO₄, and purified by reverse phase HPLC (20-100% MeCN/H₂O, 0.1% formic acid buffer) over 40 min to give
- 30 8',8'-diethyl-2'-(2,2,2-trifluoroethoxy)-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (15 mg) as a solid.

Example 26

A mixture of bis(cyclopentadienyl)zirconium(IV) dichloride (20 mg) and sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al, 3.4 M in toluene, 1.8 g) was stirred for 10 min and then cooled with ice bath. To the mixture was then added

5 2'-chloro-8',8'-diethyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (200 mg), and the mixture was stirred for 30 min. The mixture was warmed to room temperature and diluted with sat. aq. NaHCO₃ (10 mL). EtOAc (30 mL) and H₂O (20 mL) were then added, and the organic layer was separated, washed with brine, dried over Na₂SO₄, and purified by reverse phase HPLC (20-100% MeCN/H₂O, 0.1% formic acid buffer) over 40

10 min to give 8',8'-diethyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (150 mg) as a solid.

Example 27

A mixture of

15 2-chloro-8,8-diethyl-5,5-dimethyl-5,8-dihydropyrido[3,4-b]pyrazin-7(6H)-one (100 mg) and sodium ethoxide (25% solution in EtOH, 5 mL) was heated in the microwave reactor at 190°C for 30 min. EtOAc (100 mL) and H₂O (50 mL) were added to the mixture, and the organic layer was then separated. The organic layer was then washed with H₂O (50 mL), dried over Na₂SO₄, concentrated under reduced pressure, and purified by silica gel

20 column chromatography (EtOAc/hexanes) to give 2-ethoxy-8,8-diethyl-5,5-dimethyl-5,8-dihydropyrido[3,4-b]pyrazin-7(6H)-one (45 mg) as a solid.

Example 28

25 A mixture of 8',8'-diethyl-2'-vinyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (6 mg), 10% palladium on carbon (12 mg), and MeOH (2 mL) was stirred under a hydrogen atmosphere (20 psi) for 2 hours. The mixture was then filtered through a pad of Celite, and the filtrate was concentrated. The residue was purified by reverse phase HPLC (20-100%

30 MeCN/H₂O, 0.1% formic acid buffer) over 40 min to give 2',8',8'-triethyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (4 mg) as a solid.

Example 29

To a mixture of

5 5-([tert-butyl(dimethyl)silyl]oxy)methyl)-2-chloro-8,8-diethyl-5-methyl-5,8-dihydropyrid
o[3,4-b]pyrazin-7(6H)-one (20 mg) and anhydrous THF (1 mL) was added TBAF (1 M in
THF, 0.070 mL) under ice bath cooling, and the mixture was stirred for 5 min under ice
bath cooling, followed by 15 min at room temperature. The mixture was diluted with sat.
aq. NaHCO₃ (5 mL), and extracted with EtOAc (2 x 20 mL). The combined organic
extracts were washed with brine and dried over Na₂SO₄, and concentrated under reduced
pressure. The residue was purified by silica gel chromatography (EtOAc/hexanes) to give
10 2-chloro-8,8-diethyl-5-(hydroxymethyl)-5-methyl-5,8-dihydropyrido[3,4-b]pyrazin-7(6H)-
one (11 mg) as a solid.

Example 30

A mixture of

15 2'-chloro-8',8'-diethyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one (28 mg)
and Me₂NH (2 M in THF, 1 mL) was heated in the microwave reactor at 130°C for 1 hour.
The reaction was cooled and purified directly by reverse phase HPLC (20-100%
MeCN/H₂O, 0.1% formic acid buffer) over 40 min to give
2'-(dimethylamino)-8',8'-diethyl-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazin]-7'(8'H)-one
20 (10 mg) as a solid.

Example 31 (31a and 31b)

A mixture of

5-allyl-2-chloro-8,8-diethyl-5-methyl-5,8-dihydro-1,6-naphthyridin-7(6H)-one (100 mg),
25 1-methyl-4-vinyl-1H-pyrazole (74 mg), Grubbs second generation catalyst (6 mg), and
CH₂Cl₂ (1 mL) was stirred at 40°C for 4 days, and more catalyst (6 mg) was added at the
beginning of days 2 and 3. The reaction was directly purified by reverse phase HPLC
(20-100% MeCN/H₂O, 0.1% formic acid buffer) over 40 min to give the cis and trans
isomers of
30 2-chloro-8,8-diethyl-5-methyl-5-[3-(1-methyl-1H-pyrazol-4-yl)prop-2-en-1-yl]-5,8-dihydr
o-1,6-naphthyridin-7(6H)-one as solids (isomer with shorter retention time, 2 mg; isomer
with longer retention time, 7 mg).

Example 32

To a mixture of methyl

(6-chloro-4-ethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetan]-4-yl)acetate (389 mg) and anhydrous THF (5 mL) was added lithium aluminum hydride (1.0 M in THF, 1.32 mL) dropwise under ice bath cooling. The mixture was stirred at under ice bath cooling for 20 min and then H₂O (0.050 mL), NaOH (3M aq., 0.050 mL), and H₂O (0.150 mL) were added. The mixture was filtered through a pad of Celite, and the filtered solids were washed with excess THF (200 mL). The filtrate was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography (EtOAc/hexanes) to give foam.

The foam was triturated and sonicated in Et₂O and filtered to give 6-chloro-4-ethyl-4-(2-hydroxyethyl)-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (235 mg) as a solid.

Example 33

To a mixture of

5,5,8-trimethyl-7-oxo-8-({1-[(trimethylsilyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitrile (27 mg) and THF (2 mL) were added H₂O (20 µL) and TBAF (1M in THF, 100 µL). The mixture was stirred at room temperature for 24 hours. The mixture was concentrated and partitioned between EtOAc (10 mL) and H₂O.

The organic layer was separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by reverse phase HPLC (5 to 100% MeCN, 0.1% formic acid) to give

5,5,8-trimethyl-8-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitrile (11 mg) as a solid.

Example 34

To a mixture of

4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (1.00 g) and DCE (15 mL) were added N-chlorosuccinimide (690 mg), palladium(II) diacetate (45 mg), and p-toluenesulfonic acid monohydrate (378 mg) at room temperature. Then the mixture was stirred at 70°C for 16 hours. To the mixture was added N-chlorosuccinimide (676 mg) at room temperature. Then the mixture was stirred at 70°C for 7 hours. To the

mixture were added N-chlorosuccinimide (676 mg), palladium(II) diacetate (47 mg), and p-toluenesulfonic acid monohydrate (375 mg) at room temperature. Then the mixture was stirred at 70°C for 1 day. After cooling to room temperature, the mixture was directly purified by silica gel column chromatography (EtOAc/hexanes). To the obtained
5 residue was added 50% hexane/EtOAc, and then the mixture was stirred at 80°C for 10 min and room temperature for 1 hour. The precipitate was collected to give 7-chloro-4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (140 mg) as a solid.

10 Example 35

To a mixture of 4-(2-{{tert-butyl(dimethyl)silyl}oxy}ethyl)-6-chloro-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (49.98 g) and THF (350 mL) was added HCl (1 M aq., 164 mL) under ice bath cooling. The mixture was stirred at room temperature for 30 min. A mixture of
15 NaHCO₃ (16.0 g) and H₂O (200 mL) was added under ice bath cooling, and then THF was evaporated under reduced pressure. To the mixture was added EtOAc (200 mL), and stirred at room temperature for 15 min. Then hexane (400 mL) was added and stirred at room temperature for 2 hours. The precipitate was collected, rinsed with H₂O (100 mL), 33% EtOAc/hexanes (50 mL) to give
20 6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (31.56 g) as a solid.

Example 36

To a mixture of tert-butyl 2-{{[3-(2,6-dichloropyridin-3-yl)oxetan-3-yl]carbamoyl}butanoate (42.9 g) and THF (500 mL) was added NaHMDS (1.1 M in THF, 250 mL) dropwise with ice bath cooling under Ar atmosphere. Then the mixture was stirred at the same temperature for 2 hours. To the mixture was added H₂O and extracted with EtOAc. The organic layer was washed with H₂O and brine, and dried over MgSO₄, filtered, and concentrated under reduced
30 pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH). The residue was washed with hexane to give tert-butyl 2-chloro-8-ethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-8-carboxylate (27.7 g) as a solid.

Example 37

A mixture of ethyl

2-chloro-6-(2,4-dimethoxybenzyl)-8-ethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-8-carboxylate (8.36 g), anisole (6 mL), and TFA (25 mL) was stirred at 80°C for 4 hours. After cooling, solvent was evaporated under reduced pressure. The residue was basified to pH 7-8 with sat. aq. NaHCO₃ under ice bath cooling, and extracted with EtOAc. The organic layer was washed with brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes) to give ethyl 2-chloro-8-ethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-8-carboxylate (5.56 g) as a solid.

Example 38

A mixture of ethyl

2-chloro-8-ethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-8-carboxylate (5.60 g) and H₂SO₄ (12 M aq., 60 mL) was stirred at 50°C for 8 hours. After cooling, the mixture was poured into iced water, and basified with 28% aq. ammonia. EtOAc and H₂O were added to the mixture, and the phases were separated. Aqueous layer was extracted with EtOAc, and combined organic layers were washed with brine, and dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give 2-chloro-8-ethyl-5,5-dimethyl-5,8-dihydro-1,6-naphthyridin-7(6H)-one (4.25 g) as a solid.

Example 39

To a mixture of tert-butyl

2-chloro-8-ethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-8-carboxylate (27.7 g) and DCE (300 mL) was added TFA (30 mL). Then the mixture was stirred at 50°C for 4 hours. The mixture was concentrated. To the residue was added H₂O and 1 M aq. NaOH under ice bath cooling, and extracted with a mixture of EtOAc and THF. The organic layer was washed with brine, and dried over MgSO₄, filtered, and concentrated under reduced pressure. To the residue was added IPE, and sonicated. The precipitate was collected to give 2-chloro-8-ethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one (17.1 g) as a solid.

Example 40

A mixture of 6-chloro-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (4.0 g), pentamethylcyclopentadienyliridium(III) dichloride dimer (73 mg), KOH (123 mg), and MeOH (16 mL) was sonicated for degassing under Ar atmosphere. The mixture was heated in the microwave reactor at 130°C for 90 min. Then the mixture was stirred under ice bath cooling for 15 min. Additional nine batches (total ten batches) were performed with the same procedure as above. The precipitate in all vials were collected on the same funnel, rinsed with EtOH to give 6-chloro-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (34.31 g) as a solid.

Example 41

To a mixture of 4,4-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (700 mg) and THF (20 mL) were added KOH (1 M aq., 6.12 mL) and H₂O₂ (35% aq., 0.56 mL). The mixture was stirred at room temperature for 15 min. The mixture was neutralized to pH 7 using 1 M aq. HCl. EtOAc (100 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (75 mL). The combined organic extracts were combined, washed with brine, and dried over Na₂SO₄, filtered, and concentration under reduced pressure to give 6-hydroxy-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (475 mg) as a solid.

Example 42

To a mixture of 6-bromo-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (3.00 g) and DMF (75 mL, degassed with nitrogen) was added NaH (60% dispersion in mineral oil, 895 mg). The reaction flask was evacuated and back-filled with nitrogen three times, and the reaction was stirred at room temperature under nitrogen for 30 min. To the mixture was added a mixture of EtI (3.49 g) and DMF (2 mL) dropwise under ice bath cooling, and the mixture was stirred at the room temperature for 30 min. To the mixture was carefully added H₂O under ice bath cooling, and the mixture was diluted with EtOAc, and the phases were separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography

(EtOAc/hexanes) to give

6-bromo-4,4-diethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (2.59 g) as a solid.

Example 52

5 A 1000 mL 3-necked flask was charged with
6-chloro-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (30.00 g), NMP (75 mL) and DMI
(75 mL). The flask was evacuated and back-filled with Ar twice, and NaH (55%
dispersion in mineral oil, 13.48 g) was added portionwise over 10 min under ice bath
cooling, and then the mixture was stirred at the same temperature for 10 min. To the
10 mixture was added a mixture of MeI (17.5 mL) and NMP (30 mL) dropwise under ice bath
cooling over 100 min. The mixture was stirred at the same temperature for 20 min.
Additional MeI (0.25 mL) was added under ice bath cooling, and the mixture was stirred at
the same temperature for 1 hour. The mixture was diluted with H₂O under ice bath
cooling and then stirred at the same temperature for 30 min. The precipitate was
15 collected, and washed with H₂O and EtOAc/hexanes (1/3) to give a crude solid. To the
solid was added EtOAc, and the mixture was warmed to 90°C, and then stirred at room
temperature overnight. The precipitate was collected to give a crude solid. The solid
was purified by silica gel chromatography (EtOAc/hexanes) to give
6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (10.88 g) as a solid.

20

Example 55

 A 250 mL round bottom flask was charged with
6-bromo-4,4-diethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (2.70 g),
1,1'-bis(diphenylphosphino)ferrocene (462 mg), Pd₂(dba)₃ (381 mg), Zn(CN)₂ (1.27 g), Zn
25 (218 mg). To the solids was added DMAc (30 mL, degassed with nitrogen for 45 min
prior to use). The flask was evacuated and backfilled with nitrogen three times and then
stirred at 80°C for 18 hours. The mixture was cooled to room temperature and diluted
with H₂O and EtOAc. The biphasic mixture was filtered through a pad of Celite and the
layers were separated. The aqueous phase was extracted with additional EtOAc three
30 times, and the combined organic layers were washed with brine, dried over Na₂SO₄,
filtered and concentrated under reduced pressure. The residue was purified by silica gel
chromatography (MeOH/CH₂Cl₂) to give a solid. The solid was washed with EtOH to

give 4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile (1.55 g) as a solid.

Example 137

5 To a mixture of methyl
(6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetan]-4-yl)acetate (60 mg) and anhydrous THF (2 mL) was added methylmagnesium bromide (3 M in Et₂O, 0.323 mL). The mixture was stirred at room temperature for 15 min. The mixture was diluted with sat. aq. NH₄Cl (1 mL) and H₂O (5 mL). The mixture was extracted with
10 EtOAc (2 x 35 mL), and combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by reverse phase HPLC using a gradient from 10-100% MeCN/H₂O over 50 min with 0.1 % formic acid (Phenomenex Gemini, 5 micron C18). The residue was solidified with Et₂O to give
6-chloro-4-(2-hydroxy-2-methylpropyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)
15)-one (38 mg) as a solid.

Example 143

 To a mixture of
8,8-diethyl-2-(hydroxymethyl)-6-{[2-(trimethylsilyl)ethoxy]methyl}-6H-spiro[1,6-naphthy
20 ridine-5,3'-oxetan]-7(8H)-one (283 mg), CuI (47 mg), and MeCN (12 mL) was added difluoro(fluorosulfonyl)acetic acid (0.14 mL) at 80°C. After 1 hour, to the mixture was added difluoro(fluorosulfonyl)acetic acid (0.14 mL) at the same temperature. After 2 hour, to the mixture were added CuI (106 mg) and difluoro(fluorosulfonyl)acetic acid (0.14 mL) at the same temperature. Then the mixture was stirred at the same temperature for 1
25 hour. After cooling to room temperature, sat. aq. NaHCO₃ was added, and extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc/hexanes) twice to give
2-[(difluoromethoxy)methyl]-8,8-diethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-o
30 ne (14 mg) as a solid.

Example 148

To a mixture of

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile (59.22 g) and EtOH (1260 mL) was added H₂O (540 mL). The mixture was stirred at 75°C for 20 min and 78°C for 15 min. To the mixture was added H₂O (1.8 L), and stirred at 65°C for 80 min, and cooled to 20°C over 1 hour, and then, stirred at 20°C for 2 hours. The precipitate was collected, washed with 35% aq. EtOH to give 4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile (54.43 g) as crystal.

As a result obtained by subjecting the crystals to powder X-ray diffraction measurement using Cu as a tube, a chart including peaks at 2θ (°) = 8.3, 12.1, 15.6, 16.6, 17.3, 20.5, 21.4, 23.4, 24.0 and 25.7 was obtained.

Example 149

6-Chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (21.59 g) was resolved with chiral column chromatography (CHIRALFLASH(trademark) IC, eluent; 40-100% EtOH/hexanes then 100% MeOH) to give (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (longer retention time). Then, the compound was purified by silica gel column chromatography (CHCl₃/MeOH). The residue was co-evaporated with EtOAc, then, EtOAc (30 mL) was added, and sonicated. To the mixture were added EtOAc (10 mL) and hexane (80 mL), and then sonicated again. The mixture was stirred at room temperature for 15min. The precipitate was collected and dried at 50°C under reduced pressure to give (-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (8.99 g) as crystal.

As a result obtained by subjecting the crystals to powder X-ray diffraction measurement using Cu as a tube, a chart including peaks at 2θ (°) = 6.7, 11.1, 12.2, 13.7, 15.5, 16.2, 17.0, 18.3, 21.7 and 22.7 was obtained.

Example 154

To a liquid of polyphosphoric acid (20 g) was added tert-butyl

4-(3-chlorophenyl)-4-cyanopiperidine-1-carboxylate (4.5 g) at 140°C, and stirred for 5 min. To the mixture was added acetone (2.3 g) dropwise over 2 hour. The mixture was then stirred at 100°C for 1 hour. The mixture was cooled to room temperature and poured slowly into a mixture of ice (ca 100 g) and EtOAc (300 mL). The organic layer was separated. The aqueous layer was treated with K₂CO₃ until the pH of the mixture was 10, followed by extraction twice with EtOAc (400 mL). The combined organic layers were washed with sat. aq. NaHCO₃, dried over MgSO₄, filtered, and concentrated to give 6-chloro-1,1-dimethyl-1,2-dihydro-3H-spiro[isoquinoline-4,4'-piperidin]-3-one (1.5 g) as a solid.

10

Example 155

A mixture of

6-chloro-1,1-dimethyl-1,2-dihydro-3H-spiro[isoquinoline-4,4'-piperidin]-3-one (56 mg), CH₂Cl₂ (2 mL), DIPEA (0.070 mL), and methanesulfonyl chloride (0.017 mL) was stirred at room temperature for 30 min and then purified directly using reverse phase HPLC (20-100% MeCN/H₂O, 0.1% formic acid buffer) over 40 min to give 6-chloro-1,1-dimethyl-1'-(methanesulfonyl)-1,2-dihydro-3H-spiro[isoquinoline-4,4'-piperidin]-3-one (34 mg) as a solid.

20 Reference Example 166

To a mixture of

6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one (259 mg) and CH₂Cl₂ (7 mL) was added 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess-Martin periodinane) (585 mg), and the mixture was stirred at room temperature for 30 min. To the mixture was added CH₂Cl₂, and washed twice with sat. aq. NaHCO₃. The organic layer was then dried over Na₂SO₄, filtered, and concentrated to give (6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetan]-4-yl)acetaldehyde (514 mg) as a solid.

30 Example 167 (167a and 167b)

To a mixture of

(6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetan]-4-yl)acetaldehyde (514 mg, crude from previous reaction) and THF (8 mL) was added methylmagnesium

bromide (3 M in Et₂O, 0.9 mL) under ice bath cooling, and the resulting mixture was stirred under ice bath cooling for 30 min. The mixture was diluted with sat. aq. NH₄Cl (5 mL) and H₂O (30 mL), followed by extraction twice with EtOAc (75 mL). Combined organic layers were washed with brine, and concentrated to a crude solid. The crude solid
5 was purified by reverse phase HPLC (Phenomenex Gemini, 5 micron C18, 10-100% MeCN/H₂O with 0.1 % formic acid over 50 minutes) to give both diastereomers as solids. As a result of a measurement of single-crystal x-ray structure analysis, the first diastereomer to elute from the column was
rac-(4R)-6-chloro-4-[(2R)-2-hydroxypropyl]-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-
10 3(4H)-one (65 mg) and the second diastereomer to elute from the column was
rac-(4R)-6-chloro-4-[(2S)-2-hydroxypropyl]-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-
3(4H)-one (69 mg).

The compounds of Preparation Examples, Reference Examples and Examples
15 shown in Tables below were produced in the same or a similar manner as the methods in Preparation Examples, Reference Examples or Examples as described above. In Table 4, "Ex. Cmpd." denotes Example Compound. In Table 4, "Reference Ex. Cmpd. 166" denotes Reference Example Compound 166. In Table 5, "Ex. Cmpd." denotes the Example Compound with reference to the structures provided in Table 4. In Table 5,
20 "Reference Ex. Cmpd. 166" denotes the Reference Example Compound 166 with reference to the structure of Reference Example Compound 166 provided in Table 4. Furthermore, each Example Compound and Reference Example Compound listed in Table 5 were prepared by a procedure described in or analogous to the procedure described in the corresponding indicated Example or Reference Example, denoted by "Syn". For
25 instance, the first entry of Table 5 pertains to Example Compound 1, having the structure shown in the first entry of Table 4. This Example Compound was prepared in accordance with the procedure described in Example 1 herein, and the data for this Example Compound is as provided in the first entry of Table 5. In Table 6, "Prep. Ex. Cmpd." denotes Preparation Example Compound. In Table 7, "Prep. Ex. Cmpd." denotes the
30 Preparation Example Compound with reference to the structures provided in Table 6. Furthermore, each Preparation Example Compound listed in Table 7 was prepared by a procedure described in or analogous to the procedure described in the corresponding indicated Preparation Example, denoted by "PSyn". For instance, the first entry of Table

7 pertains to Preparation Example Compound 1a, having the structure shown in the first entry of Table 6. This Preparation Example Compound was prepared in accordance with the procedure described in Preparation Example 1 herein, and the data for this Preparation Example Compound is as provided in the first entry of Table 7.













5

Table 4















Ex. Cmpd.	Str	Ex. Cmpd.	Str
1		2	
3		4	
5		6	
7		8	
9a		9b	











Ex. Cmpd.	Str	Ex. Cmpd.	Str
10		11	
12		13	
14		15	
16		17	
18		19	
20		21	
22a		22b	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
23		24	
25		26	
27		28	
29		30	
31a		31b	
32		33	













Ex. Cmpd.	Str	Ex. Cmpd.	Str
34		35	
36		37	
38		39	
40		41	
42		43	
44		45	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
46		47	
48		49	
50		51	
52		53	
54		55	
56		57	
58		59	













Ex. Cmpd.	Str	Ex. Cmpd.	Str
60		61	
62		63	
64		65	
66		67	
68		69	
70		71	
72		73	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
74		75	
76		77	
78		79	
80		81	
82		83	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
84		85	
86		87	
88		89	
90		91	
92a		92b	
93		94	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
95		96	
97		98	
99		100	
101		102	
103		104	
105		106	









Ex. Cmpd.	Str	Ex. Cmpd.	Str
107		108	
109		110	
111		112	
113		114	
115		116	
117		118	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
119		120	
121		122	
123		124	
125		126	
127		128	
129		130	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
131	#	132	#
133	#	134a	*
134b	*	135	#
136	#	137	#
138	#	139	#

Ex. Cmpd.	Str	Ex. Cmpd.	Str
140		141	
142		143	
144		145	
146		147	
148		149	
150		151	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
152		153	
154		155	
156		157	
158		159	
160		161	
162		163	

Ex. Cmpd.	Str	Ex. Cmpd.	Str
164		165	
Refere nce Ex. Cmpd. 166		167a	Mixture of  and 
167b	Mixture of  and 	168	



Ex. Cmpd.	Str	Ex. Cmpd.	Str
169		170	

Table 5

Ex. Cmpd.	Syn	DAT
1	1	ESI+ ; 298;
2	2	ESI+ ; 218
3	3	ESI+ ; 276
4	4	ESI+ ; 257 ¹ H-NMR(DMSO-d ₆)δ: 8.29 (s, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.71 (dd, J = 8.3, 1.6 Hz, 1H), 7.66 (d, 8.3 Hz, 1H), 2.09-1.98 (m, 2H), 1.81-1.71 (m, 2H), 1.50 (s, 6H), 0.45 (t, J = 7.4 Hz, 6H)
5	5	ESI+ ; 365, 367
6	6	ESI+ ; 281
7	7	ESI+ ; 416, 418
8	8	ESI+ ; 367, 369
9a	9	ESI+ ; 326, 328 ¹ H-NMR(DMSO-d ₆)δ: 8.15(s, 1H), 7.54(d, J = 2.0 Hz, 1H), 7.43 (dd, J = 8.5, 2.1 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 4.30 (t, J = 5.1 Hz, 1H), 3.13-3.04 (m, 1H), 2.88-2.79 (m, 1H), 2.27-2.19 (m, 1H), 2.08-1.98 (m, 1H), 1.93-1.85 (m, 1H), 1.77-1.67 (m, 1H), 1.46 (s, 3H), 1.45 (s, 3H), 0.45 (t, J = 7.3 Hz, 3H) optical rotation (EtOH): (+)
9b	9	ESI+ ; 326, 328 ¹ H-NMR(DMSO-d ₆)δ: 8.15(s, 1H), 7.54(d, J = 2.0 Hz, 1H), 7.43 (dd, J = 8.5, 2.1 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 4.30 (t, J = 5.1 Hz, 1H), 3.13-3.04 (m, 1H), 2.88-2.79 (m, 1H), 2.27-2.19 (m, 1H), 2.08-1.98 (m, 1H), 1.93-1.85 (m, 1H), 1.87-1.67 (m, 1H), 1.46 (s, 3H), 1.45 (s, 3H), 0.45 (t, J = 7.3 Hz, 3H) optical rotation (EtOH): (-)
10	10	ESI+ ; 261
11	11	ESI+ ; 345
12	12	ESI+ ; 247
13	13	ESI+ ; 297 ¹ H-NMR(DMSO-d ₆) δ: 9.26 (s, 1H), 8.53 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 6.98 (t, J = 54.9 Hz, 1H), 4.96 (d, J = 6.7 Hz, 2H), 4.65 (d, J = 6.7 Hz, 2H), 1.98-1.87 (m, 4H), 0.38 (t, J = 7.4 Hz, 6H)
14	14	ESI+ ; 291
15	15	ESI+ ; 329

Ex. Cmpd.	Syn	DAT
		¹ H-NMR(DMSO-d ₆)δ: 9.07 (s, 1H), 8.37 (d, J = 8.6 Hz, 1H), 7.76 (t, J = 72.7 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 4.92 (d, J = 6.4 Hz, 1H), 4.89 (d, J = 6.4 Hz, 1H), 4.63 (d, J = 6.3 Hz, 1H), 4.55 (d, J = 6.4 Hz, 1H), 4.15 (t, J = 5.1 Hz, 1H), 2.98-2.87 (m, 2H), 2.12-2.01 (m, 2H), 1.98-1.82 (m, 2H), 0.37 (t, J = 7.3 Hz, 3H), optical rotation (EtOH): (-)
16	16	ESI+ ; 272 ¹ H-NMR(DMSO-d ₆)δ: 9.32 (s, 1H), 8.56 (d, J = 8.2 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 4.96 (d, J = 6.8 Hz, 2H), 4.66 (d, J = 6.8 Hz, 2H), 1.99-1.83 (m, 4H), 0.39 (t, J = 7.3 Hz, 6H)
17	17	ESI+ ; 293
18	18	ESI+ ; 285 ¹ H-NMR(DMSO-d ₆)δ: 8.97 (s, 1H), 8.38 (d, J = 8.6 Hz, 1H), 7.79 (t, J = 72.7 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 4.95 (d, J = 6.8 Hz, 2H), 4.64 (d, J = 6.8 Hz, 2H), 1.36 (s, 6H)
19	19	ESI+ ; 315
20	20	ESI+ ; 243 ¹ H-NMR(DMSO-d ₆)δ: 8.99 (s, 1H), 8.10 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 1.6 Hz, 1H), 7.90 (dd, J = 8.2, 1.7 Hz, 1H), 4.97 (d, J = 6.9 Hz, 2H), 4.69 (d, J = 6.8 Hz, 2H), 1.37 (s, 6H)
21	21	ESI+ ; 287
22a	22	ESI+ ; 282, 284 ¹ H-NMR(DMSO-d ₆)δ: 8.91 (s, 1H), 7.95-7.90 (m, 1H), 7.52-7.47 (m, 2H), 4.94 (d, J = 6.4 Hz, 1H), 4.89 (d, J = 6.2 Hz, 1H), 4.68 (d, J = 6.4 Hz, 1H), 4.53 (d, J = 6.2 Hz, 1H), 4.27 (t, J = 5.0 Hz, 1H), 2.97-2.88 (m, 2H), 2.19-2.09 (m, 1H), 1.87-1.78 (m, 1H), 1.39 (s, 3H) optical rotation (EtOH): (+)
22b	22	ESI+ ; 282, 284 ¹ H-NMR(DMSO-d ₆)δ: 8.91 (s, 1H), 7.95-7.90 (m, 1H), 7.52-7.47 (m, 2H), 4.94 (d, J = 6.4 Hz, 1H), 4.89 (d, J = 6.2 Hz, 1H), 4.68 (d, J = 6.4 Hz, 1H), 4.53 (d, J = 6.2 Hz, 1H), 4.27 (t, J = 5.0 Hz, 1H), 2.97-2.88 (m, 2H), 2.19-2.09 (m, 1H), 1.87-1.78 (m, 1H), 1.39 (s, 3H) optical rotation (EtOH): (-)
23	23	APCI ; 268 ¹ H NMR (DMSO-d ₆)δ: 8.96 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.68-7.62 (m, 2H), 7.07 (t, J = 56 Hz, 1H), 4.97 (d, J = 6.7 Hz, 2H), 4.70 (d, J = 6.7 Hz, 2H), 1.37 (s, 6H)
24	24	APCI ; 284 ¹ H NMR (DMSO-d ₆)δ: 8.92 (s, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.32 (t, J = 74 Hz, 1H), 7.28-7.22 (m, 2H), 4.95 (d, J = 6.7 Hz, 2H), 4.67 (d, J = 6.6 Hz, 2H), 1.35 (s, 6H)
25	25	APCI ; 346 ¹ H NMR (CDCl ₃)δ: 8.45 (s, 1H), 6.99 (s, 1H), 5.19 (d, J = 6.6 Hz, 2H), 4.88-4.79 (m, 4H), 2.14 (dq, J = 13.3, 7.4 Hz, 2H), 1.99 (dq, J = 13.3, 7.4 Hz, 2H), 0.55 (t, J = 7.4 Hz, 6H)

Ex. Cmpd.	Syn	DAT
26	26	APCI; 248 ¹ H NMR (CDCl ₃)δ: 8.72 (d, J = 2.3 Hz, 1H), 8.69 (d, J = 2.3 Hz, 1H), 7.09 (s, 1H), 5.21 (d, J = 6.5 Hz, 2H), 4.85 (d, J = 6.5 Hz, 2H), 2.23-2.01 (m, 4H), 0.54 (t, J = 7.4 Hz, 6H)
27	27	APCI ; 278 ¹ H NMR (DMSO-d ₆) δ : 8.38 (s, 1H), 8.19 (s, 1H), 4.36 (q, J = 7.0 Hz, 2H), 1.91 (qd, J = 7.4, 4.7 Hz, 4H), 1.48 (s, 6H), 1.34 (t, J = 7.0 Hz, 3H), 0.49 (t, J = 7.4 Hz, 6H)
28	28	APCI ; 276 ¹ H NMR (CDCl ₃)δ: 8.44 (s, 1H), 6.97 (s, 1H), 5.11 (d, J = 6.5 Hz, 2H), 4.73 (d, J = 6.5 Hz, 2H), 2.84 (q, J = 7.6 Hz, 2H), 2.02 (q, J = 7.4 Hz, 4H), 1.28 (t, J = 7.6 Hz, 3H), 0.43 (t, J = 7.4 Hz, 6H)
29	29	APCI ; 284 ¹ H NMR (DMSO-d ₆)δ: 8.73 (s, 1H), 8.15 (s, 1H), 4.87 (t, J = 6.0 Hz, 1H), 3.78-3.68 (m, 1H), 3.53-3.46 (m, 1H), 2.03-1.87 (m, 3H), 1.79-1.71 (m, 1H), 1.39 (s, 3H), 0.58 (t, J = 7.4 Hz, 3H), 0.49 (t, J = 7.4 Hz, 3H)
30	30	APCI ; 291 ¹ H NMR (CDCl ₃)δ: 8.09 (s, 1H), 7.31 (s, 1H), 5.15 (d, J = 6.3 Hz, 2H), 4.78 (d, J = 6.4 Hz, 2H), 3.18 (s, 6H), 2.04 (q, J = 7.4 Hz, 4H), 0.54 (t, J = 7.4 Hz, 6H).
31a	31	APCI ; 373 shorter retention time in a reverse phase HPLC (20-100% MeCN/H ₂ O, 0.1% formic acid buffer)
31b	31	APCI ; 373 longer retention time in a reverse phase HPLC (20-100% MeCN/H ₂ O, 0.1% formic acid buffer)
32	32	APCI ; 296 ¹ H NMR (DMSO-d ₆)δ: 9.02 (s, 1H), 7.94 (d, J = 8.6 Hz, 1H), 7.53-7.42 (m, 2H), 4.90 (t, J = 6.6 Hz, 2H), 4.61 (d, J = 6.2 Hz, 1H), 4.55 (d, J = 6.2 Hz, 1H), 4.25 (t, J = 5.1 Hz, 1H), 2.95-2.82 (m, 2H), 2.24-2.15 (m, 1H), 2.04-1.93 (m, 1H), 1.93-1.83 (m, 1H), 1.78-1.68 (m, 1H), 0.38 (t, J = 7.3 Hz, 3H)
33	33	APCI ; 311 ¹ H NMR (CD ₃ OD)δ: 7.94 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.38 (s, 1H), 3.94 (s, 3H), 3.56 (d, J = 13.9 Hz, 1H), 3.46 (d, J = 13.9 Hz, 1H), 1.70 (s, 3H), 1.55 (s, 3H), 1.13 (s, 3H)
34	34	ESI+ ; 291
35	35	ESI+ ; 282
36	36	ESI+ ; 253, 255 [M+H-Boc] ⁺ ¹ H-NMR(DMSO-d ₆)δ: 9.49 (s, 1H), 8.42 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 4.99 (d, J = 6.4 Hz, 1H), 4.95 (d, J = 6.5 Hz, 1H), 4.69 (d, J = 6.4 Hz, 1H), 4.65 (d, J = 6.4 Hz, 1H), 2.28-2.07 (m, 2H), 1.20 (s, 9H), 0.41 (t, J = 7.5 Hz, 3H)
37	37	ESI+ ; 311, 313
38	38	ESI+ ; 239, 241
39	39	ESI+ ; 253

Ex. Cmpd.	Syn	DAT
40	40	ESI+ ; 238
41	41	APCI ; 234
42	1 or 42	APCI ; 324
43	1	APCI ; 280 ¹ H NMR (DMSO-d ₆)δ: 9.15 (s, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 1H), 7.53 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.44 (d, <i>J</i> = 2.2 Hz, 1H), 4.93 (d, <i>J</i> = 6.4 Hz, 2H), 4.66-4.57 (m, 2H), 1.98 (dq, <i>J</i> = 13.4, 7.3 Hz, 2H), 1.71 (dq, <i>J</i> = 14.5, 7.4 Hz, 2H), 0.40 (t, <i>J</i> = 7.4 Hz, 6H)
44	1	APCI ; 324
45	1	APCI ; 302
46	1	ESI+ ; 246
47	1	ESI+ ; 310, 312
48	1	ESI+ ; 288, 290 [M+Na] ⁺
49	1	ESI+ ; 310, 312
50	1	ESI+ ; 292
51	1	ESI+ ; 282
52	1 or 52	ESI+ ; 252, 254 ¹ H-NMR(DMSO-d ₆)δ: 8.92 (s, 1H), 7.93-7.90 (m, 1H), 7.51-7.48 (m, 2H), 4.94 (d, <i>J</i> = 6.7 Hz, 2H), 4.66 (d, <i>J</i> = 6.7 Hz, 2H), 1.35 (s, 6H)
53	2	ESI+ ; 282, 284
54	3	ESI+ ; 340, 342
55	20 or 55	APCI ; 271 ¹ H NMR (400 MHz, DMSO-d ₆)δ: 8.28 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 7.85 (dt, <i>J</i> = 8.3, 1.5 Hz, 1H), 7.81 (d, <i>J</i> = 1.6 Hz, 1H), 5.10-5.02 (m, 2H), 4.83-4.77 (m, 2H), 2.16 (dt, <i>J</i> = 13.7, 7.4 Hz, 2H), 1.90-1.76 (m, 2H), 0.52 (td, <i>J</i> = 7.4, 1.2 Hz, 6H)
56	20	APCI ; 273 ¹ H NMR (DMSO-d ₆)δ: 8.97 (s, 1H), 8.10 (d, <i>J</i> = 8.2 Hz, 1H), 8.00 (d, <i>J</i> = 1.6 Hz, 1H), 7.89 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 4.97 (d, <i>J</i> = 6.5 Hz, 1H), 4.90 (d, <i>J</i> = 6.3 Hz, 1H), 4.72 (d, <i>J</i> = 6.4 Hz, 1H), 4.55 (d, <i>J</i> = 6.3 Hz, 1H), 4.25 (t, <i>J</i> = 5.0 Hz, 1H), 2.97-2.86 (m, 2H), 2.22-2.11 (m, 1H), 1.94-1.81 (m, 1H), 1.42 (s, 3H)
57	16	ESI+ ; 258 ¹ H NMR (CDCl ₃)δ: 8.71 (d, <i>J</i> = 2.0 Hz, 1H), 7.76 (d, <i>J</i> = 2.0 Hz, 1H), 6.32 (s, 1H), 2.26 (dq, <i>J</i> = 13.7, 7.4 Hz, 2H), 1.60 (dq, <i>J</i> = 13.7, 7.4 Hz, 2H), 1.58 (s, 6H), 0.56 (t, <i>J</i> = 7.4 Hz, 6H)
58	16	APCI ; 230 ¹ H NMR (CD ₃ OD)δ: 8.83 (d, <i>J</i> = 1.9 Hz, 1H), 8.34 (d, <i>J</i> = 1.9 Hz, 1H), 1.64 (s, 6H), 1.57 (s, 6H)
59	16	APCI ; 293
60	16	APCI ; 256
61	16	APCI ; 229
62	16	APCI ; 271
63	4	ESI+ ; 257

Ex. Cmpd.	Syn	DAT
64	4	ESI+ ; 258 ¹ H-NMR(DMSO-d ₆)δ: 8.42 (s, 1H), 8.21 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 2.01-1.86 (m, 4H), 1.52 (s, 6H), 0.45 (t, J = 7.4 Hz, 6H)
65	5	ESI+ ; 325, 327
66	5	ESI+ ; 359, 361
67	6	APCI ; 324
68	6	APCI ; 282
69	6	APCI ; 268
70	6	APCI ; 305
71	6	APCI ; 253 ¹ H NMR (CD ₃ OD)δ: 7.83 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 2.20-1.98 (m, 2H), 1.59 (s, H), 1.56 (s, 3H), 1.49 (s, 3H), 0.56 (t, J = 7.4 Hz, 3H)
72	6	APCI ; 267 ¹ H NMR (CDCl ₃)δ: 8.49 (d, J = 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 6.32 (s, 1H), 2.31 (dq, J = 13.7, 7.4 Hz, 2H), 1.60 (dq, J = 13.7, 7.4 Hz, 2H), 1.58 (s, 6H), 0.66 (t, J = 7.4 Hz, 6H)
73	6	APCI ; 239
74	6	ESI+; 281 ¹ H NMR (CDCl ₃)δ: 8.69 (d, J = 2.2 Hz, 1H), 7.92 (s, 1H), 7.56 (d, J = 2.2 Hz, 1H), 5.20 (d, J = 6.5 Hz, 2H), 4.85 (d, J = 6.5 Hz, 2H), 2.27 (dt, J = 14.8, 7.4 Hz, 2H), 1.67 (dq, J = 14.6, 7.4 Hz, 2H), 0.58 (t, J = 7.4 Hz, 6H)
75	6	APCI ; 318
76	6	APCI ; 265
77	6	APCI ; 293
78	6	APCI ; 354
79	6	ESI+ ; 406, 408
80	6	ESI+ ; 406, 408
81	6	ESI+ ; 350, 352 [M+Na] ⁺
82	6	ESI+ ; 428, 430 [M+Na] ⁺
83	6	ESI+ ; 368, 370 [M+Na] ⁺
84	6	ESI+ ; 267, 269
85	6	ESI+ ; 430, 432
86	6	ESI+ ; 368, 370
87	6	ESI+ ; 333, 335 [M+Na] ⁺
88	6	ESI+ ; 333
89	6	ESI+ ; 325, 327 [M+Na] ⁺
90	6	ESI+ ; 253
91	7	ESI+ ; 340, 342
92a	9	ESI+ ; 283 shorter retention time in a chiral supercritical fluid chromatography (SFC) using CHIRALCEL® OZ-H (elute CO ₂ :MeOH = 80:20) optical rotation (EtOH): (-)

Ex. Cmpd.	Syn	DAT
92b	9	ESI+ ; 283 longer retention time in a chiral supercritical fluid chromatography (SFC) using CHIRALCEL® OZ-H (elute CO ₂ :MeOH = 80:20) optical rotation (EtOH): (+)
93	10	APCI ; 244
94	10	APCI ; 274
95	10	ESI+ ; 283
96	10	ESI+ ; 291
97	10	ESI+ ; 271
98	10	ESI+ ; 297
99	12	ESI+ ; 219
100	13	ESI+ ; 269
101	15	ESI+ ; 288
102	15	ESI+ ; 277
103	15	ESI+ ; 313 ¹ H-NMR(DMSO-d ₆)δ: 9.12 (s, 1H), 8.49 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 6.97(t, J = 54.9 Hz, 1H), 4.96 (d, J = 6.4 Hz, 1H), 4.92 (d, J = 6.4 Hz, 1H), 4.68 (d, J = 6.4 Hz, 1H), 4.57 (d, J = 6.4 Hz, 1H), 4.19 (t, J = 4.8 Hz, 1H), 2.93-2.87 (m, 2H), 2.18-2.03 (m, 2H), 2.01-1.90 (m, 2H), 0.36 (t, J = 7.4 Hz, 3H) optical rotation (EtOH): (-)
104	15	ESI+ ; 313 optical rotation (EtOH): (+)
105	15	ESI+ ; 329 optical rotation (EtOH): (+)
106	16	APCI ; 273 ¹ H NMR (CDCl ₃)δ: 9.00 (s, 1H), 7.08 (s, 1H), 5.19 (d, J = 6.7 Hz, 2H), 4.87 (d, J = 6.7 Hz, 2H), 2.27-2.13 (m, 2H), 2.08 (dq, J = 14.6, 7.4 Hz, 2H), 0.55 (t, J = 7.4 Hz, 6H)
107	16	APCI ; 296 ¹ H NMR (DMSO-d ₆)δ: 8.34 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.29 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 1.8 Hz, 1H), 6.08 (t, J = 2.1 Hz, 1H), 4.77 (d, J = 13.2 Hz, 1H), 4.68 (d, J = 13.1 Hz, 1H), 1.59 (s, 3H), 1.50 (s, 3H), 1.09 (s, 3H)
108	16	APCI ; 244 ¹ H NMR (CD ₃ OD)δ: 8.06 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 2.28-2.03 (m, 2H), 1.64 (s, 3H), 1.60 (s, 3H), , 0.56 (t, J = 7.4 Hz, 3H)
109	16	APCI ; 296
110	16	APCI ; 296 ¹ H NMR (CD ₃ OD)δ: 7.91 (dd, J = 8.2, 0.5 Hz, 1H), 7.76 (dd, J = 8.1, 0.5 Hz, 1H), 6.86 (s, 2H), 3.27 (s, 2H), 1.66 (s, 3H), 1.49 (s, 3H), 0.97 (s, 3H)
111	16	APCI ; 254
112	16	ESI+ ; 302
113	19	ESI+ ; 335
114	32	APCI ; 326













Ex. Cmpd.	Syn	DAT
115	32	ESI+ ; 326, 328
116	34	ESI+ ; 335
117	36	ESI+ ; 377 [M+Na] ⁺
118	36	APCI ; 240 [M+H-Boc] ⁺
119	36	APCI ; 239 [M+H-Boc] ⁺
120	36	APCI ; 253 [M+H-Boc] ⁺
121	36	APCI ; 265 [M+H-Boc] ⁺
122	36	APCI ; 269 [M+H-C ₄ H ₉] ⁺
123	36	ESI+ ; 361, 363 [M+Na] ⁺
124	37	APCI ; 297
125	38	APCI ; 225
126	39	APCI ; 254
127	39	APCI ; 240
128	39	ESI+ ; 239
129	39	ESI+ ; 253
130	39	APCI ; 265
131	39	APCI ; 225
132	39	ESI+ ; 239
133	40	APCI ; 252
134a	9	APCI ; 296 longer retention time in a chiral supercritical fluid chromatography (SFC) using ChromegaChiral CC4 (elute CO ₂ :EtOH with 0.5% isopropylamine = 85:15), optical rotation (CHCl ₃): (+)
134b	9	APCI ; 296 shorter retention time in a chiral supercritical fluid chromatography (SFC) using ChromegaChiral CC4 (elute CO ₂ :EtOH with 0.5% isopropylamine = 85:15), optical rotation (CHCl ₃): (-)
135	40	APCI ; 282
136	6	APCI ; 310
137	137	APCI; 310 ¹ H NMR (DMSO-d ₆)δ: 8.69 (s, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.54-7.35 (m, 2H), 4.96 (d, J = 6.4 Hz, 1H), 4.85 (d, J = 6.4 Hz, 1H), 4.72 (d, J = 6.4 Hz, 1H), 4.47 (d, J = 6.4 Hz, 1H), 3.89 (s, 1H), 2.33 (d, J = 14.1 Hz, 1H), 1.92 (d, J = 14.1 Hz, 1H), 1.36 (s, 3H), 0.83 (s, 3H), 0.51 (s, 3H).
138	2	ESI+ ; 252
139	8	ESI+ ; 451, 453 [M+Na] ⁺
140	1	ESI+ ; 368, 370 [M+Na] ⁺
141	1	ESI+ ; 306, 308 [M+Na] ⁺
142	16	ESI+ ; 244
143	143	ESI+ ; 327
144	6	ESI+ ; 339, 341 [M+Na] ⁺
145	11	ESI+ ; 313
146	18	ESI+ ; 299















Ex. Cmpd.	Syn	DAT
147	11	ESI+ ; 249
148	148	ESI+ ; 243
149	149	ESI+ ; 282
150	37	APCI ; 298
151	38	APCI ; 226
152	6	APCI ; 240
153	16	APCI ; 231
154	154	APCI ; 279
155	155	APCI ; 357 ¹ H-NMR (CD ₃ OD)δ: 7.52 (s, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 3.73-3.60 (m, 4H), 2.90 (s, 3H), 2.24-2.12 (m, 2H), 2.09-1.93 (m, 2H), 1.58 (s, 6H)
156	155	APCI ; 337
157	1	APCI ; 236
158	6	APCI ; 297
159	32	ESI+ ; 269
160	1	APCI ; 281
161	16	ESI+ ; 272
162	40	APCI ; 296
163	6	APCI ; 368
164	32	APCI ; 340
165	20	APCI ; 287
Reference Ex. Cmpd. 166	Reference Example 166	APCI ; 280
167a	167	APCI ; 296 ¹ H-NMR (DMSO-d ₆) δ: 8.99 (s, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.50-7.39 (m, 2H), 4.95 (d, J = 6.4 Hz, 1H), 4.89 (d, J = 6.4 Hz, 1H), 4.71 (d, J = 6.4 Hz, 1H), 4.52 (d, J = 6.4 Hz, 1H), 4.05 (d, J = 4.9 Hz, 1H), 3.29-3.19 (m, 1H), 1.94 (dd, J = 13.8, 5.5 Hz, 1H), 1.86 (dd, J = 13.8, 7.0 Hz, 1H), 1.38 (s, 3H), 0.83 (d, J = 6.1 Hz, 3H)
167b	167	APCI ; 296 ¹ H-NMR (DMSO-d ₆) δ: 8.59 (s, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.53-7.35 (m, 2H), 4.95 (d, J = 6.4 Hz, 1H), 4.81 (d, J = 6.4 Hz, 1H), 4.72 (d, J = 6.4 Hz, 1H), 4.43 (d, J = 6.4 Hz, 1H), 3.95 (d, J = 4.9 Hz, 1H), 2.93-2.83 (m, 1H), 2.13 (dd, J = 13.8, 10.3 Hz, 1H), 1.71 (dd, J = 13.8, 3.2 Hz, 1H), 1.38 (s, 3H), 0.84 (d, J = 6.1 Hz, 3H)
168	12	ESI+ ; 219
169	13	ESI+ ; 269
170	6	ESI+ ; 289, 291 [M+Na] ⁺















Table 6













Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
1a		1b	Mixture of
2		3	
4		5	
6		7	
8		9	

Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
10		11	
12		13	
14		15	
16		17	
18		19	
20		21	
22		23	















Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
24		25	
26		27	
28		29	
30		31	
32		33	
34		35	

Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
36		37	
38		39	
40		41	
42a		42b	
43		44	
45		46	
47		48	

Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
49		50	
51		52	
53		54	
55		56	
57		58	
59		60	
61		62	

Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
63		64	
65		66	
67		68	
69		70	
71		72	
73		74	

Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
75		76	
77		78	
79		80	
81		82	
83		84	
85		86	

Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
87a		87b	
88		89	
90		91	
92		93	
94		95	
96		97	
98		99	







Prep. Ex. Cmpd.	Str	Prep. Ex. Cmpd.	Str
100		101	
102		103	
104		105	

Table 7

Prep. Ex. Cmpd.	PSyn	DAT
1a	1	ESI+ ; 254, 256
1b	1	6-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one: ¹ H-NMR (DMSO-d ₆)δ: 8.03(s, 1H), 7.45-7.39 (m, 2H), 7.34 (d, J = 8.3 Hz, 1H), 3.54 (s, 2H), 1.46 (s, 6H) 8-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one: ¹ H-NMR (DMSO-d ₆)δ: 8.03(s, 1H), 7.55 (dd, J = 7.8, 1.6 Hz, 1H), 7.21-7.12 (m, 2H), 3.58 (s, 2H), 1.73 (s, 6H)
2	2	¹ H-NMR (CDCl ₃)δ: 7.55 (d, J = 2.0 Hz, 1H), 7.50 (dd, J = 8.5, 2.0 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H), 6.34 (s, 1H), 5.40 (s, 1H), 1.70 (s, 3H), 1.66 (s, 3H)
3	3	ESI+ ; 242, 244
4	4	APCI ; 293
5	5	APCI ; 336
6	6	APCI ; 199
7	7	ESI+ ; 233, 235, 237
8	8	ESI+ ; 205, 207
9	9	ESI+ ; 355, 357
10	10	ESI+ ; 497, 499, 501
11	11	APCI ; 370 [M+H-C ₄ H ₉] ⁺
12	12	APCI ; 383
13	13	¹ H NMR (DMSO-d ₆) δ : 3.12 (t, J = 7.5 Hz, 1H), 1.75-1.67(m, 2H), 1.40 (s, 9H), 0.88 (t, J = 7.4 Hz, 3H).
14	14	APCI ; 217

Prep. Ex. Cmpd.	PSyn	DAT
15	15	ESI+ ; 323, 325
16	16	ESI+ ; 219, 221
17	17	APCI ; 390
18	18	ESI+ ; 411
19	19	ESI+ ; 403
20	20	ESI+ ; 405
21	21	ESI+ ; 407
22	22	ESI+ ; 421
23	23	ESI+ ; 402
24	24	ESI+ ; 418, 420 [M+Na] ⁺
25	25	APCI ; 370
26	26	APCI ; 344
27	27	ESI+ ; 389
28	28	ESI+ ; 463
29	29	ESI+ ; 483
30	30	ESI+ ; 393
31	31	ESI+ ; 437 [M+Na] ⁺
32	32	APCI ; 215
33	33	ESI+ ; 443
34	34	ESI+ ; 445
35	35	APCI ; 247
36	36	ESI+ ; 346
37	37	ESI+ ; 418
38	38	ESI+ ; 314
39	39	ESI+ ; 270
40	40	ESI+ ; 215, 217
41	41	APCI ; 189
42a	42	ESI+ ; 443 shorter retention time in a chiral column chromatography using CHIRALFLASH(trademark) IA (elute Hexane/EtOAc 80/20 – 0/100)
42b	42	ESI+ ; 443 longer retention time in a chiral column chromatography using CHIRALFLASH(trademark) IA (elute Hexane/EtOAc 80/20 – 0/100)
43	1	APCI ; 246
44	1	ESI+ ; 190
45	1	¹ H-NMR(CDCl ₃) δ : 7.25-7.22 (m, 2H), 7.16-7.14 (m, 1H), 6.08 (s, 1H), 3.62 (s, 2H), 1.57 (s, 6H)
46	1	ESI+ ; 236
47	10	APCI ; 320 [M+H-C ₄ H ₉] ⁺
48	10	APCI ; 483
49	10	APCI ; 259 [M+H-Boc] ⁺
50	10	APCI ; 289 [M+H-C ₄ H ₉] ⁺
51	11	APCI ; 447
52	11	ESI+ ; 461

Prep. Ex. Cmpd.	PSyn	DAT
53	15	APCI ; 324
54	15	APCI ; 310
55	15	APCI ; 440
56	16	APCI ; 206
57	16	APCI ; 231
58	17	APCI ; 506
59	17	APCI ; 373
60	18	ESI+ ; 455, 457 [M+Na] ⁺
61	18	ESI+ ; 405, 407 [M+Na] ⁺
62	18	ESI+ ; 549, 551 [M+Na] ⁺
63	19	ESI+ ; 391
64	20	APCI ; 276
65	24	APCI ; 398
66	24	APCI ; 405
67	24	APCI ; 305 [M+H-Boc] ⁺
68	24	APCI ; 335
69	24	ESI+ ; 419, 421 [M+Na] ⁺
70	24	ESI+ ; 427
71	24	ESI+ ; 433, 435 [M+Na] ⁺
72	27	APCI ; 399 [M-H] ⁻
73	27	ESI+ ; 397, 399 [M+Na] ⁺
74	29	ESI+ ; 505
75	29	ESI+ ; 455
76	29	ESI+ ; 599
77	30	APCI/ESI+ ; 415
78	30	ESI+ ; 365
79	30	ESI+ ; 509
80	31	ESI+ ; 487 [M+Na] ⁺
81	33	ESI+ ; 559
82	36	APCI ; 307
83	36 or 83	ESI+ ; 302
84	37 or 84	ESI+ ; 374
85	38 or 85	ESI+ ; 270, 272
86	39 or 86	ESI+ ; 224
87a	42	ESI+ ; 427 shorter retention time in a chiral chromatography using CHIRALFLASH(trademark) IA, (eluent; Hexane/EtOAc 100/0-40/60)
87b	42	ESI+ ; 427 longer retention time in a chiral chromatography using CHIRALFLASH(trademark) IA, (eluent; Hexane/EtOAc 100/0-40/60)

Prep. Ex. Cmpd.	PSyn	DAT
88	1	ESI+ ; 250, 252 [M+Na] ⁺
89	18	ESI+ ; 419, 421 [M+Na] ⁺
90	29	ESI+ ; 469
91	30	ESI+ ; 379
92	31	ESI+ ; 451 [M+Na] ⁺
93	40	APCI ; 216
94	7	APCI ; 234
95	95	APCI ; 235
96	96	APCI ; 206
97	9	APCI ; 351
98	10	APCI ; 484
99	11	APCI ; 448
100	100	APCI ; 350
101	101	APCI ; 330
102	102	APCI ; 208
103	101	APCI ; 347
104	104	APCI ; 225
105	36	APCI ; 367

While the methods and compositions have been described in detail with reference to certain exemplary aspects thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

5

INDUSTRIAL APPLICABILITY

The compounds of the formula (I) or the formula (I'), or a salt thereof modulate the contractility of the skeletal sarcomere, and thus are expected to be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.

15

As used herein the words “a” and “an” and the like carry the meaning of “one or more.”


Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the

scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.

CLAIMS

1. A compound of the formula (I) or a salt thereof:



wherein,

X^1 : C- R^{11} or N;

X^2 : C- R^{12} or N;

R^{11} : i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl;

R^{12} : H or halogen;

R^1 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s), and pyrazolyl(s), iii) C_{2-6} alkenyl, or iv) $-OR^0$;

R^2 : i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $-OR^0$ (s), halogen(s), $-COOR^0$ (s), $-CONR^{21}R^{22}$ (s), phenyl(s) which may be substituted with one or more substituent(s) selected from the G^1 group, and heteroaryl(s) which is selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, oxazolyl, isoxazolyl, and triazolyl, wherein, the heteroaryl may be substituted with one or more substituent(s) selected from the G^2 group, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $-OR^0$, v) $-NR^{23}R^{24}$, vi) $-COOR^0$, or vii) phenyl;

R^{21} : H or C_{1-6} alkyl;

R^{22} : i) C_{1-6} alkyl which may be substituted with one or more phenyl(s), or ii) phenyl;

R^{23} : i) H, or ii) C_{1-6} alkyl which may be substituted with one or more $-OH$ (s);

R^{24} : i) C_{1-6} alkyl which may be substituted with one or more phenyl(s) which may be substituted with one or more halogen(s), ii) C_{3-8} cycloalkyl which may be substituted with one or more C_{1-6} alkyl(s), iii) phenyl which may be substituted with one or more halogen(s), or iv) tetrahydropyranyl; or

R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom;

R^3 , R^4 : the same or different each other, i) C_{1-3} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and -OH(s) or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and heteroaryl(s) which is selected from the group consisting of pyrazolyl and thienyl, wherein the heteroaryl may be substituted with one or more C_{1-6} alkyl(s), or,

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 may interact to form a 3-oxetane ring and the carbon atom bounded by R^3 and R^4 is a spiro atom;

R^5 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more -O-(C_{1-6} alkyl)(s), iii) -O- C_{1-6} alkyl, iv) halogen, v) -COO-(C_{1-6} alkyl), or vi) C_{3-8} cycloalkyl;

R^6 : i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -O-(C_{1-6} alkyl(s) which may be substituted with one or more halogen(s)) and halogen(s), iii) -OH, iv) -O-(C_{1-6} alkyl which may be substituted with one or more halogen(s)), v) halogen, vi) -CN, vii) -S-(C_{1-6} alkyl), viii) C_{3-8} cycloalkyl, ix) -NR⁰R⁰, or x) C_{2-6} alkenyl;

G^1 group : i) halogen, ii) -COOR⁰, iii) -CONR⁰R⁰, iv) -OH, v) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen, or vi) -O-(C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s));

G^2 group: i) halogen, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and halogen(s) or iii) -CONR⁰R⁰;

R^0 : the same or different each other, H or C_{1-6} alkyl, provided that said compound is not methyl

1,1-diallyl-3-oxo-2,4-dihydroisoquinoline-4-carboxylate or a salt thereof.

2. The compound or salt of claim 1, wherein

R^1 is i) H, or ii) C_{1-6} alkyl;

R^2 is i) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of -OR⁰(s), halogen(s), -CONR²¹R²²(s), phenyl(s) which may be substituted with one or more substituent(s) selected from the group consisting of

halogen(s) and -COOR^0 (s), and heteroaryl(s) which is selected from the group consisting of pyrazolyl, and triazolyl, ii) C_{2-6} alkenyl, iii) C_{2-6} alkynyl, iv) $\text{-NR}^{23}\text{R}^{24}$, or v) -COOR^0 ;

R^{21} is C_{1-6} alkyl;

R^{22} is C_{1-6} alkyl;

R^{23} is C_{1-6} alkyl; and

R^{24} is i) C_{3-8} cycloalkyl, or ii) phenyl; or

R^1 , R^2 , and a carbon atom bounded by R^1 and R^2 may interact to form a 4-tetrahydropyran ring, and the carbon atom bounded by R^1 and R^2 is a spiro atom.

3. The compound or salt of claim 1 or claim 2, wherein

R^3 and R^4 are the same or different each other, i) C_{1-3} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of halogen(s) and -OH(s) or ii) C_{2-6} alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of -OH(s) and pyrazolyl(s) which may be substituted with one or more C_{1-6} alkyl(s), or,

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 may interact to form a 3-oxetane ring and the carbon atom bounded by R^3 and R^4 is a spiro atom.

4. The compound or salt of any of the preceding claims, wherein

R^5 is i) H, ii) C_{1-6} alkyl, iii) -O-C_{1-6} alkyl, iv) halogen, or v) C_{3-8} cycloalkyl; and

R^6 is i) H, ii) C_{1-6} alkyl which may be substituted with one or more substituent(s) selected from the group consisting of $\text{-O-(C}_{1-6}\text{ alkyl)(s)}$ and halogen(s), iii) -OH , iv) $\text{-O-(C}_{1-6}\text{ alkyl which may be substituted with one or more halogen(s))}$, v) halogen, vi) -CN , vii) -S-C_{1-6} alkyl, viii) $\text{-NR}^0\text{R}^0$, or ix) C_{2-6} alkenyl.

5. The compound or salt of any of the preceding claims, wherein

X^1 is C-R^{11} or N;

X^2 is C-R^{12} or N;

R^{11} is i) H, ii) halogen, iii) -CN , or iv) -O-C_{1-6} alkyl; and


R^{12} is H.

6. The compound or salt of any of the preceding claims, wherein

R^1 is C_{1-6} alkyl;

R^2 is C_{1-6} alkyl which may be substituted with a -OR^0 ;

R^3 , R^4 , and a carbon atom bounded by R^3 and R^4 interact to form a 3-oxetane ring and the carbon atom bounded by R^3 and R^4 is a spiro atom as represented by formula (II) below:



R^5 is H; and

R^6 is i) C_{1-6} alkyl, ii) $-O-C_{1-6}$ alkyl which is substituted with one to three halogen(s), iii) halogen, or iv) $-CN$.

7. The compound or salt of any of the preceeding claims, wherein

X^1 is $C-R^{11}$;

X^2 is $C-R^{12}$;

R^{11} is i) H, ii) halogen, iii) $-CN$, or iv) $-O-C_{1-6}$ alkyl; and

R^{12} is H.

8. The compound or salt of claim 1, which is a compound selected from the group consisting of

(-)-2-(difluoromethyl)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,

4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile,
8,8-diethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitrile,

(-)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one,

(+)-6-bromo-4-ethyl-4-(2-hydroxyethyl)-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one,

8,8-diethyl-7-oxo-7,8-dihydro-6H-spiro[1,6-naphthyridine-5,3'-oxetane]-2-carbonitrile,

8',8'-diethyl-7'-oxo-7',8'-dihydro-6'H-spiro[oxetane-3,5'-pyrido[3,4-b]pyrazine]-2'-carbonitrile,

4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,

2-(difluoromethoxy)-8,8-dimethyl-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,

(+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,

(-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, and

(-)-2-(difluoromethoxy)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one,

or a salt of said compound.

9. A compound or a salt thereof, which is a compound selected from the group consisting of

4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,

(+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one, and

(-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,

or a salt of said compound.

10. The compound or salt of claim 1, which is

4,4-diethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
or a salt thereof.

11. The compound or salt of claim 1, which is

6-chloro-4,4-dimethyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,

or a salt thereof.

12. The compound or salt of claim 1, which is

4,4-dimethyl-3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,3'-oxetane]-6-carbonitrile,
or a salt thereof.

13. The compound or salt of claim 1, which is

(+)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
or a salt thereof.

14. The compound or salt of claim 1, which is

(-)-6-chloro-4-(2-hydroxyethyl)-4-methyl-2H-spiro[isoquinoline-1,3'-oxetan]-3(4H)-one,
or a salt thereof.

15. A pharmaceutical composition comprising a compound or salt of any one of the
preceding claims 1 and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition for use in treating a disease or condition selected from
the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence
(MUI) and fecal incontinence comprising a compound or salt of any one of claims 9 to 14.

17. A pharmaceutical composition for use in treating a disease or condition selected from
the group consisting of frailty and sarcopenia comprising a compound or salt of any one of
claims 9 to 14.

18. A pharmaceutical composition for use in treating cachexia induced muscle weakness
associated with chronic obstructive pulmonary disease (COPD) comprising a compound of
any one of claims 9 to 14, or a salt thereof.

19. A pharmaceutical composition for use in treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis comprising a compound or salt of any one of claims 9 to 14.
20. A pharmaceutical composition for use in treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies comprising a compound or salt of any one of claims 9 to 14.
21. A pharmaceutical composition for use in treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction comprising a compound or salt of any one of claims 9 to 14.
22. A pharmaceutical composition for use in treating muscle weakness and fatigue associated with peripheral vascular disease or peripheral artery disease-comprising a compound or salt of any one of claims 9 to 14.
23. A pharmaceutical composition for use in treating post-surgical muscle weakness comprising a compound or salt of any one of claims 9 to 14.
24. A pharmaceutical composition for use in treating muscle weakness associated with metabolic syndrome or obesity comprising a compound or salt of any one of claims 9 to 14.
25. A pharmaceutical composition for use in treating ventilator-induced muscle weakness and chronic fatigue syndrome comprising a compound or salt of any one of claims 9 to 14.
26. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence.
27. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of frailty and sarcopenia.

28. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating cachexia induced muscle weakness associated with chronic obstructive pulmonary disease (COPD).

29. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis.

30. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and myasthenia gravis, muscular myopathies.

31. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction.

32. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating muscle weakness and fatigue associated with peripheral vascular disease or peripheral artery disease.

33. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating post-surgical muscle weakness.

34. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating muscle weakness associated with metabolic syndrome or obesity.

35. Use of a compound or salt of any one of claims 9 to 14 in the manufacture of a medicament for treating ventilator-induced muscle weakness and chronic fatigue syndrome.

36. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of a disease or

condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence.

37. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of frailty and sarcopenia.

38. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of cachexia induced muscle weakness associated with chronic obstructive pulmonary disease (COPD).

39. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis.

40. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies.

41. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction.

42. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of muscle weakness and fatigue associated with peripheral vascular disease or peripheral artery disease .

43. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of post-surgical muscle weakness.

44. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of muscle weakness associated with metabolic syndrome or obesity.
45. Use of a pharmaceutical composition comprising a compound of any one of claims 9 to 14 or salt thereof in the manufacture of a medicament for the treatment of ventilator-induced muscle weakness and chronic fatigue syndrome.
46. A compound or salt of any one of claims 9 to 14 for use in the treatment of a disease or condition selected from the group consisting of stress urinary incontinence (SUI), mixed urinary incontinence (MUI) and fecal incontinence.
47. A compound or salt of any one of claims 9 to 14 for use in the treatment of a disease or condition selected from the group consisting of frailty and sarcopenia.
48. A compound or salt of any one of claims 9 to 14 for use in the treatment of cachexia induced muscle weakness associated with chronic obstructive pulmonary disease (COPD).
49. A compound or salt of any one of claims 9 to 14 for use in the treatment of cachexia syndrome and/or muscle wasting caused by heart failure, cancer, or chronic kidney disease/dialysis.
50. A compound or salt of any one of claims 9 to 14 for use in the treatment of a disease or condition selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis and muscular myopathies.
51. A compound or salt of any one of claims 9 to 14 for use in the treatment of a disease or condition selected from the group consisting of post-spinal cord injury (SCI) muscle dysfunction and post-stroke muscle dysfunction.
52. A compound or salt of any one of claims 9 to 14 for use in the treatment of muscle weakness and fatigue associated with peripheral vascular disease or peripheral artery disease.

53. A compound or salt of any one of claims 9 to 14 for use in the treatment of post-surgical muscle weakness.

54. A compound or salt of any one of claims 9 to 14 for use in the treatment of muscle weakness associated with metabolic syndrome or obesity.

55. A compound or salt of any one of claims 9 to 14 for use in the treatment of ventilator-induced muscle weakness and chronic fatigue syndrome.